investment in our securities involves a high degree of risk.
−Removed: You should consider carefully all of the risks described below, together
−Removed: with the other information contained in this report, including the financial statements, before making a decision to invest in our units.
−Removed: If any of the following events occur, our business, financial condition and operating results may be materially and adversely affected.
−Removed: In that event, the trading price of our securities could decline, and you could lose all or part of your investment.
−Removed: The risk factors
−Removed: described below are not necessarily exhaustive and you are encouraged to perform your own investigation with respect to us and our business.
−Removed: For the complete list of risks relating to the Conduit Business Combination, see the section titled “Risk Factors” contained
−Removed: in the Form S-4 which the Company intends to file after the filing of this annual report.
−Removed: Relating to our Search for, Consummation of, or Inability to Consummate,
−Removed: Business Combination and Post-Business Combination Risks
−Removed: search for a business combination, and any target business with which we ultimately consummate a business combination, may be materially
−Removed: adversely affected by the recent coronavirus (COVID-19) pandemic.
−Removed: COVID-19 pandemic has resulted in a widespread health crisis that has adversely affected the economies and financial markets worldwide,
−Removed: and the business of any potential target business with which we consummate a business combination could be materially and adversely affected.
−Removed: Furthermore, we may be unable to complete a business combination if continued concerns relating to COVID-19 restrict travel, limit the
−Removed: ability to have meetings with potential investors or the target company’s personnel, vendors and services providers are unavailable
−Removed: to negotiate and consummate a transaction in a timely manner.
−Removed: The extent to which COVID-19 impacts our search for a business combination
−Removed: will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning
−Removed: the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others.
−Removed: If the disruptions posed by COVID-19
−Removed: or other matters of global concern continue for an extensive period of time, our ability to consummate a business combination, or the
−Removed: operations of a target business with which we ultimately consummate a business combination, may be materially adversely affected.
−Removed: public stockholders may not be afforded an opportunity to vote on our proposed initial business combination, which means we may complete
−Removed: our initial business combination even though a majority of our public stockholders do not support such a combination.
−Removed: may choose not to hold a stockholder vote to approve our initial business combination unless the initial business combination would require
−Removed: stockholder approval under applicable law or stock exchange listing requirements or if we decide to hold a stockholder vote for business
−Removed: or other legal reasons.
−Removed: Except as required by applicable law or stock exchange requirements, the decision as to whether we will seek
−Removed: stockholder approval of a proposed initial business combination or will allow stockholders to sell their shares to us in a tender offer
−Removed: will be made by us, solely in our discretion, and will be based on a variety of factors, such as the timing of the transaction and whether
−Removed: the terms of the transaction would otherwise require us to seek stockholder approval.
−Removed: Accordingly, we may complete our initial business
−Removed: combination even if holders of a majority of our public shares do not approve of the initial business combination we complete.
−Removed: we seek stockholder approval of our initial business combination, our initial stockholders have agreed to vote in favor of such initial
−Removed: business combination, regardless of how our public stockholders vote.
−Removed: to the letter agreement, our sponsor, officers and directors will agree to vote any founder shares held by them, as well as any public
−Removed: shares they may have acquired after our initial public offering (including in open market and privately negotiated transactions), in
−Removed: favor of our initial business combination.
−Removed: As a result, in addition to the Class A shares held by our initial stockholders, we would
−Removed: need 716,864, or approximately 33%, of the 2,187,728 public shares to be voted in favor of an initial business combination in order to
−Removed: have our initial business combination approved (assuming only the minimum number of shares representing a quorum are voted).
−Removed: if we seek stockholder approval of our initial business combination, the agreement by our initial stockholders to vote in favor of our
−Removed: initial business combination will increase the likelihood that we will receive the requisite stockholder approval for such initial business
−Removed: only opportunity to affect the investment decision regarding a potential business combination will be limited to the exercise of your
−Removed: right to redeem your shares from us for cash, unless we seek stockholder approval of the initial business combination.
−Removed: the time of your investment in us, you will not be provided with an opportunity to evaluate the specific merits or risks of our initial
−Removed: business combination.
−Removed: Since our board of directors may complete an initial business combination without seeking stockholder approval,
−Removed: public stockholders may not have the right or opportunity to vote on the initial business combination, unless we seek such stockholder
−Removed: Accordingly, if we do not seek stockholder approval, your only opportunity to affect the investment decision regarding a potential
−Removed: business combination may be limited to exercising your redemption rights within the period of time (which will be at least 20 business
−Removed: days) set forth in our tender offer documents mailed to our public stockholders in which we describe our initial business combination.
−Removed: ability of our public stockholders to redeem their shares for cash may make our financial condition unattractive to potential business
−Removed: combination targets, which may make it difficult for us to enter into an initial business combination with a target.
−Removed: may seek to enter into an initial business combination agreement with a prospective target that requires as a closing condition that
−Removed: we have a minimum net worth or a certain amount of cash.
−Removed: If too many public stockholders exercise their redemption rights, we would not
−Removed: be able to meet such closing condition and, as a result, would not be able to proceed with the initial business combination.
−Removed: targets will be aware of these risks and, thus, may be reluctant to enter into an initial business combination with us.
−Removed: ability of our public stockholders to exercise redemption rights with respect to a large number of our shares may not allow us to complete
−Removed: the most desirable business combination or optimize our capital structure.
−Removed: the time we enter into an agreement for our initial business combination, we will not know how many stockholders may exercise their redemption
−Removed: rights, and therefore will need to structure the transaction based on our expectations as to the number of shares that will be submitted
−Removed: for redemption.
−Removed: If our initial business combination agreement requires us to use a portion of the cash in the Trust Account to pay the
−Removed: purchase price, or requires us to have a minimum amount of cash at closing, we will need to reserve a portion of the cash in the Trust
−Removed: Account to meet such requirements, or arrange for third party financing.
−Removed: In addition, if a larger number of shares are submitted for
−Removed: redemption than we initially expected, we may need to restructure the transaction to reserve a greater portion of the cash in the Trust
−Removed: Account or arrange for third party financing.
−Removed: Raising additional third-party financing may involve dilutive equity issuances or the incurrence
−Removed: of indebtedness at higher than desirable levels.
−Removed: The above considerations may limit our ability to complete the most desirable business
−Removed: combination available to us or optimize our capital structure.
−Removed: ability of our public stockholders to exercise redemption rights with respect to a large number of our shares could increase the probability
−Removed: that our initial business combination would be unsuccessful and that you would have to wait for liquidation in order to redeem your stock.
−Removed: our initial business combination agreement requires us to use a portion of the cash in the Trust Account to pay the purchase price, or
−Removed: requires us to have a minimum amount of cash at closing, the probability that our initial business combination would be unsuccessful
−Removed: is increased.
−Removed: If our initial business combination is unsuccessful, you would not receive your pro rata portion of the Trust Account until
−Removed: we liquidate the Trust Account.
−Removed: If you are in need of immediate liquidity, you could attempt to sell your stock in the open market;
−Removed: at such time our stock may trade at a discount to the pro rata amount per share in the Trust Account.
−Removed: In either situation, you may suffer
−Removed: a material loss on your investment or lose the benefit of funds expected in connection with our redemption until we liquidate or you
−Removed: are able to sell your stock in the open market.
−Removed: requirement that we complete our initial business combination within the prescribed time frame may give potential target businesses leverage
−Removed: over us in negotiating an initial business combination and may decrease our ability to conduct due diligence on potential business combination
−Removed: targets as we approach our dissolution deadline, which could undermine our ability to complete our initial business combination on terms
−Removed: that would produce value for our stockholders.
−Removed: potential target business with which we enter into negotiations concerning an initial business combination will be aware that we must
−Removed: complete our initial business combination within 12 months from the consummation of our initial public offering (or up to February 7,
−Removed: 2024 at the election of the Company subject to satisfaction of certain conditions) .
−Removed: Consequently, such target business may obtain leverage
−Removed: over us in negotiating an initial business combination, knowing that if we do not complete our initial business combination with that
−Removed: particular target business, we may be unable to complete our initial business combination with any target business.
−Removed: This risk will increase
−Removed: as we get closer to the timeframe described above.
−Removed: In addition, we may have limited time to conduct due diligence and may enter into
−Removed: our initial business combination on terms that we would have rejected upon a more comprehensive investigation.
−Removed: may not be able to complete our initial business combination within the prescribed time frame, in which case we would cease all operations
−Removed: except for the purpose of winding up and we would redeem our public shares and liquidate, in which case our public stockholders may only
−Removed: receive approximately $11.05 per share, or less than such amount in certain circumstances, and our warrants will expire worthless.
−Removed: certificate of incorporation provides that we must complete our initial business combination on or prior to February 7, 2024 at the election
−Removed: of the Company subject to certain conditions.
−Removed: We may not be able to find a suitable target business and complete our initial business
−Removed: combination within such time period.
−Removed: Our ability to complete our initial business combination may be negatively impacted by general market
−Removed: conditions, volatility in the capital and debt markets and the other risks described herein.
−Removed: For example, the conflict between Russia
−Removed: and Ukraine could lead to disruption, instability and volatility in global markets and industries.
−Removed: Further, if the outbreak of COVID-19
−Removed: continues to grow both in the U.S.
−Removed: and globally and, while the extent of the impact of the outbreak on us will depend on future developments,
−Removed: it could limit our ability to complete our initial business combination, including as a result of increased market volatility, decreased
−Removed: market liquidity and third-party financing being unavailable on terms acceptable to us or at all.
−Removed: Additionally, the outbreak of COVID-19
−Removed: may negatively impact businesses we may seek to acquire.
−Removed: we have not completed our initial business combination within such time period, we will:
−Removed: (i) cease all operations except for the purpose
−Removed: of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a
−Removed: per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the
−Removed: funds held in the Trust Account and not previously released to us to pay our taxes (less up to $100,000 of interest to pay dissolution
−Removed: expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’
−Removed: rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)
−Removed: as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of
−Removed: directors, dissolve and liquidate, subject in the case of clauses (ii) and (iii) above to our obligations under Delaware law to provide
−Removed: for claims of creditors and the requirements of other applicable law.
−Removed: In such case, our public stockholders may only receive approximately
−Removed: $11.05 per share, assuming our sponsor makes the Maximum Contribution and less any tax obligations, and our warrants will expire worthless.
−Removed: In certain circumstances, our public stockholders may receive less than approximately $11.05 per share on the redemption of their shares.
−Removed: See “— If third parties bring claims against us, the proceeds held in the Trust Account could be reduced and the per-share
−Removed: redemption amount received by stockholders may be less than approximately $11.05 per share” and other risk factors below.
−Removed: the number of special purpose acquisition companies evaluating targets increases, attractive targets may become scarcer and there may
−Removed: be more competition for attractive targets.
−Removed: This could increase the cost of our initial business combination and could even result in
−Removed: our inability to find a target or to consummate an initial business combination.
−Removed: recent years and especially in the last several months, the number of SPACs that have been formed has increased substantially.
−Removed: Many potential
−Removed: targets for SPACs have already entered into an initial business combination, and there are still many SPACs seeking targets for their
−Removed: initial business combination, as well as many such companies currently in registration.
−Removed: As a result, at times, fewer attractive targets
−Removed: may be available, and it may require more time, more effort and more resources to identify a suitable target and to consummate an initial
−Removed: business combination.
−Removed: addition, because there are more SPACs seeking to enter into an initial business combination with available targets, the competition
−Removed: for available targets with attractive fundamentals or business models may increase, which could cause targets companies to demand improved
−Removed: financial terms.
−Removed: Attractive deals could also become scarcer for other reasons, such as economic or industry sector downturns, geopolitical
−Removed: tensions, or increases in the cost of additional capital needed to close business combinations or operate targets post-business combination.
−Removed: This could increase the cost of, delay or otherwise complicate or frustrate our ability to find and consummate an initial business combination,
−Removed: and may result in our inability to consummate an initial business combination on terms favorable to our investors altogether.
−Removed: we seek stockholder approval of our initial business combination, our sponsor, directors, officers and their affiliates may elect to
−Removed: purchase shares or warrants from public stockholders, which may influence a vote on a proposed initial business combination and reduce
−Removed: the public “float” of our common stock.
−Removed: we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business
−Removed: combination pursuant to the tender offer rules, our sponsor, directors, officers or their affiliates may purchase public shares or public
−Removed: warrants or a combination thereof in privately negotiated transactions or in the open market either prior to or following the completion
−Removed: of our initial business combination, although they are under no obligation to do so.
−Removed: However, they have no current commitments, plans
−Removed: or intentions to engage in such transactions and have not formulated any terms or conditions for any such transactions.
−Removed: None of the funds
−Removed: in the Trust Account will be used to purchase shares or public warrants in such transactions.
−Removed: a purchase may include a contractual acknowledgement that such stockholder, although still the record holder of our shares is no longer
−Removed: the beneficial owner thereof and therefore agrees not to exercise its redemption rights.
−Removed: In the event that our sponsor, directors, officers
−Removed: or their affiliates purchase shares in privately negotiated transactions from public stockholders who have already elected to exercise
−Removed: their redemption rights or submitted a proxy to vote against our initial business combination, such selling stockholders would be required
−Removed: to revoke their prior elections to redeem their shares and any proxy to vote against our initial business combination.
−Removed: The price per
−Removed: share paid in any such transaction may be different than the amount per share a public stockholder would receive if it elected to redeem
−Removed: its shares in connection with our initial business combination.
−Removed: The purpose of such purchases could be to vote such shares in favor of
−Removed: the initial business combination and thereby increase the likelihood of obtaining stockholder approval of the initial business combination,
−Removed: or to satisfy a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain amount of cash
−Removed: at the closing of our initial business combination, where it appears that such requirement would otherwise not be met.
−Removed: The purpose of
−Removed: any such purchases of public warrants could be to reduce the number of public warrants outstanding or to vote such warrants on any matters
−Removed: submitted to the warrant holders for approval in connection with our initial business combination.
−Removed: such purchases of our securities may result in the completion of our initial business combination that may not otherwise have been possible.
−Removed: We expect that any such purchases will be reported pursuant to Section 13 and Section 16 of the Exchange Act to the extent such purchasers
−Removed: are subject to such reporting requirements.
−Removed: addition, if such purchases are made, the public “float” of our common stock or public warrants and the number of beneficial
−Removed: holders of our securities may be reduced, possibly making it difficult to obtain or maintain the quotation, listing or trading of our
−Removed: securities on a national securities exchange.
−Removed: a stockholder fails to receive notice of our offer to redeem our public shares in connection with our initial business combination, or
−Removed: fails to comply with the procedures for tendering its shares, such shares may not be redeemed.
−Removed: will comply with the tender offer rules or proxy rules, as applicable, when conducting redemptions in connection with our initial business
−Removed: Despite our compliance with these rules, if a stockholder fails to receive our tender offer or proxy materials, as applicable,
−Removed: such stockholder may not become aware of the opportunity to redeem its shares.
−Removed: In addition, proxy materials or tender offer documents,
−Removed: as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will describe
−Removed: the various procedures that must be complied with in order to validly tender or redeem public shares.
−Removed: For example, we may require our
−Removed: public stockholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in “street
−Removed: name,” to either deliver their stock certificates to our transfer agent prior to the date set forth in the tender offer documents
−Removed: mailed to such holders, or up to two business days prior to the vote on the proposal to approve the initial business combination in the
−Removed: event we distribute proxy materials, or to deliver their shares to the transfer agent electronically.
−Removed: In the event that a stockholder
−Removed: fails to comply with these or any other procedures disclosed in the proxy or tender offer materials, as applicable, its shares may not
−Removed: will not have any rights or interests in funds from the Trust Account, except under certain limited circumstances.
−Removed: To liquidate your
−Removed: investment, therefore, you may be forced to sell your public shares or warrants, potentially at a loss.
−Removed: public stockholders will be entitled to receive funds from the Trust Account only upon the earliest to occur of:
−Removed: (i) our completion of
−Removed: an initial business combination, and then only in connection with those shares of common stock that such stockholder properly elected
−Removed: to redeem, subject to the limitations described herein, (ii) the redemption of any public shares properly submitted in connection with
−Removed: a stockholder vote to amend our certificate of incorporation (A) to modify the substance or timing of our obligation to allow redemption
−Removed: in connection with our initial business combination or certain amendments to our charter prior thereto or to redeem 100% of our public
−Removed: shares if we do not complete our initial business combination within 12 months from the consummation of our initial public offering (or
−Removed: up to February 7, 2024 at the election of the Company subject to satisfaction of certain conditions) , or (B) with respect to any other
−Removed: provision relating to stockholders’ rights or pre-initial business combination activity and (iii) the redemption of our public
−Removed: shares if we are unable to complete an initial business combination within 12 months from the consummation of our initial public offering
−Removed: (or up to February 7, 2024 at the election of the Company subject to satisfaction of certain conditions), subject to applicable law and
−Removed: as further described herein.
−Removed: In no other circumstances will a public stockholder have any right or interest of any kind in the Trust
−Removed: Holders of warrants will not have any right to the proceeds held in the Trust Account with respect to the warrants.
−Removed: to liquidate your investment, you may be forced to sell your public shares or warrants, potentially at a loss.
−Removed: representative may have a conflict of interest if they render services to us in connection with our initial business combination.
−Removed: may elect to engage A.G.P.
−Removed: (who was the representative of the underwriters of our initial public offering) to assist us in connection
−Removed: with our initial business combination.
−Removed: A portion (3.5%) of the representatives’ discounts and commissions is not payable unless
−Removed: the Company completes its initial business combination.
−Removed: Therefore, if the representative provides services to us in connection with our
−Removed: initial business combination, these financial interests may result in the representative having a conflict of interest when providing
−Removed: such services to us.
−Removed: has been engaged by Conduit as its financial advisor for the Conduit Business Combination.
−Removed: of our limited resources and the significant competition for business combination opportunities, it may be more difficult for us to complete
−Removed: our initial business combination.
−Removed: If we are unable to complete our initial business combination, our public stockholders may receive
−Removed: only approximately $11.05 per share on our redemption of our public shares, or less than such amount in certain circumstances, and our
−Removed: warrants will expire worthless.
−Removed: expect to encounter intense competition from other entities having a business objective similar to ours, including private investors
−Removed: (which may be individuals or investment partnerships), other blank check companies and other entities competing for the types of businesses
−Removed: we intend to acquire.
−Removed: Many of these individuals and entities are well-established and have extensive experience in identifying and effecting,
−Removed: directly or indirectly, acquisitions of companies operating in or providing services to various industries.
−Removed: Many of these competitors
−Removed: possess greater technical, human and other resources or more industry knowledge than we do, and our financial resources will be relatively
−Removed: limited when contrasted with those of many of these competitors.
−Removed: While we believe there are numerous target businesses we could potentially
−Removed: acquire with the net proceeds of our initial public offering and the sale of the placement units, our ability to compete with respect
−Removed: to the acquisition of certain target businesses that are sizable will be limited by our available financial resources.
−Removed: This inherent
−Removed: competitive limitation gives others an advantage in pursuing the acquisition of certain target businesses.
−Removed: Furthermore, because we are
−Removed: obligated to pay cash for the shares of Class A common stock which our public stockholders redeem in connection with our initial business
−Removed: combination, target companies will be aware that this may reduce the resources available to us for our initial business combination.
−Removed: This may place us at a competitive disadvantage in successfully negotiating and completing an initial business combination.
−Removed: unable to complete our initial business combination, our public stockholders may receive only approximately $11.05 per share, assuming
−Removed: our sponsor makes the Maximum Contribution and less any tax obligations, on the liquidation of our Trust Account and our warrants will
−Removed: expire worthless.
−Removed: In certain circumstances, our public stockholders may receive less than $11.05 per share upon our liquidation.
−Removed: “— If third parties bring claims against us, the proceeds held in the Trust Account could be reduced and the per-share redemption
−Removed: amount received by stockholders may be less than $11.05 per share” and other risk factors herein.
−Removed: the net proceeds of our initial public offering and the sale of the placement units not being held in the Trust Account are
−Removed: insufficient to allow us to operate, we may be unable to complete our initial business combination, in which case our public
−Removed: stockholders may only receive approximately $11.05 per share, or less than such amount in certain circumstances, and our warrants
−Removed: will expire worthless.
−Removed: funds available to us outside of the Trust Account to fund our working capital requirements may not be sufficient to allow us to operate
−Removed: until February 7, 2024, assuming that our initial business combination is not completed during that time.
−Removed: We believe that the funds available
−Removed: to us outside of the Trust Account will be sufficient to allow us to operate until February 7, 2024;
−Removed: however, we cannot assure you that
−Removed: our estimate is accurate.
−Removed: Of the funds available to us, we could use a portion of the funds available to us to pay fees to consultants
−Removed: to assist us with our search for a target business.
−Removed: We could also use a portion of the funds as a down payment or to fund a “no-shop”
−Removed: provision (a provision in letters of intent or merger agreements designed to keep target businesses from “shopping” around
−Removed: for transactions with other companies or investors on terms more favorable to such target businesses) with respect to a particular proposed
−Removed: initial business combination, although we do not have any current intention to do so.
−Removed: If we entered into a letter of intent or merger
−Removed: agreement where we paid for the right to receive exclusivity from a target business and were subsequently required to forfeit such funds
−Removed: (whether as a result of our breach or otherwise), we might not have sufficient funds to continue searching for, or conduct due diligence
−Removed: with respect to, a target business.
−Removed: If we are unable to complete our initial business combination, our public stockholders may receive
−Removed: only approximately $11.05 per share, assuming our sponsor makes the Maximum Contribution and less any tax obligations, on the liquidation
−Removed: of our Trust Account and our warrants will expire worthless.
−Removed: In certain circumstances, our public stockholders may receive less than
−Removed: approximately $11.05 per share upon our liquidation.
−Removed: See “— If third parties bring claims against us, the proceeds held in
−Removed: the Trust Account could be reduced and the per-share redemption amount received by stockholders may be less than approximately $11.05
−Removed: per share” and other risk factors herein.
−Removed: depend on loans from our sponsor or management team to fund our search for an initial business combination, to pay our taxes and to complete
−Removed: our initial business combination.
−Removed: If we are unable to obtain these loans, we may be unable to complete our initial business combination.
−Removed: connection with the extension of our business combination termination date and related payments into the trust account and continued
−Removed: operating expenses, we have borrowed $300,000 from our sponsor and may borrow up to $1,500,000 in total.
−Removed: None of our sponsor, members of our management team nor any of
−Removed: their affiliates is under any obligation to advance funds to us in such circumstances.
−Removed: Any such advances would be repaid only from
−Removed: funds held outside the Trust Account or from funds released to us upon completion of our initial business combination.
−Removed: $1,500,000 of such loans may be convertible into units, at a price of $10.00 per unit at the option of the lender, upon consummation
−Removed: of our initial business combination.
−Removed: The units would be identical to the placement units.
−Removed: Prior to the completion of our initial
−Removed: business combination, we do not expect to seek loans from parties other than our sponsor or an affiliate of our sponsor as we do not
−Removed: believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in
−Removed: our Trust Account.
−Removed: If we are unable to obtain these loans, we may be unable to complete our initial business combination.
−Removed: unable to complete our initial business combination because we do not have sufficient funds available to us, we will be forced to
−Removed: cease operations and liquidate the Trust Account.
−Removed: Consequently, our public stockholders may only receive approximately $11.05 per
−Removed: share, assuming our sponsor makes the Maximum Contribution and less any tax obligations, on our redemption of our public shares, and
−Removed: our warrants will expire worthless.
−Removed: In certain circumstances, our public stockholders may receive less than $11.05 per share on the
−Removed: redemption of their shares.
−Removed: See “— If third parties bring claims against us, the proceeds held in the Trust Account
−Removed: could be reduced and the per-share redemption amount received by stockholders may be less than $11.05 per share” and other
−Removed: risk factors below.
−Removed: to the completion of our initial business combination, we may be required to take write-downs or write-offs, restructuring and impairment
−Removed: or other charges that could have a significant negative effect on our financial condition, results of operations and our stock price,
−Removed: which could cause you to lose some or all of your investment.
−Removed: if we conduct extensive due diligence on a target business with which we combine, we cannot assure you that this diligence will surface
−Removed: all material issues that may be present inside a particular target business, that it would be possible to uncover all material issues
−Removed: through a customary amount of due diligence, or that factors outside of the target business and outside of our control will not later
−Removed: As a result of these factors, we may be forced to later write-down or write-off assets, restructure our operations, or incur impairment
−Removed: or other charges that could result in our reporting losses.
−Removed: Even if our due diligence successfully identifies certain risks, unexpected
−Removed: risks may arise and previously known risks may materialize in a manner not consistent with our preliminary risk analysis.
−Removed: these charges may be non-cash items and not have an immediate impact on our liquidity, the fact that we report charges of this nature
−Removed: could contribute to negative market perceptions about us or our securities.
−Removed: In addition, charges of this nature may cause us to violate
−Removed: net worth or other covenants to which we may be subject as a result of assuming pre-existing debt held by a target business or by virtue
−Removed: of our obtaining debt financing to partially finance the initial business combination.
−Removed: Accordingly, any stockholders who choose to remain
−Removed: stockholders following the initial business combination could suffer a reduction in the value of their shares.
−Removed: Such stockholders are
−Removed: unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach
−Removed: by our officers or directors of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private
−Removed: claim under securities laws that the proxy solicitation or tender offer materials, as applicable, relating to the initial business combination
−Removed: constituted an actionable material misstatement or omission.
−Removed: third parties bring claims against us, the proceeds held in the Trust Account could be reduced and the per-share redemption amount received
−Removed: by stockholders may be less than $10.20 per share.
−Removed: placing of funds in the Trust Account may not protect those funds from third-party claims against us.
−Removed: Although we will seek to have all
−Removed: vendors, service providers, prospective target businesses and other entities with which we do business execute agreements with us waiving
−Removed: any right, title, interest or claim of any kind in or to any monies held in the Trust Account for the benefit of our public stockholders,
−Removed: such parties may not execute such agreements, or even if they execute such agreements they may not be prevented from bringing claims
−Removed: against the Trust Account, including, but not limited to, fraudulent inducement, breach of fiduciary responsibility or other similar
−Removed: claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain advantage with respect to a claim
−Removed: against our assets, including the funds held in the Trust Account.
−Removed: If any third party refuses to execute an agreement waiving such claims
−Removed: to the monies held in the Trust Account, our management will perform an analysis of the alternatives available to it and will only enter
−Removed: into an agreement with a third party that has not executed a waiver if management believes that such third party’s engagement would
−Removed: be significantly more beneficial to us than any alternative.
−Removed: Marcum LLP, our independent registered public accounting firm, and the underwriters
−Removed: of our initial public offering, will not execute agreements with us waiving such claims to the monies held in the Trust Account.
−Removed: of possible instances where we may engage a third party that refuses to execute a waiver include the engagement of a third party consultant
−Removed: whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would
−Removed: agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a waiver.
−Removed: there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of,
−Removed: any negotiations, contracts or agreements with us and will not seek recourse against the Trust Account for any reason.
−Removed: Upon redemption
−Removed: of our public shares, if we are unable to complete our initial business combination within the prescribed timeframe, or upon the exercise
−Removed: of a redemption right in connection with our initial business combination, we will be required to provide for payment of claims of creditors
−Removed: that were not waived that may be brought against us within the 10 years following redemption.
−Removed: Accordingly, the per-share redemption amount
−Removed: received by public stockholders could be less than the $10.20 per share initially held in the Trust Account, due to claims of such creditors.
−Removed: Pursuant to the letter agreement, our sponsor will agree that it will be liable to us if and to the extent any claims by a third party
−Removed: for services rendered or products sold to us, or a prospective target business with which we have entered into a written letter of intent,
−Removed: confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the
−Removed: lesser of (i) $10.20 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation
−Removed: of the Trust Account, if less than $10.20 per share due to reductions in the value of the trust assets, less taxes payable, provided
−Removed: that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all
−Removed: rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under our
−Removed: indemnity of the underwriters of our initial public offering against certain liabilities, including liabilities under the Securities
−Removed: However, we have not asked our sponsor to reserve for such indemnification obligations, nor have we independently verified whether
−Removed: our sponsor has sufficient funds to satisfy its indemnity obligations and believe that our sponsor’s only assets are securities
−Removed: of our company.
−Removed: Therefore, we cannot assure you that our sponsor would be able to satisfy those obligations.
−Removed: None of our officers or
−Removed: directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective target businesses.
−Removed: directors may decide not to enforce the indemnification obligations of our sponsor, resulting in a reduction in the amount of funds in
−Removed: the Trust Account available for distribution to our public stockholders.
−Removed: the event that the proceeds in the Trust Account are reduced below the lesser of (i) $10.20 per share and (ii) the actual amount per
−Removed: share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.20 per share due to reductions
−Removed: in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes, and our sponsor asserts that
−Removed: it is unable to satisfy its obligations or that it has no indemnification obligations related to a particular claim, our independent
−Removed: directors would determine whether to take legal action against our sponsor to enforce its indemnification obligations.
−Removed: we currently expect that our independent directors would take legal action on our behalf against our sponsor to enforce its indemnification
−Removed: obligations to us, it is possible that our independent directors in exercising their business judgment and subject to their fiduciary
−Removed: duties may choose not to do so in any particular instance if, for example, the cost of such legal action is deemed by the independent
−Removed: directors to be too high relative to the amount recoverable or if the independent directors determine that a favorable outcome is not
−Removed: If our independent directors choose not to enforce these indemnification obligations, the amount of funds in the Trust Account
−Removed: available for distribution to our public stockholders may be reduced below $10.20 per share.
−Removed: may not have sufficient funds to satisfy indemnification claims of our directors and executive officers.
−Removed: have agreed to indemnify our officers and directors to the fullest extent permitted by law.
−Removed: However, our officers and directors have
−Removed: agreed to waive any right, title, interest or claim of any kind in or to any monies in the Trust Account and to not seek recourse against
−Removed: the Trust Account for any reason whatsoever.
−Removed: Accordingly, any indemnification provided will be able to be satisfied by us only if (i)
−Removed: we have sufficient funds outside of the Trust Account or (i) we consummate an initial business combination.
−Removed: Our obligation to indemnify
−Removed: our officers and directors may discourage stockholders from bringing a lawsuit against our officers or directors for breach of their
−Removed: fiduciary duty.
−Removed: These provisions also may have the effect of reducing the likelihood of derivative litigation against our officers and
−Removed: directors, even though such an action, if successful, might otherwise benefit us and our stockholders.
−Removed: Furthermore, a stockholder’s
−Removed: investment may be adversely affected to the extent we pay the costs of settlement and damage awards against our officers and directors
−Removed: pursuant to these indemnification provisions.
−Removed: after we distribute the proceeds in the Trust Account to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy
−Removed: petition is filed against us that is not dismissed, a bankruptcy court may seek to recover such proceeds, and we and our board may be
−Removed: exposed to claims of punitive damages.
−Removed: after we distribute the proceeds in the Trust Account to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy
−Removed: petition is filed against us that is not dismissed, any distributions received by stockholders could be viewed under applicable debtor/creditor
−Removed: and/or bankruptcy laws as either a “preferential transfer” or a “fraudulent conveyance.” As a result, a bankruptcy
−Removed: court could seek to recover some or all amounts received by our stockholders.
−Removed: In addition, our board of directors may be viewed as having
−Removed: breached its fiduciary duty to our creditors and/or having acted in bad faith, thereby exposing itself and us to claims of punitive damages,
−Removed: by paying public stockholders from the Trust Account prior to addressing the claims of creditors.
−Removed: before distributing the proceeds in the Trust Account to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy
−Removed: petition is filed against us that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of our
−Removed: stockholders and the per-share amount that would otherwise be received by our stockholders in connection with our liquidation may be
−Removed: before distributing the proceeds in the Trust Account to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy
−Removed: petition is filed against us that is not dismissed, the proceeds held in the Trust Account could be subject to applicable bankruptcy
−Removed: law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our stockholders.
−Removed: To the extent any bankruptcy claims deplete the Trust Account, the per-share amount that would otherwise be received by our stockholders
−Removed: in connection with our liquidation may be reduced.
−Removed: we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements
−Removed: and our activities may be restricted, which may make it difficult for us to complete our initial business combination.
−Removed: we are deemed to be an investment company under the Investment Company Act, our activities may be restricted, including:
−Removed: on the nature of our investments;
−Removed: on the issuance of securities, each of which may make it difficult for us to complete our initial business combination.
−Removed: addition, we may have imposed upon us burdensome requirements, including:
−Removed: as an investment company with the SEC;
−Removed: of a specific form of corporate structure;
−Removed: record keeping, voting, proxy and disclosure requirements and other rules and regulations that we are currently not subject to.
−Removed: order not to be regulated as an investment company under the Investment Company Act, unless we can qualify for an exclusion, we must
−Removed: ensure that we are engaged primarily in a business other than investing, reinvesting or trading in securities and that our activities
−Removed: do not include investing, reinvesting, owning, holding or trading “investment securities” constituting more than 40% of our
−Removed: total assets (exclusive of U.S.
−Removed: government securities and cash items) on an unconsolidated basis.
−Removed: Our business will be to identify and
−Removed: complete an initial business combination and thereafter to operate the post-transaction business or assets for the long term.
−Removed: plan to buy businesses or assets with a view to resale or profit from their resale.
−Removed: We do not plan to buy unrelated businesses or assets
−Removed: or to be a passive investor.
−Removed: do not believe that our anticipated principal activities will subject us to the Investment Company Act.
−Removed: To this end, the proceeds held
−Removed: in the Trust Account may only be invested in United States “government securities” within the meaning of Section 2(a)(16)
−Removed: of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7
−Removed: promulgated under the Investment Company Act which invest only in direct U.S.
−Removed: government treasury obligations.
−Removed: Pursuant to the trust
−Removed: agreement, the trustee is not permitted to invest in other securities or assets.
−Removed: By restricting the investment of the proceeds to these
−Removed: instruments, and by having a business plan targeted at acquiring and growing businesses for the long term (rather than on buying and
−Removed: selling businesses in the manner of a merchant bank or private equity fund), we intend to avoid being deemed an “investment company”
−Removed: within the meaning of the Investment Company Act.
−Removed: Our initial public offering is not intended for persons who are seeking a return on
−Removed: investments in government securities or investment securities.
−Removed: The Trust Account is intended as a holding place for funds pending the
−Removed: earliest to occur of:
−Removed: (i) the completion of our initial business combination;
−Removed: (ii) the redemption of any public shares properly submitted
−Removed: in connection with a stockholder vote to amend our certificate of incorporation (A) to modify the substance or timing of our obligation
−Removed: to allow redemption in connection with our initial business combination or certain amendments to our charter prior thereto or to redeem
−Removed: 100% of our public shares if we do not complete our initial business combination within 12 months from the consummation of our initial
−Removed: public offering (or up to February 7, 2024 at the election of the Company subject to satisfaction of certain conditions) or (B) with
−Removed: respect to any other provision relating to stockholders’ rights or pre-initial business combination activity;
−Removed: or (iii) absent an
−Removed: initial business combination within 12 months from the consummation of our initial public offering (or up to February 7, 2024 at the
−Removed: election of the Company subject to satisfaction of certain conditions), our return of the funds held in the Trust Account to our public
−Removed: stockholders as part of our redemption of the public shares.
−Removed: If we do not invest the proceeds as discussed above, we may be deemed to
−Removed: be subject to the Investment Company Act.
−Removed: If we were deemed to be subject to the Investment Company Act, compliance with these additional
−Removed: regulatory burdens would require additional expenses for which we have not allotted funds and may hinder our ability to complete an initial
−Removed: business combination or may result in our liquidation.
−Removed: If we are unable to complete our initial business combination, our public stockholders
−Removed: may receive only approximately $11.05 per share, assuming our sponsor makes the Maximum Contribution and less any tax obligations, on
−Removed: the liquidation of our Trust Account and our warrants will expire worthless.
−Removed: stockholders may be held liable for claims by third parties against us to the extent of distributions received by them upon redemption
−Removed: of their shares.
−Removed: the DGCL, stockholders may be held liable for claims by third parties against a corporation to the extent of distributions received by
−Removed: them in a dissolution.
−Removed: The pro rata portion of our Trust Account distributed to our public stockholders upon the redemption of our public
−Removed: shares in the event we do not complete our initial business combination within 12 months from the consummation of our initial public
−Removed: offering (or up to February 7, 2024 at the election of the Company subject to satisfaction of certain conditions) in accordance with
−Removed: our certificate of incorporation) may be considered a liquidating distribution under Delaware law.
−Removed: If a corporation complies with certain
−Removed: procedures set forth in Section 280 of the DGCL intended to ensure that it makes reasonable provision for all claims against it, including
−Removed: a 60-day notice period during which any third-party claims can be brought against the corporation, a 90-day period during which the corporation
−Removed: may reject any claims brought, and an additional 150-day waiting period before any liquidating distributions are made to stockholders,
−Removed: any liability of stockholders with respect to a liquidating distribution is limited to the lesser of such stockholder’s pro rata
−Removed: share of the claim or the amount distributed to the stockholder, and any liability of the stockholder would be barred after the third
−Removed: anniversary of the dissolution.
−Removed: However, it is our intention to redeem our public shares as soon as reasonably possible following 12
−Removed: months from the consummation of our initial public offering (or up to February 7, 2024 at the election of the Company subject to satisfaction
−Removed: of certain conditions) in the event we do not complete our initial business combination and, therefore, we do not intend to comply with
−Removed: the foregoing procedures.
−Removed: we will not be complying with Section 280, Section 281(b) of the DGCL requires us to adopt a plan, based on facts known to us at such
−Removed: time that will provide for our payment of all existing and pending claims or claims that may be potentially brought against us within
−Removed: the 10 years following our dissolution.
−Removed: However, because we are a blank check company, rather than an operating company, and our operations
−Removed: will be limited to searching for prospective target businesses to acquire, the only likely claims to arise would be from our vendors
−Removed: (such as lawyers, investment bankers, etc.) or prospective target businesses.
−Removed: If our plan of distribution complies with Section 281(b)
−Removed: of the DGCL, any liability of stockholders with respect to a liquidating distribution is limited to the lesser of such stockholder’s
−Removed: pro rata share of the claim or the amount distributed to the stockholder, and any liability of the stockholder would likely be barred
−Removed: after the third anniversary of the dissolution.
−Removed: We cannot assure you that we will properly assess all claims that may be potentially
−Removed: brought against us.
−Removed: As such, our stockholders could potentially be liable for any claims to the extent of distributions received by them
−Removed: (but no more) and any liability of our stockholders may extend beyond the third anniversary of such date.
−Removed: Furthermore, if the pro rata
−Removed: portion of our Trust Account distributed to our public stockholders upon the redemption of our public shares in the event we do not complete
−Removed: our initial business combination within 12 months from the consummation of our initial public offering (or up to February 7, 2024 at
−Removed: the election of the Company subject to satisfaction of certain conditions) is not considered a liquidating distribution under Delaware
−Removed: law and such redemption distribution is deemed to be unlawful (potentially due to the imposition of legal proceedings that a party may
−Removed: bring or due to other circumstances that are currently unknown), then pursuant to Section 174 of the DGCL, the statute of limitations
−Removed: for claims of creditors could then be six years after the unlawful redemption distribution, instead of three years, as in the case of
−Removed: a liquidating distribution.
−Removed: may not hold an annual meeting of stockholders until after the consummation of our initial business combination, which could delay the
−Removed: opportunity for our stockholders to elect directors.
−Removed: accordance with Nasdaq corporate governance requirements, we are not required to hold an annual meeting until no later than one year
−Removed: after our first fiscal year end following our listing on the Nasdaq.
−Removed: Under Section 211(b) of the DGCL, we are, however, required to hold
−Removed: an annual meeting of stockholders for the purposes of electing directors in accordance with our bylaws unless such election is made by
−Removed: written consent in lieu of such a meeting.
−Removed: We may not hold an annual meeting of stockholders to elect new directors prior to the consummation
−Removed: of our initial business combination, and thus we may not be in compliance with Section 211(b) of the DGCL, which requires an annual meeting.
−Removed: Therefore, if our stockholders want us to hold an annual meeting prior to the consummation of our initial business combination, they
−Removed: may attempt to force us to hold one by submitting an application to the Delaware Court of Chancery in accordance with Section 211(c)
−Removed: grant of registration rights to our initial stockholders may make it more difficult to complete our initial business combination, and
−Removed: the future exercise of such rights may adversely affect the market price of our Class A common stock.
−Removed: to an agreement to be entered into concurrently with the issuance and sale of the securities in our initial public offering, our initial
−Removed: stockholders, and their permitted transferees can demand that we register the resale of the founder shares, the placement units, the
−Removed: shares of Class A common stock issuable upon exercise of the placement units and holders of warrants that may be issued upon conversion
−Removed: of working capital loans may demand that we register the resale of such shares of Class A common stock, warrants or the Class A common
−Removed: stock issuable upon exercise of such warrants.
−Removed: We will bear the cost of registering these securities.
−Removed: The registration and availability
−Removed: of such a significant number of securities for trading in the public market may have an adverse effect on the market price of our Class
−Removed: A common stock.
−Removed: In addition, the existence of the registration rights may make our initial business combination more costly or difficult
−Removed: This is because the stockholders of the target business may increase the equity stake they seek in the combined entity or
−Removed: ask for more cash consideration to offset the negative impact on the market price of our Class A common stock that is expected when the
−Removed: securities owned by our initial stockholders or holders of working capital loans or their respective permitted transferees are registered.
−Removed: we are neither limited to evaluating a target business in a particular industry sector nor have we selected any specific target businesses
−Removed: with which to pursue our initial business combination, you will be unable to ascertain the merits or risks of any particular target business’s
−Removed: will seek to complete an initial business combination with companies in the Proptecch industry but may also pursue other business combination
−Removed: opportunities, except that we will not, under our certificate of incorporation, be permitted to effectuate our initial business combination
−Removed: with another blank check company or similar company with nominal operations.
−Removed: Because we have not yet selected or approached any specific
−Removed: target business with respect to a business combination, there is no basis to evaluate the possible merits or risks of any particular
−Removed: target business’s operations, results of operations, cash flows, liquidity, financial condition or prospects.
−Removed: To the extent we
−Removed: complete our initial business combination, we may be affected by numerous risks inherent in the business operations with which we combine.
−Removed: For example, if we combine with a financially unstable business or an entity lacking an established record of sales or earnings, we may
−Removed: be affected by the risks inherent in the business and operations of a financially unstable or a development stage entity.
−Removed: officers and directors will endeavor to evaluate the risks inherent in a particular target business, we cannot assure you that we will
−Removed: properly ascertain or assess all of the significant risk factors or that we will have adequate time to complete due diligence.
−Removed: some of these risks may be outside of our control and leave us with no ability to control or reduce the chances that those risks will
−Removed: adversely impact a target business.
−Removed: We also cannot assure you that an investment in our units will ultimately prove to be more favorable
−Removed: to investors than a direct investment, if such opportunity were available, in a business combination target.
−Removed: Accordingly, any stockholders
−Removed: who choose to remain stockholders following our initial business combination could suffer a reduction in the value of their securities.
−Removed: Such stockholders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction
−Removed: was due to the breach by our officers or directors of a duty of care or other fiduciary duty owed to them, or if they are able to successfully
−Removed: bring a private claim under securities laws that the proxy solicitation or tender offer materials, as applicable, relating to the business
−Removed: combination contained an actionable material misstatement or material omission.
−Removed: may seek business combination opportunities in industries or sectors which may or may not be outside of our management’s area of
−Removed: we intend to focus on identifying companies in the real estate industry, including construction, homebuilding, real estate owners and
−Removed: operators, arrangers of financing, insurance, and other services for real estate, and adjacent businesses and technologies targeting
−Removed: the real estate space, which we may refer to as “Proptech” businesses, we will consider an initial business combination outside
−Removed: of our management’s area of expertise if an initial business combination candidate is presented to us and we determine that such
−Removed: candidate offers an attractive business combination opportunity for our company or we are unable to identify a suitable candidate in
−Removed: this sector after having expanded a reasonable amount of time and effort in an attempt to do so.
−Removed: Although our management will endeavor
−Removed: to evaluate the risks inherent in any particular business combination candidate, we cannot assure you that we will adequately ascertain
−Removed: or assess all of the significant risk factors.
−Removed: We also cannot assure you that an investment in our units will not ultimately prove to
−Removed: be less favorable to investors in our initial public offering than a direct investment, if an opportunity were available, in an initial
−Removed: business combination candidate.
−Removed: In the event we elect to pursue a business combination outside of the areas of our management’s
−Removed: expertise, our management’s expertise may not be directly applicable to its evaluation or operation, and the information contained
−Removed: in this annual report regarding the areas of our management’s expertise would not be relevant to an understanding of the business
−Removed: that we elect to acquire.
−Removed: As a result, our management may not be able to adequately ascertain or assess all of the significant risk factors.
−Removed: Accordingly, any stockholders who choose to remain stockholders following our initial business combination could suffer a reduction in
−Removed: the value of their shares.
−Removed: Such stockholders are unlikely to have a remedy for such reduction in value.
−Removed: we have identified general criteria and guidelines that we believe are important in evaluating prospective target businesses, we may
−Removed: enter into our initial business combination with a target that does not meet such criteria and guidelines, and as a result, the target
−Removed: business with which we enter into our initial business combination may not have attributes entirely consistent with our general criteria
−Removed: and guidelines.
−Removed: we have identified general criteria and guidelines for evaluating prospective target businesses, it is possible that a target business
−Removed: with which we enter into our initial business combination will not have all of these positive attributes.
−Removed: If we complete our initial
−Removed: business combination with a target that does not meet some or all of these guidelines, such combination may not be as successful as a
−Removed: combination with a business that does meet all of our general criteria and guidelines.
−Removed: In addition, if we announce a prospective business
−Removed: combination with a target that does not meet our general criteria and guidelines, a greater number of stockholders may exercise their
−Removed: redemption rights, which may make it difficult for us to meet any closing condition with a target business that requires us to have a
−Removed: minimum net worth or a certain amount of cash.
−Removed: In addition, if stockholder approval of the transaction is required by applicable law
−Removed: or stock exchange requirements, or we decide to obtain stockholder approval for business or other legal reasons, it may be more difficult
−Removed: for us to attain stockholder approval of our initial business combination if the target business does not meet our general criteria and
−Removed: If we are unable to complete our initial business combination, our public stockholders may receive only approximately $11.05
−Removed: per share, assuming our sponsor makes the Maximum Contribution and less any tax obligations, on the liquidation of our Trust Account
−Removed: and our warrants will expire worthless.
−Removed: In certain circumstances, our public stockholders may receive less than approximately $11.05
−Removed: per share on the redemption of their shares.
−Removed: See “— If third parties bring claims against us, the proceeds held in the Trust
−Removed: Account could be reduced and the per-share redemption amount received by stockholders may be less than approximately $11.05 per share”
−Removed: and other risk factors herein.
−Removed: may seek business combination opportunities with a financially unstable business or an entity lacking an established record of revenue,
−Removed: cash flow or earnings, which could subject us to volatile revenues, cash flows or earnings or difficulty in retaining key personnel.
−Removed: the extent we complete our initial business combination with a financially unstable business or an entity lacking an established record
−Removed: of revenues or earnings, we may be affected by numerous risks inherent in the operations of the business with which we combine.
−Removed: risks include volatile revenues or earnings and difficulties in obtaining and retaining key personnel.
−Removed: Although our officers and directors
−Removed: will endeavor to evaluate the risks inherent in a particular target business, we may not be able to properly ascertain or assess all
−Removed: of the significant risk factors and we may not have adequate time to complete due diligence.
−Removed: Furthermore, some of these risks may be
−Removed: outside of our control and leave us with no ability to control or reduce the chances that those risks will adversely impact a target
−Removed: are not required to obtain a fairness opinion and consequently, you may have no assurance from an independent source that the price we
−Removed: are paying for the business is fair to our company from a financial point of view.
−Removed: we complete our initial business combination with an entity affiliated with the representative, our sponsor, directors or officers, or
−Removed: our board cannot independently determine the fair market value of the target business or businesses, we are not required to obtain an
−Removed: opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions that the price
−Removed: we are paying is fair to our company from a financial point of view.
−Removed: If no opinion is obtained, our stockholders will be relying on the
−Removed: judgment of our board of directors, who will determine fair market value based on standards generally accepted by the financial community.
−Removed: Such standards used will be disclosed in our proxy materials or tender offer documents, as applicable, related to our initial business
−Removed: conflict of interest may arise if we seek an initial business combination with an entity that is also an acquisition target of our sponsor’s
−Removed: corporate parent, Presidio Property Trust, Inc.
−Removed: sponsor’s corporate parent, Presidio Property Trust, Inc., is also engaged in the real estate business, and is not formally constrained
−Removed: in any way from pursuing acquisitions or business combinations that could be suitable transactions for the Company.
−Removed: We do not believe
−Removed: it is likely that Presidio Property Trust, Inc.
−Removed: will compete against the Company for suitable acquisition targets based upon our management’s
−Removed: understanding of Presidio Property Trust, Inc.
−Removed: current business model.
−Removed: Nevertheless, it is possible that a potential business combination
−Removed: could arise that would be suitable for both the Company and Presidio Property Trust, Inc., giving rise to a conflict of interest.
−Removed: such a circumstance were to occur, we anticipate that the board of directors would recuse any conflicted members of our management from
−Removed: taking any role in the consideration of such a transaction and, to the extent necessary, retain appropriately qualified, non-conflicted
−Removed: personnel to advise us in accordance with the provisions of our certificate of incorporation relating to transactions with affiliates
−Removed: and our conflict of interest policy.
−Removed: could be wasted in researching business combinations that are not completed, which could materially adversely affect subsequent attempts
−Removed: to locate and acquire or merge with another business.
−Removed: If we are unable to complete our initial business combination, our public stockholders
−Removed: may receive only approximately $11.05 per share, or less than such amount in certain circumstances, on the liquidation of our Trust Account
−Removed: and our warrants will expire worthless.
−Removed: anticipate that the investigation of each specific target business and the negotiation, drafting and execution of relevant agreements,
−Removed: disclosure documents and other instruments will require substantial management time and attention and substantial costs for accountants,
−Removed: attorneys, consultants and others.
−Removed: If we decide not to complete a specific initial business combination, the costs incurred up to that
−Removed: point for the proposed transaction likely would not be recoverable.
−Removed: Furthermore, if we reach an agreement relating to a specific target
−Removed: business, we may fail to complete our initial business combination for any number of reasons including those beyond our control.
−Removed: such event will result in a loss to us of the related costs incurred which could materially adversely affect subsequent attempts to locate
−Removed: and acquire or merge with another business.
−Removed: If we are unable to complete our initial business combination, our public stockholders may
−Removed: receive only approximately $11.05 per share, assuming our sponsor makes the Maximum Contribution and less any tax obligations, on the
−Removed: liquidation of our Trust Account and our warrants will expire worthless.
−Removed: In certain circumstances, our public stockholders may receive
−Removed: less than approximately $11.05 per share on the redemption of their shares.
−Removed: See “— If third parties bring claims against
−Removed: us, the proceeds held in the Trust Account could be reduced and the per-share redemption amount received by stockholders may be less
−Removed: than approximately $11.05 per share” and other risk factors herein.
−Removed: may issue notes or other debt securities, or otherwise incur substantial debt, to complete an initial business combination, which may
−Removed: adversely affect our leverage and financial condition and thus negatively impact the value of our stockholders’ investment in us.
−Removed: we have no commitments as of the date of this annual report to issue any notes or other debt securities, or to otherwise incur outstanding
−Removed: debt following our initial public offering, we may choose to incur substantial debt to complete our initial business combination.
−Removed: have agreed that we will not incur any indebtedness unless we have obtained from the lender a waiver of any right, title, interest or
−Removed: claim of any kind in or to the monies held in the Trust Account.
−Removed: As such, no issuance of debt will affect the per-share amount available
−Removed: for redemption from the Trust Account.
−Removed: Nevertheless, the incurrence of debt could have a variety of negative effects, including:
−Removed: and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt
−Removed: of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants
−Removed: that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;
−Removed: immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;
−Removed: inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such
−Removed: financing while the debt security is outstanding;
−Removed: inability to pay dividends on our Class A common stock;
−Removed: a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends
−Removed: on our Class A common stock if declared, our ability to pay expenses, make capital expenditures and acquisitions, and fund other
−Removed: general corporate purposes;
−Removed: on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;
−Removed: vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;
−Removed: on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, and execution
−Removed: of our strategy;
−Removed: disadvantages compared to our competitors who have less debt.
−Removed: may only be able to complete one business combination with the proceeds of our initial public offering, the sale of the placement units,
−Removed: which will cause us to be solely dependent on a single business which may have a limited number of services and limited operating activities.
−Removed: This lack of diversification may negatively impact our operating results and profitability.
−Removed: the net proceeds from our initial public offering and the sale of the placement units, and after redemptions in February 2023, approximately
−Removed: $23 million will be available to complete our initial business combination and pay related fees and expenses.
−Removed: may effectuate our initial business combination with a single target business or multiple target businesses simultaneously or within
−Removed: a short period of time.
−Removed: However, we may not be able to effectuate our initial business combination with more than one target business
−Removed: because of various factors, including the existence of complex accounting issues and the requirement that we prepare and file pro forma
−Removed: financial statements with the SEC that present operating results and the financial condition of several target businesses as if they
−Removed: had been operated on a combined basis.
−Removed: By completing our initial business combination with only a single entity, our lack of diversification
−Removed: may subject us to numerous economic, competitive and regulatory developments.
−Removed: Further, we would not be able to diversify our operations
−Removed: or benefit from the possible spreading of risks or offsetting of losses, unlike other entities which may have the resources to complete
−Removed: several business combinations in different industries or different areas of a single industry.
−Removed: In addition, we intend to focus our search
−Removed: for an initial business combination in a single industry.
−Removed: Accordingly, the prospects for our success may be:
−Removed: dependent upon the performance of a single business, property or asset, or
−Removed: upon the development or market acceptance of a single or limited number of products, processes or services.
−Removed: lack of diversification may subject us to numerous economic, competitive and regulatory risks, any or all of which may have a substantial
−Removed: adverse impact upon the particular industry in which we may operate subsequent to our initial business combination.
−Removed: may attempt to simultaneously complete business combinations with multiple prospective targets, which may hinder our ability to complete
−Removed: our initial business combination and give rise to increased costs and risks that could negatively impact our operations and profitability.
−Removed: we determine to simultaneously acquire several businesses that are owned by different sellers, we will need for each of such sellers
−Removed: to agree that our purchase of its business is contingent on the simultaneous closings of the other business combinations, which may make
−Removed: it more difficult for us, and delay our ability, to complete our initial business combination.
−Removed: We do not, however, intend to purchase
−Removed: multiple businesses in unrelated industries in conjunction with our initial business combination.
−Removed: With multiple business combinations,
−Removed: we could also face additional risks, including additional burdens and costs with respect to possible multiple negotiations and due diligence
−Removed: investigations (if there are multiple sellers) and the additional risks associated with the subsequent assimilation of the operations
−Removed: and services or products of the acquired companies in a single operating business.
−Removed: If we are unable to adequately address these risks,
−Removed: it could negatively impact our profitability and results of operations.
−Removed: may attempt to complete our initial business combination with a private company about which little information is available, which may
−Removed: result in an initial business combination with a company that is not as profitable as we suspected, if at all.
−Removed: pursuing our initial business combination strategy, we may seek to effectuate our initial business combination with a privately held
−Removed: Very little public information generally exists about private companies, and we could be required to make our decision on whether
−Removed: to pursue a potential initial business combination on the basis of limited information, which may result in an initial business combination
−Removed: with a company that is not as profitable as we suspected, if at all.
−Removed: management may not be able to maintain control of a target business after our initial business combination.
−Removed: may structure an initial business combination so that the post-transaction company in which our public stockholders own shares will own
−Removed: less than 100% of the equity interests or assets of a target business, but we will only complete such business combination if the post-transaction
−Removed: company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest
−Removed: in the target sufficient for us not to be required to register as an investment company under the Investment Company Act.
−Removed: consider any transaction that does not meet such criteria.
−Removed: Even if the post-transaction company owns 50% or more of the voting securities
−Removed: of the target, our stockholders prior to the initial business combination may collectively own a minority interest in the post business
−Removed: combination company, depending on valuations ascribed to the target and us in the initial business combination.
−Removed: For example, we could
−Removed: pursue a transaction in which we issue a substantial number of new shares of Class A common stock in exchange for all of the outstanding
−Removed: capital stock of a target.
−Removed: In this case, we would acquire a 100% interest in the target.
−Removed: However, as a result of the issuance of a substantial
−Removed: number of new shares of Class A common stock, our stockholders immediately prior to such transaction could own less than a majority of
−Removed: our outstanding shares of common stock subsequent to such transaction.
−Removed: In addition, other minority stockholders may subsequently combine
−Removed: their holdings resulting in a single person or group obtaining a larger share of the company’s stock than we initially acquired.
−Removed: Accordingly, this may make it more likely that our management will not be able to maintain our control of the target business.
−Removed: provide assurance that, upon loss of control of a target business, new management will possess the skills, qualifications or abilities
−Removed: necessary to profitably operate such business.
−Removed: do not have a specified maximum redemption threshold.
−Removed: The absence of such a redemption threshold may make it possible for us to complete
−Removed: an initial business combination with which a substantial majority of our stockholders do not agree.
−Removed: certificate of incorporation will not provide a specified maximum redemption threshold.
−Removed: As a result, we may be able to complete our initial
−Removed: business combination even though a substantial majority of our public stockholders do not agree with the transaction and have redeemed
−Removed: their shares or, if we seek stockholder approval of our initial business combination and do not conduct redemptions in connection with
−Removed: our initial business combination pursuant to the tender offer rules, have entered into privately negotiated agreements to sell their
−Removed: shares to our sponsor, officers, directors or their affiliates.
−Removed: In the event the aggregate cash consideration we would be required to
−Removed: pay for all shares of common stock that are validly submitted for redemption plus any amount required to satisfy cash conditions pursuant
−Removed: to the terms of the proposed initial business combination exceed the aggregate amount of cash available to us, we will not complete the
−Removed: initial business combination or redeem any shares, all shares of common stock submitted for redemption will be returned to the holders
−Removed: thereof, and we instead may search for an alternate business combination.
−Removed: order to effectuate an initial business combination, blank check companies have, in the recent past, amended various provisions of their
−Removed: charters and other governing instruments, including their warrant agreements.
−Removed: We cannot assure you that we will not seek to amend our
−Removed: certificate of incorporation or governing instruments in a manner that will make it easier for us to complete our initial business combination
−Removed: that our stockholders may not support.
−Removed: order to effectuate an initial business combination, blank check companies have, in the recent past, amended various provisions of their
−Removed: charters and modified governing instruments, including their warrant agreements.
−Removed: For example, blank check companies have amended the
−Removed: definition of business combination, increased redemption thresholds and extended the time to consummate an initial business combination
−Removed: and, with respect to their warrants, amended their warrant agreements to require the warrants to be exchanged for cash and/or other securities.
−Removed: Amending our certificate of incorporation will require the approval of holders of 65% of our common stock, and amending our warrant agreement
−Removed: will require a vote of holders of at least a majority of the public warrants (which may include public warrants acquired by our sponsor
−Removed: or its affiliates in our initial public offering or thereafter in the open market).
−Removed: In addition, our certificate of incorporation requires
−Removed: us to provide our public stockholders with the opportunity to redeem their public shares for cash if we propose an amendment to our certificate
−Removed: of incorporation (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business
−Removed: combination or certain amendments to our charter prior thereto or to redeem 100% of our public shares if we do not complete our initial
−Removed: business combination within 12 months from the consummation of our initial public offering (or up to February 7, 2024 at the election
−Removed: of the Company subject to satisfaction of certain conditions) or (B) with respect to any other provision relating to stockholders’
−Removed: rights or pre-initial business combination activity.
−Removed: the extent any such amendments would be deemed to fundamentally change the nature of any securities offered through this registration
−Removed: statement, we would register, or seek an exemption from registration for, the affected securities.
−Removed: We cannot assure you that we will
−Removed: not seek to amend our charter or governing instruments or extend the time to consummate an initial business combination in order to effectuate
−Removed: our initial business combination.
−Removed: provisions of our certificate of incorporation that relate to our pre-business combination activity (and corresponding provisions of
−Removed: the agreement governing the release of funds from our Trust Account), including an amendment to permit us to withdraw funds from the
−Removed: Trust Account such that the per share amount investors will receive upon any redemption or liquidation is substantially reduced or eliminated,
−Removed: may be amended with the approval of holders of at least 65% of our common stock, which is a lower amendment threshold than that of some
−Removed: other blank check companies.
−Removed: It may be easier for us, therefore, to amend our certificate of incorporation and the trust agreement to
−Removed: facilitate the completion of an initial business combination that some of our stockholders may not support.
−Removed: certificate of incorporation provides that any of its provisions related to pre-initial business combination activity (including the
−Removed: requirement to deposit proceeds of our initial public offering and the sale of the placement units into the Trust Account and not release
−Removed: such amounts except in specified circumstances, and to provide redemption rights to public stockholders as described herein and including
−Removed: to permit us to withdraw funds from the Trust Account such that the per share amount investors will receive upon any redemption or liquidation
−Removed: is substantially reduced or eliminated) may be amended if approved by holders of at least 65% of our common stock entitled to vote thereon,
−Removed: and corresponding provisions of the trust agreement governing the release of funds from our Trust Account may be amended if approved
−Removed: by holders of at least 65% of our common stock entitled to vote thereon.
−Removed: In all other instances, our certificate of incorporation may
−Removed: be amended by holders of a majority of our outstanding common stock entitled to vote thereon, subject to applicable provisions of the
−Removed: DGCL or applicable stock exchange rules.
−Removed: We may not issue additional securities that can vote on amendments to our certificate of incorporation.
−Removed: Our sponsor, which owns approximately 65% of our common stock, will participate in any vote to amend our certificate of incorporation
−Removed: and/or trust agreement and will have the discretion to vote in any manner they choose.
−Removed: As a result, we may be able to amend the provisions
−Removed: of our certificate of incorporation which govern our pre-initial business combination behavior more easily than some other blank check
−Removed: companies, and this may increase our ability to complete an initial business combination with which you do not agree.
−Removed: Our stockholders
−Removed: may pursue remedies against us for any breach of our certificate of incorporation.
−Removed: sponsor, officers and directors will agree, pursuant to a written agreement with us, that they will not propose any amendment to our
−Removed: certificate of incorporation (i) to modify the substance or timing of our obligation to allow redemption in connection with our initial
−Removed: business combination or certain amendments to our charter prior thereto or to redeem 100% of our public shares if we do not complete
−Removed: our initial business combination within 12 months from the consummation of our initial public offering (or up to February 7, 2024 at
−Removed: the election of the Company subject to satisfaction of certain conditions) or (ii) with respect to any other provision relating to stockholders’
−Removed: rights or pre-initial business combination activity, unless we provide our public stockholders with the opportunity to redeem their shares
−Removed: of common stock upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit
−Removed: in the Trust Account, divided by the number of then outstanding public shares.
−Removed: These agreements are contained in a letter agreement that
−Removed: we will enter into with our sponsor, officers and directors.
−Removed: Our stockholders are not parties to, or third-party beneficiaries of, these
−Removed: agreements and, as a result, will not have the ability to pursue remedies against our sponsor, officers or directors for any breach of
−Removed: these agreements.
−Removed: As a result, in the event of a breach, our stockholders would need to pursue a stockholder derivative action, subject
−Removed: to applicable law.
−Removed: letter agreement with our sponsor, directors, director nominees and officers may be amended without stockholder approval.
−Removed: letter agreement with our sponsor, directors, director nominees and officers contains provisions relating to transfer restrictions of
−Removed: our founder shares and placement units, indemnification of the Trust Account, waiver of redemption rights and participation in liquidation
−Removed: distributions from the Trust Account.
−Removed: This letter agreement may be amended without stockholder approval (although releasing the parties
−Removed: from the restriction not to transfer our founder shares for a period of six months following the date we complete our initial business
−Removed: combination except in certain circumstances will require the prior written consent of the underwriters).
−Removed: While we do not expect our board
−Removed: to approve an amendment to the letter agreement prior to our initial business combination, it may be possible that our board, in exercising
−Removed: its business judgment and subject to its fiduciary duties, chooses to approve one or more amendments to this agreement.
−Removed: Any such amendments
−Removed: to the letter agreement would not require approval from our stockholders and may have an adverse effect on the value of an investment
−Removed: in our securities.
−Removed: may be unable to obtain additional financing to complete our initial business combination or to fund the operations and growth of a target
−Removed: business, which could compel us to restructure or abandon a particular business combination.
−Removed: have not selected any specific business combination target, but intend to target businesses larger than we could acquire with the net
−Removed: proceeds of our initial public offering and the sale of the placement units.
−Removed: As a result, we may be required to seek additional financing
−Removed: to complete such proposed initial business combination.
−Removed: We cannot assure you that such financing will be available on acceptable terms,
−Removed: To the extent that additional financing proves to be unavailable when needed to complete our initial business combination,
−Removed: we would be compelled to either restructure the transaction or abandon that particular business combination and seek an alternative target
−Removed: business candidate.
−Removed: Further, the amount of additional financing we may be required to obtain could increase as a result of future growth
−Removed: capital needs for any particular transaction, the depletion of the available net proceeds in search of a target business, the obligation
−Removed: to repurchase for cash a significant number of shares from stockholders who elect redemption in connection with our initial business
−Removed: combination and/or the terms of negotiated transactions to purchase shares in connection with our initial business combination.
−Removed: are unable to complete our initial business combination, our public stockholders may receive only approximately $11.05 per share, assuming
−Removed: the sponsor makes the Maximum Contribution and less any tax obligations, plus any pro rata interest earned on the funds held in the Trust
−Removed: Account and not previously released to us to pay our taxes on the liquidation of our Trust Account and our warrants will expire worthless.
−Removed: In addition, even if we do not need additional financing to complete our initial business combination, we may require such financing
−Removed: to fund the operations or growth of the target business.
−Removed: The failure to secure additional financing could have a material adverse effect
−Removed: on the continued development or growth of the target business.
−Removed: None of our officers, directors or stockholders is required to provide
−Removed: any financing to us in connection with or after our initial business combination.
−Removed: If we are unable to complete our initial business combination,
−Removed: our public stockholders may only receive approximately $11.05 per share on the liquidation of our Trust Account, assuming the sponsor
−Removed: makes the Maximum Contribution and less any tax obligations, and our warrants will expire worthless.
−Removed: Furthermore, as described in the
−Removed: risk factor entitled “If third parties bring claims against us, the proceeds held in the Trust Account could be reduced and the
−Removed: per-share redemption amount received by stockholders may be less than approximately $11.05 per share,” under certain circumstances
−Removed: our public stockholders may receive less than approximately $11.05 per share upon the liquidation of the Trust Account.
−Removed: initial stockholders may exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not
−Removed: sponsor owns shares representing approximately 23% of our issued and outstanding shares of common stock.
−Removed: Accordingly, it may exert a
−Removed: substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not support, including amendments
−Removed: to our certificate of incorporation and approval of major corporate transactions.
−Removed: If our sponsor purchases any additional shares of common
−Removed: stock in the open market or in privately negotiated transactions, this would increase its control.
−Removed: Factors that would be considered in
−Removed: making such additional purchases would include consideration of the current trading price of our common stock.
−Removed: Additionally, we may not
−Removed: hold an annual meeting of stockholders to elect new directors prior to the completion of our initial business combination, in which case
−Removed: all of the current directors will continue in office until at least the completion of the initial business combination.
−Removed: our sponsor will continue to exert control at least until the completion of our initial business combination.
−Removed: sponsor paid an aggregate of $25,000 for the founder shares, or approximately $0.008 per founder share.
−Removed: As a result of this low initial
−Removed: price, our sponsor and our management team stand to make a substantial profit even if an initial business combination subsequently declines
−Removed: in value or is unprofitable for our public stockholders.
−Removed: a result of the low acquisition cost of our founder shares, our sponsor, its affiliates and our management team could make a substantial
−Removed: profit even if we select and consummate an initial business combination with an acquisition target that subsequently declines in value
−Removed: or is unprofitable for our public stockholders.
−Removed: Thus, such parties may have more of an economic incentive for us to enter into an initial
−Removed: business combination with a riskier, weaker-performing or financially unstable business, or an entity lacking an established record of
−Removed: revenues or earnings, than would be the case if such parties had paid the full offering price for their founder shares.
−Removed: we must furnish our stockholders with target business financial statements, we may lose the ability to complete an otherwise advantageous
−Removed: initial business combination with some prospective target businesses.
−Removed: federal proxy rules require that a proxy statement with respect to a vote on an initial business combination meeting certain financial
−Removed: significance tests include historical and/or pro forma financial statement disclosure in periodic reports.
−Removed: We will include the same financial
−Removed: statement disclosure in connection with our tender offer documents, whether or not they are required under the tender offer rules.
−Removed: financial statements may be required to be prepared in accordance with, or be reconciled to, accounting principles generally accepted
−Removed: in the United States of America, or GAAP, or international financial reporting standards as issued by the International Accounting Standards
−Removed: Board, or IFRS, depending on the circumstances and the historical financial statements may be required to be audited in accordance with
−Removed: the standards of the Public Company Accounting Oversight Board (United States), or PCAOB.
−Removed: These financial statement requirements may
−Removed: limit the pool of potential target businesses we may acquire because some targets may be unable to provide such financial statements
−Removed: in time for us to disclose such statements in accordance with federal proxy rules and complete our initial business combination within
−Removed: the prescribed time frame.
−Removed: in the market for directors and officers liability insurance could make it more difficult and more expensive for us to negotiate and
−Removed: complete an initial business combination.
−Removed: recent months, the market for directors and officers liability insurance for special purpose acquisition companies has changed.
−Removed: insurance companies are offering quotes for directors and officers liability coverage, the premiums charged for such policies have generally
−Removed: increased and the terms of such policies have generally become less favorable.
−Removed: There can be no assurance that these trends will not continue.
−Removed: increased cost and decreased availability of directors and officers liability insurance could make it more difficult and more expensive
−Removed: for us to negotiate an initial business combination.
−Removed: In order to obtain directors and officers liability insurance or modify its coverage
−Removed: as a result of becoming a public company, the post-business combination entity might need to incur greater expense, accept less favorable
−Removed: terms or both.
−Removed: However, any failure to obtain adequate directors and officers liability insurance could have an adverse impact on the
−Removed: post-business combination’s ability to attract and retain qualified officers and directors.
−Removed: addition, even after we complete an initial business combination, our directors and officers could still be subject to potential liability
−Removed: from claims arising from conduct alleged to have occurred prior to the initial business combination.
−Removed: As a result, in order to protect
−Removed: our directors and officers, the post-business combination entity may need to purchase additional insurance with respect to any such claims
−Removed: (“run-off insurance”).
−Removed: The need for run-off insurance would be an added expense for the post-business combination entity,
−Removed: and could interfere with or frustrate our ability to consummate an initial business combination on terms favorable to our investors.
−Removed: the number of special purpose acquisition companies evaluating targets increases, attractive targets may become scarcer and there may
−Removed: be more competition for attractive targets.
−Removed: This could increase the cost of our initial business combination and could even result in
−Removed: our inability to find a target or to consummate an initial business combination.
−Removed: recent years, the number of special purpose acquisition companies that have been formed has increased substantially.
−Removed: Many potential targets
−Removed: for special purpose acquisition companies have already entered into an initial business combination, and there are still many special
−Removed: purpose acquisition companies seeking targets for their initial business combination, as well as many such companies currently in registration.
−Removed: As a result, at times, fewer attractive targets may be available, and it may require more time, more effort and more resources to identify
−Removed: a suitable target and to consummate an initial business combination.
−Removed: addition, because there are more special purpose acquisition companies seeking to enter into an initial business combination with available
−Removed: targets, the competition for available targets with attractive fundamentals or business models may increase, which could cause target
−Removed: companies to demand improved financial terms.
−Removed: Attractive deals could also become scarcer for other reasons, such as economic or industry
−Removed: sector downturns, geopolitical tensions, or increases in the cost of additional capital needed to close business combinations or operate
−Removed: targets post-business combination.
−Removed: This could increase the cost of, delay or otherwise complicate or frustrate our ability to find and
−Removed: consummate an initial business combination, and may result in our inability to consummate an initial business combination on terms favorable
−Removed: to our investors altogether.
−Removed: obligations under the Sarbanes-Oxley Act may make it more difficult for us to effectuate our initial business combination, require substantial
−Removed: financial and management resources, and increase the time and costs of completing an initial business combination.
−Removed: 404 of the Sarbanes-Oxley Act requires that we evaluate and report on our system of internal controls beginning with our Annual Report
−Removed: on Form 10-K for the year ending December 31, 2022.
−Removed: Only in the event we are deemed to be a large accelerated filer or an accelerated
−Removed: filer, and no longer qualify as an emerging growth company, will we be required to comply with the independent registered public accounting
−Removed: firm attestation requirement on our internal control over financial reporting.
−Removed: Further, for as long as we remain an emerging growth company,
−Removed: we will not be required to comply with the independent registered public accounting firm attestation requirement on our internal control
−Removed: over financial reporting.
−Removed: The fact that we are a blank check company makes compliance with the requirements of the Sarbanes-Oxley Act
−Removed: particularly burdensome on us as compared to other public companies because a target company with which we seek to complete our initial
−Removed: business combination may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy of its internal controls.
−Removed: The development of the internal control of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the time and
−Removed: costs necessary to complete any such business combination.
−Removed: only opportunity to affect the investment decision regarding a potential business combination will be limited to the exercise of your
−Removed: right to redeem your shares from us for cash, unless we seek stockholder approval of the initial business combination.
−Removed: the time of your investment in us, you will not be provided with an opportunity to evaluate the specific merits or risks of our initial
−Removed: business combination.
−Removed: Since our board of directors may complete an initial business combination without seeking stockholder approval,
−Removed: public stockholders may not have the right or opportunity to vote on the initial business combination, unless we seek such stockholder
−Removed: Accordingly, if we do not seek stockholder approval, your only opportunity to affect the investment decision regarding a potential
−Removed: business combination may be limited to exercising your redemption rights within the period of time (which will be at least 20 business
−Removed: days) set forth in our tender offer documents mailed to our public stockholders in which we describe our initial business combination.
−Removed: may not be able to complete our initial business combination within the prescribed time frame, in which case we would cease all operations
−Removed: except for the purpose of winding up and we would redeem our public shares and liquidate, in which case our public stockholders may only
−Removed: receive approximately $11.05 per share, or less than such amount in certain circumstances, and our warrants will expire worthless.
−Removed: certificate of incorporation provides that we must complete our initial business combination within 12 months from the consummation of
−Removed: our initial public offering (or up to February 7, 2024 at the election of the Company subject to satisfaction of certain conditions).
−Removed: We may not be able to find a suitable target business and complete our initial business combination within such time period.
−Removed: to complete our initial business combination may be negatively impacted by general market conditions, volatility in the capital and debt
−Removed: markets and the other risks described herein.
−Removed: For example, the conflict between Russia and Ukraine could lead to disruption, instability
−Removed: and volatility in global markets and industries.
−Removed: Further, if the outbreak of COVID-19 continues to grow both in the U.S.
−Removed: and, while the extent of the impact of the outbreak on us will depend on future developments, it could limit our ability to complete
−Removed: our initial business combination, including as a result of increased market volatility, decreased market liquidity and third-party financing
−Removed: being unavailable on terms acceptable to us or at all.
−Removed: Additionally, the outbreak of COVID-19 may negatively impact businesses we may
−Removed: seek to acquire.
−Removed: we have not completed our initial business combination within such time period, we will:
−Removed: (i) cease all operations except for the purpose
−Removed: of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a
−Removed: per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the
−Removed: funds held in the Trust Account and not previously released to us to pay our taxes (less up to $100,000 of interest to pay dissolution
−Removed: expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’
−Removed: rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)
−Removed: as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of
−Removed: directors, dissolve and liquidate, subject in the case of clauses (ii) and (iii) above to our obligations under Delaware law to provide
−Removed: for claims of creditors and the requirements of other applicable law.
−Removed: In such case, our public stockholders may only receive approximately
−Removed: $11.05 per share, assuming our sponsor makes the Maximum Contribution and less any tax obligations, and our warrants will expire worthless.
−Removed: In certain circumstances, our public stockholders may receive less than approximately $11.05 per share on the redemption of their shares.
−Removed: See “— If third parties bring claims against us, the proceeds held in the Trust Account could be reduced and the per-share
−Removed: redemption amount received by stockholders may be less than approximately $11.05 per share” and other risk factors below.
−Removed: we seek stockholder approval of our initial business combination, our sponsor, directors, officers and their affiliates may elect to
−Removed: purchase shares or warrants from public stockholders, which may influence a vote on a proposed initial business combination and reduce
−Removed: the public “float” of our Class A common stock.
−Removed: we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business
−Removed: combination pursuant to the tender offer rules, our sponsor, directors, officers or their affiliates may purchase public shares or public
−Removed: warrants or a combination thereof in privately negotiated transactions or in the open market either prior to or following the completion
−Removed: of our initial business combination, although they are under no obligation to do so.
−Removed: However, they have no current commitments, plans
−Removed: or intentions to engage in such transactions and have not formulated any terms or conditions for any such transactions.
−Removed: None of the funds
−Removed: in the Trust Account will be used to purchase shares or public warrants in such transactions.
−Removed: a purchase may include a contractual acknowledgement that such stockholder, although still the record holder of our shares is no longer
−Removed: the beneficial owner thereof and therefore agrees not to exercise its redemption rights.
−Removed: In the event that our sponsor, directors, officers
−Removed: or their affiliates purchase shares in privately negotiated transactions from public stockholders who have already elected to exercise
−Removed: their redemption rights or submitted a proxy to vote against our initial business combination, such selling stockholders would be required
−Removed: to revoke their prior elections to redeem their shares and any proxy to vote against our initial business combination.
−Removed: The price per
−Removed: share paid in any such transaction may be different than the amount per share a public stockholder would receive if it elected to redeem
−Removed: its shares in connection with our initial business combination.
−Removed: The purpose of such purchases could be to vote such shares in favor of
−Removed: the initial business combination and thereby increase the likelihood of obtaining stockholder approval of the initial business combination,
−Removed: or to satisfy a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain amount of cash
−Removed: at the closing of our initial business combination, where it appears that such requirement would otherwise not be met.
−Removed: The purpose of
−Removed: any such purchases of public warrants could be to reduce the number of public warrants outstanding or to vote such warrants on any matters
−Removed: submitted to the warrant holders for approval in connection with our initial business combination.
−Removed: Any such purchases of our securities
−Removed: may result in the completion of our initial business combination that may not otherwise have been possible.
−Removed: We expect that any such purchases
−Removed: will be reported pursuant to Section 13 and Section 16 of the Exchange Act to the extent such purchasers are subject to such reporting
−Removed: requirements.
−Removed: addition, if such purchases are made, the public “float” of our Class A common stock or public warrants and the number of
−Removed: beneficial holders of our securities may be reduced, possibly making it difficult to obtain or maintain the quotation, listing or trading
−Removed: of our securities on a national securities exchange.
−Removed: a stockholder fails to receive notice of our offer to redeem our public shares in connection with our initial business combination, or
−Removed: fails to comply with the procedures for tendering its shares, such shares may not be redeemed.
−Removed: will comply with the tender offer rules or proxy rules, as applicable, when conducting redemptions in connection with our initial business
−Removed: Despite our compliance with these rules, if a stockholder fails to receive our tender offer or proxy materials, as applicable,
−Removed: such stockholder may not become aware of the opportunity to redeem its shares.
−Removed: In addition, proxy materials or tender offer documents,
−Removed: as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will describe
−Removed: the various procedures that must be complied with in order to validly tender or redeem public shares.
−Removed: For example, we may require our
−Removed: public stockholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in “street
−Removed: name,” to either deliver their stock certificates to our transfer agent prior to the date set forth in the tender offer documents
−Removed: mailed to such holders, or up to two business days prior to the vote on the proposal to approve the initial business combination in the
−Removed: event we distribute proxy materials, or to deliver their shares to the transfer agent electronically.
−Removed: In the event that a stockholder
−Removed: fails to comply with these or any other procedures disclosed in the proxy or tender offer materials, as applicable, its shares may not
−Removed: will not have any rights or interests in funds from the Trust Account, except under certain limited circumstances.
−Removed: To liquidate your
−Removed: investment, therefore, you may be forced to sell your public shares or warrants, potentially at a loss.
−Removed: public stockholders will be entitled to receive funds from the Trust Account only upon the earliest to occur of:
−Removed: (i) our completion of
−Removed: an initial business combination, and then only in connection with those shares of common stock that such stockholder properly elected
−Removed: to redeem, subject to the limitations described herein, (ii) the redemption of any public shares properly submitted in connection with
−Removed: a stockholder vote to amend our certificate of incorporation (A) to modify the substance or timing of our obligation to allow redemption
−Removed: in connection with our initial business combination or certain amendments to our charter prior thereto or to redeem 100% of our public
−Removed: shares if we do not complete our initial business combination within 12 months from the consummation of our initial public offering (or
−Removed: up to February 7, 2024 at the election of the Company subject to satisfaction of certain conditions) or (B) with respect to any other
−Removed: provision relating to stockholders’ rights or pre-initial business combination activity and (iii) the redemption of our public
−Removed: shares if we are unable to complete an initial business combination within 12 months from the consummation of our initial public offering
−Removed: (or up to February 7, 2024 at the election of the Company subject to satisfaction of certain conditions), subject to applicable law and
−Removed: as further described herein.
−Removed: In no other circumstances will a public stockholder have any right or interest of any kind in the Trust
−Removed: Holders of warrants will not have any right to the proceeds held in the Trust Account with respect to the warrants.
−Removed: to liquidate your investment, you may be forced to sell your public shares or warrants, potentially at a loss.
−Removed: we effect our initial business combination with a company with operations or opportunities outside of the United States, we would be
−Removed: subject to a variety of additional risks that may negatively impact our operations.
−Removed: we effect our initial business combination with a company with operations or opportunities outside of the United States, we would be
−Removed: subject to any special considerations or risks associated with companies operating in an international setting, including any of the
−Removed: costs and difficulties inherent in managing cross-border business operations and complying with different commercial and legal requirements
−Removed: of overseas markets;
−Removed: and regulations regarding currency redemption;
−Removed: corporate withholding taxes on individuals;
−Removed: governing the manner in which future business combinations may be effected;
−Removed: and trade barriers;
−Removed: related to customs and import/export matters;
−Removed: payment cycles and challenges in collecting accounts receivable;
−Removed: issues, including but not limited to tax law changes and variations in tax laws as compared to the United States;
−Removed: fluctuations and exchange controls;
−Removed: of inflation;
−Removed: and language differences;
−Removed: strikes, riots, civil disturbances, terrorist attacks, natural disasters and wars;
−Removed: deterioration
−Removed: of political relations with the United States;
−Removed: appropriations of assets.
−Removed: may not be able to adequately address these additional risks.
−Removed: If we are unable to do so, our operations might suffer, which may adversely
−Removed: impact our results of operations and financial condition.
−Removed: our management team following our initial business combination is unfamiliar with United States securities laws, they may have to expend
−Removed: time and resources becoming familiar with such laws, which could lead to various regulatory issues.
−Removed: our initial business combination, our founding team may resign from their positions as officers or directors of the company and the management
−Removed: of the business combination partner may assume the roles of executive officers and directors of our company.
−Removed: Such officers and directors
−Removed: may not be familiar with United States securities laws.
−Removed: If our new management following our initial business combination is unfamiliar
−Removed: with United States securities laws, they may have to expend time and resources becoming familiar with such laws.
−Removed: This could be expensive
−Removed: and time-consuming and could lead to various regulatory issues which may adversely affect our operations.
−Removed: our initial business combination, substantially all of our assets may be located in a foreign country and substantially all of our revenue
−Removed: may be derived from our operations in such country.
−Removed: Accordingly, our results of operations and prospects will be subject, to a significant
−Removed: extent, to the economic, political and social conditions and government policies, developments and conditions in the country in which
−Removed: we may acquire a business or businesses located outside of the United States as part of our initial business combination, the economic,
−Removed: political and social conditions, as well as government policies, of the country in which our operations would be located following our
−Removed: initial business combination could affect our business.
−Removed: Economic growth could be uneven, both geographically and among various sectors
−Removed: of the economy and such growth may not be sustained in the future.
−Removed: If in the future such country’s economy experiences a downturn
−Removed: or grows at a slower rate than expected, there may be less demand for spending in certain industries.
−Removed: A decrease in demand for spending
−Removed: in certain industries could materially and adversely affect our ability to find an attractive target business with which to consummate
−Removed: our initial business combination and if we effect our initial business combination, the ability of that target business to become profitable.
−Removed: rate fluctuations and currency policies may cause our target business’ ability to succeed in the international markets to be diminished.
−Removed: the event we acquire a non-U.S.
−Removed: business as part of our initial business combination, all revenues and income would likely be received
−Removed: in a foreign currency, and the dollar equivalent of our net assets and distributions, if any, could be adversely affected by reductions
−Removed: in the value of the local currency.
−Removed: The value of the currencies in our target regions fluctuate and are affected by, among other things,
−Removed: changes in political and economic conditions.
−Removed: Any change in the relative value of such currency against our reporting currency may affect
−Removed: the attractiveness of any target business or, following consummation of our initial business combination, our financial condition and
−Removed: results of operations.
−Removed: Additionally, if a currency appreciates in value against the dollar prior to the consummation of our initial business
−Removed: combination, the cost of a target business as measured in dollars will increase, which may make it less likely that we are able to consummate
−Removed: such transaction.
−Removed: may reincorporate in another jurisdiction in connection with our initial business combination, and the laws of such jurisdiction may
−Removed: govern some or all of our future material agreements and we may not be able to enforce our legal rights.
−Removed: connection with our initial business combination, we may relocate the home jurisdiction of our business from the U.S.
−Removed: to another jurisdiction.
−Removed: If we determine to do this, the laws of such jurisdiction may govern some or all of our future material agreements.
−Removed: The system of laws
−Removed: and the enforcement of existing laws in such jurisdiction may not be as certain in implementation and interpretation as in the United
−Removed: The inability to enforce or obtain a remedy under any of our future agreements could result in a significant loss of business,
−Removed: business opportunities or capital.
−Removed: may be subject to the Excise Tax included in the Inflation Reduction Act of 2022 in the event of a liquidation or in connection with
−Removed: redemptions of our common stock after December 31, 2022.
−Removed: the Inflation Reduction Act of 2022 (the “IRA”), adding Section 4501 to the Internal Revenue Code, a domestic corporation
−Removed: whose stock is traded on an established securities market (a “covered corporation” under the IRA) is subject to an excise
−Removed: tax of 1% on repurchases (redemptions) of its stock after December 31, 2022 (the “Excise Tax”).
−Removed: Because we are a Delaware
−Removed: corporation and our securities trade on the Nasdaq, we are a “covered corporation” within the meaning of the IRA.
−Removed: IRA became law on August 16, 2022.
−Removed: On December 27, 2022, the Internal Revenue Service published Notice 2023-2, providing “Initial
−Removed: Guidance” regarding the application of the Excise Tax on repurchases of corporate stock under Section 4501.
−Removed: Under these authorities
−Removed: we expect the Excise Tax to be imposed on the fair market value of stock repurchased by us.
−Removed: Under a “netting rule”, the fair
−Removed: market value of stock repurchased by us may be reduced by the fair market value of securities issued by us in the same taxable year,
−Removed: with the 1% Excise Tax then imposed on the excess, if any, of the value of redemptions over the value of issuances.
−Removed: Therefore, issuances
−Removed: of stock by us in connection with our initial business combination transaction (including any PIPE transaction at the time of our initial
−Removed: business combination) will reduce the amount of the Excise Tax in connection with redemptions occurring in the same taxable year.
−Removed: a business combination may not be completed during 2023 and, even if a business combination is completed, the fair market value of the
−Removed: securities redeemed may exceed the fair market value of the securities issued in such a combination or otherwise.
−Removed: (The fair market value
−Removed: of securities that are redeemed is determined by the market price of the stock on the day of redemption, regardless of the actual redemption
−Removed: amount.) Consequently, the Excise Tax may make a transaction with us less appealing to potential business combination targets.
−Removed: while the authorities indicate that as a general rule the Excise Tax does not apply in the event of a complete liquidation of a covered
−Removed: corporation, the availability of this exemption under circumstances that might surround the liquidation of a SPAC is not entirely clear.
−Removed: excise tax returns are generally filed on a quarterly basis, the Internal Revenue Service expects to issue regulations providing that
−Removed: reports of Excise Tax liability are due with the first quarterly excise tax return filed after the close of the taxable year.
−Removed: for franchise taxes and income taxes, the proceeds placed in the trust account and the interest earned thereon shall not be used to pay
−Removed: for possible excise tax or any other fees or taxes that may be levied on the Company pursuant to any current, pending or future rules
−Removed: or laws, including without limitation any excise tax due under the IRA on any redemptions or stock buybacks by the Company (except in
−Removed: the case of proceeds that are delivered to the Company following a business combination).
−Removed: may be tax consequences to our business combinations that may adversely affect us.
−Removed: we expect to undertake any merger or acquisition so as to minimize taxes both to the acquired business and/or asset and us, such business
−Removed: combination might not meet the statutory requirements of a tax-free reorganization, or the parties might not obtain the intended tax-free
−Removed: treatment upon a transfer of shares or assets.
−Removed: A reorganization that does not qualify as tax-free could result in the imposition of substantial
−Removed: taxes on holders of our securities.
−Removed: Conduit Business Combination is subject to conditions, including certain conditions that may not be satisfied on a timely basis, if at
−Removed: completion of the Conduit Business Combination is subject to a number of conditions.
−Removed: The completion of the Conduit Business Combination
−Removed: is not assured and is subject to risks, including the risk that approval of the Conduit Business Combination by our stockholders is not
−Removed: obtained or that other closing conditions are not satisfied.
−Removed: If we does not complete the Conduit Business Combination, we could be subject
−Removed: to several risks, including:
−Removed: reactions from the financial markets, including declines in the price of our Class A common stock due to the fact that current prices
−Removed: may reflect a market assumption that the Conduit Business Combination will be completed;
−Removed: attention of our management will have been diverted to the Conduit Business Combination rather than the pursuit of other opportunities
−Removed: in respect of an initial business combination.
−Removed: Relating to our Sponsor and Management Team
−Removed: ability to successfully effect our initial business combination and to be successful thereafter will be totally dependent upon the efforts
−Removed: of our key personnel, some of whom may join us following our initial business combination.
−Removed: The loss of key personnel could negatively
−Removed: impact the operations and profitability of our post-combination business.
−Removed: ability to successfully effect our initial business combination is dependent upon the efforts of our key personnel.
−Removed: The role of our key
−Removed: personnel in the target business, however, cannot presently be ascertained.
−Removed: Although some of our key personnel may remain with the target
−Removed: business in senior management or advisory positions following our initial business combination, it is likely that some or all of the
−Removed: management of the target business will remain in place.
−Removed: While we intend to closely scrutinize any individuals we employ after our initial
−Removed: business combination, we cannot assure you that our assessment of these individuals will prove to be correct.
−Removed: These individuals may be
−Removed: unfamiliar with the requirements of operating a company regulated by the SEC, which could cause us to have to expend time and resources
−Removed: helping them become familiar with such requirements.
−Removed: In addition, the officers and directors of an initial business combination candidate
−Removed: may resign upon completion of our initial business combination.
−Removed: The departure of an initial business combination target’s key personnel
−Removed: could negatively impact the operations and profitability of our post-combination business.
−Removed: The role of an initial business combination
−Removed: candidate’s key personnel upon the completion of our initial business combination cannot be ascertained at this time.
−Removed: we contemplate that certain members of an initial business combination candidate’s management team will remain associated with
−Removed: the initial business combination candidate following our initial business combination, it is possible that members of the management
−Removed: of an initial business combination candidate will not wish to remain in place.
−Removed: The loss of key personnel could negatively impact the
−Removed: operations and profitability of our post-combination business.
−Removed: are dependent upon our executive officers and directors and their departure could adversely affect our ability to operate.
−Removed: operations are dependent upon a relatively small group of individuals and, in particular, our executive officers and directors.
−Removed: that our success depends on the continued service of our executive officers and directors, at least until we have completed our initial
−Removed: business combination.
−Removed: We do not have an employment agreement with, or key-man insurance on the life of, any of our directors or executive
−Removed: The unexpected loss of the services of one or more of our directors or executive officers could have a detrimental effect on
−Removed: key personnel may negotiate employment or consulting agreements with a target business in connection with a particular business combination.
−Removed: These agreements may provide for them to receive compensation following our initial business combination and as a result, may cause them
−Removed: to have conflicts of interest in determining whether a particular business combination is the most advantageous.
−Removed: key personnel may be able to remain with the company after the completion of our initial business combination only if they are able to
−Removed: negotiate employment or consulting agreements in connection with the initial business combination.
−Removed: Such negotiations would take place
−Removed: simultaneously with the negotiation of the initial business combination and could provide for such individuals to receive compensation
−Removed: in the form of cash payments and/or our securities for services they would render to us after the completion of the initial business
−Removed: The personal and financial interests of such individuals may influence their motivation in identifying and selecting a target
−Removed: However, we believe the ability of such individuals to remain with us after the completion of our initial business combination
−Removed: will not be the determining factor in our decision as to whether or not we will proceed with any potential business combination.
−Removed: is no certainty, however, that any of our key personnel will remain with us after the completion of our initial business combination.
−Removed: We cannot assure you that any of our key personnel will remain in senior management or advisory positions with us.
−Removed: The determination
−Removed: as to whether any of our key personnel will remain with us will be made at the time of the consummation of our initial business combination.
−Removed: may have a limited ability to assess the management of a prospective target business and, as a result, may effect our initial business
−Removed: combination with a target business whose management may not have the skills, qualifications or abilities to manage a public company,
−Removed: which could, in turn, negatively impact the value of our stockholders’ investment in us.
−Removed: evaluating the desirability of effecting our initial business combination with a prospective target business, our ability to assess the
−Removed: target business’s management may be limited due to a lack of time, resources or information.
−Removed: Our assessment of the capabilities
−Removed: of the target’s management, therefore, may prove to be incorrect and such management may lack the skills, qualifications or abilities
−Removed: we suspected.
−Removed: Should the target’s management not possess the skills, qualifications or abilities necessary to manage a public company,
−Removed: the operations and profitability of the post-combination business may be negatively impacted.
−Removed: Accordingly, any stockholders who choose
−Removed: to remain stockholders following the initial business combination could suffer a reduction in the value of their shares.
−Removed: Such stockholders
−Removed: are unlikely to have a remedy for such reduction in value.
−Removed: officers and directors will allocate their time to other businesses thereby causing conflicts of interest in their determination as to
−Removed: how much time to devote to our affairs.
−Removed: This conflict of interest could have a negative impact on our ability to complete our initial
−Removed: business combination.
−Removed: officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest
−Removed: in allocating their time between our operations and our search for an initial business combination and their other businesses.
−Removed: not intend to have any full-time employees prior to the completion of our initial business combination.
−Removed: Each of our officers is engaged
−Removed: in other business endeavors for which he may be entitled to substantial compensation and our officers are not obligated to contribute
−Removed: any specific number of hours per week to our affairs.
−Removed: Our independent directors may also serve as officers or board members for other
−Removed: If our officers’ and directors’ other business affairs require them to devote substantial amounts of time to such
−Removed: affairs in excess of their current commitment levels, it could limit their ability to devote time to our affairs which may have a negative
−Removed: impact on our ability to complete our initial business combination.
−Removed: of our officers and directors are now, and all of them may in the future become, affiliated with entities engaged in business activities
−Removed: similar to those intended to be conducted by us and, accordingly, may have conflicts of interest in allocating their time and determining
−Removed: to which entity a particular business opportunity should be presented.
−Removed: we consummate our initial business combination, we intend to engage in the business of identifying and combining with one or more businesses.
−Removed: Our sponsor and officers and directors are, and may in the future become, affiliated with entities (such as operating companies or investment
−Removed: vehicles) that are engaged in a similar business and our officers and directors may become officers or directors of another special purpose
−Removed: acquisition company with a class of securities intended to be registered under the Exchange Act, even prior to us entering into a definitive
−Removed: agreement for our initial business combination.
−Removed: Our officers and directors also may become aware of business opportunities which may
−Removed: be appropriate for presentation to us and the other entities to which they owe certain fiduciary or contractual duties.
−Removed: they may have conflicts of interest in determining to which entity a particular business opportunity should be presented.
−Removed: These conflicts
−Removed: may not be resolved in our favor and a potential target business may be presented to another entity prior to its presentation to us.
−Removed: Our certificate of incorporation provides that we renounce our interest in any corporate opportunity offered to any director or officer
−Removed: unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of our company and
−Removed: such opportunity is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue, and
−Removed: to the extent the director or officer is permitted to refer that opportunity to us without violating another legal obligation.
−Removed: officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our
−Removed: have not adopted a policy that expressly prohibits our directors, officers, security holders or affiliates from having a direct or indirect
−Removed: pecuniary or financial interest in any investment to be acquired or disposed of by us or in any transaction to which we are a party or
−Removed: have an interest.
−Removed: In fact, we may enter into an initial business combination with a target business that is affiliated with our sponsor,
−Removed: our directors or officers, although we do not intend to do so.
−Removed: We do not have a policy that expressly prohibits any such persons from
−Removed: engaging for their own account in business activities of the types conducted by us.
−Removed: Accordingly, such persons or entities may have a
−Removed: conflict between their interests and ours.
−Removed: particular, our sponsor, Murphy Canyon Acquisition Sponsor, LLC., and its corporate parent, Presidio Property Trust, Inc., as well as
−Removed: other entities affiliated with our officers and directors, may also invest in companies or businesses within the real estate industry,
−Removed: including those that focus on construction, homebuilding, real estate owners and operators, arrangers of financing, insurance, and other
−Removed: services for real estate, and adjacent businesses and technologies targeting the real estate space, which we may refer to as “Proptech”
−Removed: As a result, there may be substantial overlap between companies that would be a suitable business combination for us and
−Removed: companies that would make an attractive target for such other affiliates.
−Removed: may engage in an initial business combination with one or more target businesses that have relationships with entities that may be affiliated
−Removed: with our sponsor, officers, directors or existing holders which may raise potential conflicts of interest.
−Removed: light of the involvement of our sponsor, officers and directors with other entities, we may decide to acquire one or more businesses
−Removed: affiliated with our sponsor, officers or directors.
−Removed: Our directors and officers also serve as officers and board members for other entities.
−Removed: Such entities may compete with us for business combination opportunities.
−Removed: Our sponsor, officers and directors are not currently aware
−Removed: of any specific opportunities for us to complete our initial business combination with any entities with which they are affiliated, and
−Removed: there have been no preliminary discussions concerning an initial business combination with any such entity or entities.
−Removed: Although we will
−Removed: not be specifically focusing on, or targeting, any transaction with any affiliated entities, we would pursue such a transaction if we
−Removed: determined that such affiliated entity met our criteria for an initial business combination as described herein and such transaction
−Removed: was approved by a majority of our disinterested directors.
−Removed: Despite our agreement to obtain an opinion from an independent investment
−Removed: banking firm or another independent entity that commonly renders valuation opinions, regarding the fairness to our stockholders from
−Removed: a financial point of view of an initial business combination with one or more businesses affiliated with our sponsor, officers, directors
−Removed: or existing holders, potential conflicts of interest still may exist and, as a result, the terms of the initial business combination
−Removed: may not be as advantageous to our public stockholders as they would be absent any conflicts of interest.
−Removed: our sponsor, officers and directors will lose their entire investment in us if our initial business combination is not completed, a conflict
−Removed: of interest may arise in determining whether a particular business combination target is appropriate for our initial business combination.
−Removed: November 16, 2021, Murphy Canyon Acquisition Sponsor, LLC, our sponsor, purchased 4,312,500 founder shares for an aggregate purchase
−Removed: price of $25,000, or approximately $0.006 per share.
−Removed: On January 26, 2022 our sponsor surrendered and forfeited 1,006,250 founder shares
−Removed: for no consideration, following which our sponsor held 3,306,250 founder shares at approximately $0.008 per share.
−Removed: The number of founder
−Removed: shares issued was determined based on the expectation that such founder shares would represent 20% of the outstanding shares after our
−Removed: initial public offering (excluding the placement units and underlying securities).
−Removed: The founder shares will be worthless if we do not
−Removed: complete an initial business combination.
−Removed: Our sponsor 754,000 placement units for an aggregate purchase price of $7,540,000.
−Removed: warrant is exercisable to purchase one whole share of Class A common stock at $11.50 per share.
−Removed: Our Sponsor has agreed to transfer, but
−Removed: has not yet transferred, an aggregate of 45,000 placement units (15,000 each) to each of our three independent directors.
−Removed: These securities
−Removed: will also be worthless if we do not complete an initial business combination.
−Removed: Holders of founder shares have agreed (A) to vote any shares
−Removed: owned by them in favor of any proposed initial business combination and (B) not to redeem any founder shares held by them in connection
−Removed: with a stockholder vote to approve a proposed initial business combination.
−Removed: In addition, we have obtained loans from our sponsor and
−Removed: may in the future obtain additional loans from our sponsor, affiliates of our sponsor or an officer or director.
−Removed: We may not be able to
−Removed: repay our sponsor unless we complete an initial business combination.
−Removed: The personal and financial interests of our officers and directors
−Removed: may influence their motivation in identifying and selecting a target business combination, completing an initial business combination
−Removed: and influencing the operation of the business following the initial business combination.
−Removed: Relating to Our Securities
−Removed: securities in which we invest the funds held in the Trust Account could bear a negative rate of interest, which could reduce the value
−Removed: of the assets held in trust such that the per-share redemption amount received by public stockholders may be less than approximately
−Removed: $11.05 per share.
−Removed: proceeds held in the Trust Account will be invested only in U.S.
−Removed: government treasury obligations with a maturity of 185 days or less
−Removed: or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act, which invest only in direct U.S.
−Removed: government treasury obligations.
−Removed: While short-term U.S.
−Removed: government treasury obligations currently yield a positive rate of interest, they
−Removed: have briefly yielded negative interest rates in recent years.
−Removed: Central banks in Europe and Japan pursued interest rates below zero in
−Removed: recent years, and the Open Market Committee of the Federal Reserve has not ruled out the possibility that it may in the future adopt
−Removed: similar policies in the United States.
−Removed: In the event that we are unable to complete our initial business combination or make certain amendments
−Removed: to our certificate of incorporation, our public stockholders are entitled to receive their pro-rata share of the proceeds held in the
−Removed: Trust Account, plus any interest income, net of taxes paid or payable (less, in the case we are unable to complete our initial business
−Removed: combination, $100,000 of interest).
−Removed: Negative interest rates could reduce the value of the assets held in trust such that the per-share
−Removed: redemption amount received by public stockholders may be less than approximately $11.05 per share, assuming our sponsor makes the Maximum
−Removed: Contribution.
−Removed: may delist our securities from trading on its exchange which could limit investors’ ability to make transactions in our securities
−Removed: and subject us to additional trading restrictions.
−Removed: securities were listed on the Nasdaq Global Market, a national securities exchange, upon consummation of our initial public offering.
−Removed: Although we met the minimum initial listing standards of Nasdaq, which generally only requires that we meet certain requirements relating
−Removed: to shareholders’ equity, market capitalization, aggregate market value of publicly held shares and distribution requirements, we
−Removed: cannot assure you that our securities will continue to be listed on Nasdaq in the future prior to an initial business combination.
−Removed: Nasdaq’s requirements for continued listing include a public float
−Removed: of 1,100,000, a market value of public float of $15,000,000, a market value of listed securities of $50,000,000 and 400 shareholders.
−Removed: We believe that we currently fail to satisfy Nasdaq’s market value of listed securities and number of shareholders requirements
−Removed: as a result of the redemptions made in connection with our January 2023 vote
−Removed: to extend the deadline for us to complete our initial business combination .
−Removed: As of the date of this Form 10-K, we have not received
−Removed: any correspondence from Nasdaq related to such deficiencies but we cannot guarantee that Nasdaq will not issue a Staff Delisting Letter
−Removed: (which would allow us to seek review of the decision by an independent listing hearings panel), require us to submit a plan of compliance,
−Removed: or halt trading in our securities.
+Added: Investors should carefully consider the risks described below before making
+Added: an investment decision.
+Added: Our business, prospects, financial condition, or operating results could be harmed by any of these risks, as
+Added: well as other risks not currently known to us or that we currently consider immaterial.
+Added: The trading price of our securities could decline
+Added: due to any of these risks, and, as a result, stockholders may lose all or part of their investment.
+Added: Certain statements in “Risk
+Added: Factors” are forward-looking statements.
+Added: See “Cautionary Statement Regarding Forward-Looking Statements.”
+Added: Related to Our Business and Industry
+Added: have incurred significant net losses since our inception and we anticipate future losses and negative cash flow.
+Added: It is uncertain if or
+Added: when we will become profitable.
+Added: have incurred net losses since our inception.
+Added: Our net losses were $0.5 million for the year ended December 31, 2023 and $4.9 million
+Added: for the year ended December 31, 2022.
+Added: As of December 31, 2023, we had an accumulated deficit of $11.3 million.
+Added: We do not expect to generate
+Added: any significant revenues, if any, until we successfully complete adequate development of our first clinical asset.
+Added: As of December 31,
+Added: 2023, our clinical assets are still in development and have not been approved by the FDA or any other regulatory body.
+Added: have not yet demonstrated our ability to generate revenue, and we may never be able to produce revenues or operate on a profitable basis.
+Added: We expect to experience operating losses and negative cash flow for the foreseeable future.
+Added: Even if we are able to commercialize our
+Added: technology, which may include licensing, we may never recover our research and development expenses.
+Added: business is dependent on the successful development, regulatory approval, and commercialization of our clinical assets, in particular
+Added: a glucokinase activator which we believe is active in a range of autoimmune diseases, which we refer to as AZD1656, and a potent, irreversible
+Added: inhibitor of human Myeloperoxidase that has the potential to treat idiopathic male infertility, which we refer to as AZD5904.
+Added: success of our business, including our ability to finance our operations and generate any revenue in the future, will primarily depend
+Added: on the successful development, regulatory approval, and commercialization or partnering of our clinical assets.
+Added: In the future, we may
+Added: also become dependent on just one of our clinical assets or any future clinical assets that we may in-license, acquire, or develop.
+Added: preclinical, clinical and commercial success of our clinical assets will depend on a number of factors, including the following:
+Added: ability to raise additional capital to fund our current pre clinical and clinical plans on acceptable terms, or at all;
+Added: timely completion of our clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend
+Added: substantially upon the performance of third-party contractors;
+Added: we are required by the FDA or similar foreign regulatory agencies to conduct additional preclinical or clinical trials beyond those
+Added: planned to support the approval and commercialization of our clinical assets or any future clinical assets;
+Added: acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our clinical assets
+Added: by the FDA or similar foreign regulatory authorities;
+Added: ability to demonstrate the safety and efficacy of our clinical assets or any future clinical assets to the satisfaction of the FDA
+Added: and similar foreign regulatory authorities;
+Added: prevalence, duration, and severity of potential side effects experienced in connection with our clinical assets or future approved
+Added: products, if any;
+Added: timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;
+Added: and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual
+Added: obligations and with all regulatory requirements applicable to our clinical assets or any future clinical assets or approved products,
+Added: ability of third parties with whom we contract to manufacture clinical trial and commercial supplies of our clinical assets or any
+Added: future clinical assets, remain in good standing with regulatory agencies, and develop, validate, and maintain commercially viable
+Added: manufacturing processes that are compliant with cGMP;
+Added: continued acceptable safety profile during preclinical and clinical development and following approval of our clinical assets or
+Added: any future clinical assets;
+Added: ability to successfully commercialize our clinical assets or any future clinical assets in the U.S.
+Added: and internationally, if approved
+Added: for marketing, sale, and distribution in such countries and territories, whether alone or in collaboration with others;
+Added: acceptance by physicians, patients, and payors of the benefits, safety, and efficacy of our clinical assets or any future clinical
+Added: assets, if approved, including relative to alternative and competing treatments;
+Added: ability to comply with numerous post-approval regulatory requirements;
+Added: and our partners’ ability to establish and enforce intellectual property rights in and to our clinical assets or any future
+Added: clinical assets;
+Added: and our partners’ ability to avoid third-party patent interference or intellectual property infringement claims;
+Added: ability to in-license or acquire additional clinical assets or commercial-stage products that we believe that we can successfully
+Added: develop and commercialize.
+Added: we are unable to achieve one or more of the above factors, many of which are beyond our control, in a timely manner or at all, we could
+Added: experience significant delays and increased costs or an inability to obtain regulatory approvals or commercialize our clinical assets.
+Added: Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our clinical assets.
+Added: we cannot assure investors that we will be able to generate sufficient revenue through the sale of our clinical assets or any future
+Added: clinical assets to continue operations.
+Added: a result of our limited operating history, we may not be able to correctly estimate, operating expenses, need for investment capital,
+Added: or stability of operations, which could lead to cash shortfalls.
+Added: have a limited operating history from which to evaluate our business.
+Added: As a result, our historical financial data is of limited value
+Added: in estimating future operating expenses.
+Added: We have not obtained regulatory approvals for any of our clinical assets.
+Added: Therefore, our budgeted
+Added: operating expense levels are based in part on our expectations concerning the FDA approval process and expenses related to development
+Added: of other clinical assets.
+Added: Failing to reach our short-term developmental milestones within anticipated timelines due to delays caused
+Added: by the COVID-19 pandemic, serious adverse or unacceptable side effects caused by our clinical assets, or other events, many of which
+Added: may be beyond our control, may cause our financial condition and operating results to continue to fluctuate significantly from quarter
+Added: to quarter and year to year.
+Added: drug development for our clinical assets (AZD1656 and AZD5904) is expensive, time-consuming, and uncertain.
+Added: Our preclinical trials may
+Added: fail to adequately demonstrate pharmacologic activity in therapeutic areas of interest;
+Added: cause unintended short- or long-term effects
+Added: in other bodily systems;
+Added: or produce unexpected toxicity that may alter or risk benefit assessment.
+Added: scientific discoveries that form the basis for our efforts to generate and develop our clinical assets are relatively recent.
+Added: is a glucokinase activator that is in a number of Phase II ready autoimmune diseases including uveitis, Hashimoto’s thyroiditis,
+Added: preterm labor, and renal transplant, and the successful development of AZD1656 may require additional studies and efforts to optimize
+Added: its therapeutic potential.
+Added: In addition, our development pipeline includes what we believe to be a potent irreversible inhibitor of human
+Added: Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility, which we refer to as AZD5904.
+Added: AZD5904 may not demonstrate
+Added: in patients the therapeutic properties ascribed to it in the laboratory or preclinical studies, and may interact with human biological
+Added: systems in unforeseen, ineffective, or even harmful ways.
+Added: If we are not able to successfully develop and commercialize our clinical assets,
+Added: including AZD1656 and AZD5904, we may never become profitable and the value of our capital stock may decline.
+Added: is difficult to predict the time and cost of development and of subsequently obtaining regulatory approval for AZD1656 as it employs
+Added: newly developed technology.
+Added: uses a novel mechanism to reduce inflammation in many of the immune pathways.
+Added: We have concentrated our research and development efforts
+Added: of AZD1656 on a limited number of initial targeted disease indications for AZD1656.
+Added: There can be no
+Added: assurance that we will not experience problems or delays in developing our current or future indications for AZD1656 and that such problems
+Added: or delays will not cause unanticipated costs, or that any such development problems can be solved.
+Added: Moreover, AZD1656 would also represent
+Added: a novel approach for the treatment of uveitis as steroids are currently the most common treatment for uveitis even though there are numerous
+Added: side effects associated with the use of steroids.
+Added: The clinical development of these novel technologies will require review and allowance
+Added: by the FDA under an Investigational New Drug Application.
+Added: may not be successful in our efforts to use and expand our development platform to build a pipeline of clinical assets.
+Added: key element of our strategy is to use our experienced management and scientific team to build a pipeline of clinical assets that address
+Added: a broad range of human diseases in order to treat unmet medical needs.
+Added: Our current clinical assets and pipeline address the areas of
+Added: autoimmune disease and idiopathic male infertility.
+Added: Although our research and development efforts to date have resulted in potential
+Added: clinical assets, we may not be able to continue to identify and develop additional clinical assets.
+Added: Even if we are successful in continuing
+Added: to build our pipeline, the potential clinical assets that we identify may not be suitable for clinical development.
+Added: For example, these
+Added: potential clinical assets may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to
+Added: receive marketing approval and achieve market acceptance.
+Added: If we do not successfully develop and commercialize clinical assets based upon
+Added: our approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial
+Added: There is no assurance that we will be successful in our preclinical and clinical development of our current or future clinical
+Added: assets, and the process of obtaining regulatory approvals will, in any event, require the expenditure of substantial time and financial
+Added: drug development for our clinical assets is very expensive, time-consuming, difficult to design and implement, and uncertain.
+Added: trials may fail to adequately demonstrate the safety and efficacy of our clinical assets, which could prevent or delay regulatory approval
+Added: and commercialization.
+Added: drug development for our clinical assets is very expensive, time-consuming, difficult to design and implement, and its outcome is inherently
+Added: Before obtaining regulatory approval for the commercial sale of a clinical asset, we must demonstrate through clinical trials
+Added: that a clinical asset is both safe and effective for use in the target indication, which is impossible to predict.
+Added: Most clinical assets
+Added: that commence clinical trials are never approved by regulatory authorities for commercialization.
+Added: Our clinical assets are in various
+Added: stages of development and a failure of one more clinical trial can occur at any stage of testing or at any time during the trial process.
+Added: We expect that clinical trials for these clinical assets will continue for several years but may take significantly longer than expected
+Added: Not all of our clinical assets have been tested in humans and the first use in humans may reveal unexpected effects.
+Added: have not completed all clinical trials for the approval of any of our clinical assets.
+Added: may experience delays in ongoing and future clinical trials for our clinical assets and we do not know if future clinical trials, if
+Added: any, will begin on time, need to be redesigned, enroll adequate number of patients on time or be completed on schedule, if at all.
+Added: addition, the Company, any partner with which we currently or may in the future collaborate, the FDA, an Institutional Review Board (or
+Added: IRB) or other regulatory authorities, including state and local agencies and counterpart agencies in foreign countries, may suspend,
+Added: delay, require modifications to, or terminate our clinical trials at any time, for various reasons, including:
+Added: of safety or tolerability concerns, such as serious or unexpected toxicities or side effects or exposure to otherwise unacceptable
+Added: health risks, experienced by study participants or other safety issues;
+Added: of effectiveness of any clinical asset during clinical trials or the failure of our clinical assets to meet specified endpoints;
+Added: than expected rates of subject recruitment and enrollment rates or inability to enroll a sufficient number of patients in clinical
+Added: trials resulting from numerous factors, including the prevalence of other companies’ clinical trials for their clinical assets
+Added: for the same indication, or clinical trials for indications for which patients do not as commonly seek treatment;
+Added: or difficulties in our clinical trials due to quarantines or other restrictions resulting from the COVID-19 pandemic or any other
+Added: in retaining subjects who have initiated a clinical trial but may withdraw at any time due to adverse side effects from the therapy,
+Added: insufficient efficacy, fatigue with the clinical trial process, or for any other reason;
+Added: in obtaining IRB approval for studies to be conducted at each clinical trial site;
+Added: in manufacturing or obtaining, or inability to manufacture or obtain, sufficient quantities of materials for use in clinical trials;
+Added: of or changes in our manufacturing process or the product formulation or method of delivery;
+Added: in applicable laws, regulations, and regulatory policies;
+Added: or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective Contract Research
+Added: Organizations (which we refer to as “CROs”), clinical trial sites, and other third-party contractors;
+Added: to add a sufficient number of clinical trial sites;
+Added: regarding proper formulation and dosing;
+Added: by us, our employees, our CROs or their employees, or other third-party contractors to comply with contractual and applicable regulatory
+Added: requirements or to perform their services in a timely or acceptable manner;
+Added: by us, our employees, our CROs or their employees, or any partner with which we may collaborate or their employees to comply with
+Added: applicable FDA or other regulatory requirements relating to the conduct of clinical trials or the handling, storage, security, and
+Added: recordkeeping for drug and biologic products;
+Added: conflicts with participating clinicians and clinical institutions;
+Added: to design appropriate clinical trial protocols;
+Added: data to support regulatory approval;
+Added: or unwillingness of medical investigators to follow our clinical trial protocols;
+Added: in maintaining contact with subjects during or after treatment, which may result in incomplete data.
+Added: or any partner with which we may collaborate may suffer significant setbacks in their clinical trials similar to the experience of a
+Added: number of other companies in the pharmaceutical and biotechnology industries, even after receiving promising results in earlier trials.
+Added: In the event that we or our potential partners abandon or are delayed in the clinical development efforts related to our clinical assets,
+Added: we may not be able to execute on our business plan effectively and our business, financial condition, operating results, and prospects
+Added: would be harmed.
+Added: may be unable to obtain regulatory approval for our early-stage clinical assets under applicable regulatory requirements.
+Added: foreign regulatory bodies have substantial discretion in the approval process, including the ability to delay, limit, or deny approval
+Added: of clinical assets.
+Added: The delay, limitation, or denial of any regulatory approval would adversely impact commercialization, our potential
+Added: to generate revenue, our business, and our operating results.
+Added: currently have no products approved for sale, and we may never obtain regulatory approval to commercialize any of our current or future
+Added: clinical assets.
+Added: The research, testing, manufacturing, safety surveillance, efficacy, quality control, recordkeeping, labeling, packaging,
+Added: storage, approval, sale, marketing, distribution, import, export, and reporting of safety and other post-market information related to
+Added: our drug products are subject to extensive regulation by the FDA and other regulatory authorities in the U.S.
+Added: and in foreign countries,
+Added: and such regulations differ from country to country.
+Added: We are not permitted to market any of our current clinical assets in the U.S.
+Added: we receive approval of an NDA, Biologics License Application (a “BLA”), or other applicable regulatory filing from the FDA.
+Added: We are also not permitted to market any of our current clinical assets in any foreign countries until we or our partners receive the
+Added: requisite approval from the applicable regulatory authorities of such countries.
+Added: To gain approval to market a new drug such as AZD1656
+Added: and AZD5904, the FDA and/or foreign regulatory authorities must receive, among other things, preclinical and clinical data that adequately
+Added: demonstrate the safety, purity, potency, efficacy, and compliant manufacturing of the drug product for the intended indication applied
+Added: for in a NDA, BLA, or other applicable regulatory filing.
+Added: The development and approval of new drug products involves a long, expensive,
+Added: and uncertain process, and delay or failure can occur at any stage.
+Added: A number of companies in the pharmaceutical and biopharmaceutical
+Added: industry have suffered significant setbacks in nonclinical development, clinical trials, including in Phase III clinical development,
+Added: even after promising results in earlier preclinical studies or clinical trials.
+Added: These setbacks have been caused by, among other things,
+Added: findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported
+Added: adverse events.
+Added: Success in clinical trials does not ensure that later clinical trials will be successful, or that nonclinical studies
+Added: will be successful.
+Added: The results of clinical trials by other parties may not be indicative of the results in trials that we or our partners
+Added: FDA and foreign regulatory bodies have substantial discretion in the drug development and approval process, including the ability to
+Added: delay, limit drug development, or limit or deny approval of clinical assets for many reasons.
+Added: The FDA or the applicable foreign regulatory
+Added: with the design or implementation of one or more clinical trials;
+Added: deem a clinical asset safe and effective for its proposed indication, or may deem a clinical asset’s safety or other perceived
+Added: risks to outweigh its clinical or other benefits;
+Added: find the data from preclinical studies and clinical trials sufficient to support approval, or the results of clinical trials may
+Added: not meet the level of statistical or clinical significance required by the FDA or the applicable foreign regulatory body for approval;
+Added: with our interpretation of data from preclinical studies or clinical trials performed by us or third parties, or with the interpretation
+Added: of any partner with which we may collaborate;
+Added: the data collected from preclinical or clinical trials may not be sufficient to support the submission of an Investigational New
+Added: Drug Application (“IND”) or NDA, or other applicable regulatory filing;
+Added: additional preclinical studies or clinical trials;
+Added: deficiencies in the formulation, quality control, labeling, or specifications of our current or future clinical assets;
+Added: clinical trials in pediatric patients in order to establish pharmacokinetics or safety for this more drug-sensitive population;
+Added: approval contingent on the performance of costly additional post-approval clinical trials;
+Added: our current or any future clinical assets for a more limited indication or a narrower patient population than we originally requested
+Added: or with strong warnings that may affect marketability;
+Added: approve the labeling that we believe is necessary or desirable for the successful commercialization of our clinical assets;
+Added: approve of the manufacturing processes, controls, or facilities of third-party manufacturers or testing labs with which we contract;
+Added: our products a device instead of a drug requiring a different approval process and manufacturing needs;
+Added: one of our products a combination product instead of a singular drug requiring additional clinical trials or increased number of
+Added: patients per study;
+Added: its approval policies or adopt new regulations in a manner rendering our clinical data or regulatory filings insufficient for approval.
+Added: delay, limitation, or denial in any applicable regulatory approval for any of our clinical assets would delay or adversely impact commercialization
+Added: of our clinical assets and would harm our business, financial condition, operating results, and prospects.
+Added: is substantial doubt regarding our ability to continue as a going concern.
+Added: We will need to raise additional funding, which may not be
+Added: available on acceptable terms, or at all.
+Added: Failure to obtain this necessary capital when needed may force us to delay, limit or terminate
+Added: our commercial programs, product development efforts or other operations.
+Added: report of our independent registered public accounting firm on the Company’s financial statements as of and for the year ended
+Added: December 31, 2023, includes an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going
+Added: concern for at least one year from the date of filing.
+Added: Through the date of the Business Combination, Old Conduit financed its working
+Added: capital requirements by raising capital through private placements of its ordinary shares and issuing of short-term and convertible notes.
+Added: The Company has financed its working capital requirements since the Business Combination primarily through the PIPE Financing (the “PIPE
+Added: Financing”) completed in September 2023, concurrently with the completion of the Business
+Added: Combination in which the Company issued an aggregate of 2,000,000 units, with each unit consisting of one share of Company common stock
+Added: together with one warrant exercisable into one share of Company common stock, at a purchase price of $10.00 per unit, for an aggregate
+Added: purchase price of $20,000,000 which yielded net proceeds of $7.8 million.
+Added: The Company has also received a $5 million commitment for working
+Added: capital, subject to agreement and definitive documentation, from Corvus Capital, a major shareholder, and expects to use that commitment
+Added: to cover its operating costs for the coming year.
+Added: will need to raise additional funding, which may not be available on acceptable terms, or at all.
+Added: Failure to obtain this necessary capital
+Added: when needed may force us to delay, limit or terminate our commercial programs, product development efforts or other operations.
+Added: not expect to generate meaningful product revenues in the foreseeable future.
+Added: Based on our current business plan as of the date of our
+Added: consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, there is substantial doubt regarding our ability
+Added: to continue as a going concern.
+Added: We will need to raise additional funding in order to execute on our current business plans and strategy,
+Added: including prior to becoming profitable.
+Added: efforts to raise additional funding may divert our management from their day-to-day activities, which may adversely affect our ability
+Added: to develop our products.
+Added: In addition, we cannot guarantee that financing will be available in sufficient amounts or on terms acceptable
+Added: to us, if at all.
+Added: Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance
+Added: of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares
+Added: The sale of additional equity or convertible securities would dilute all of our stockholders.
+Added: The incurrence of indebtedness
+Added: would result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations
+Added: on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other
+Added: operating restrictions that could adversely impact our ability to conduct our business.
+Added: We could also be required to seek funds through
+Added: arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to
+Added: relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have
+Added: a material adverse effect on our business, operating results and prospects.
+Added: as a result of recent volatile market conditions, the cost and availability of capital has been and may continue to be adversely affected.
+Added: Concern about the stability of the banking sector has generally led many lenders and institutional investors to reduce, and in some cases,
+Added: cease to provide credit to businesses and consumers.
+Added: Continued turbulence in the U.S.
+Added: market and economy may adversely affect our liquidity
+Added: and financial condition, including our ability to access the capital markets to meet liquidity needs.
+Added: we are unable to obtain funding on a timely basis, or if revenues from collaboration arrangements are less than we have projected, we
+Added: may be required to further revise our business plan and strategy, which may result in us significantly curtailing, delaying or discontinuing
+Added: one or more of our research or development programs or may result in our being unable to expand our operations or otherwise capitalize
+Added: on our business opportunities.
+Added: As a result, our business, financial condition and results of operations could be materially affected.
+Added: have identified material weaknesses in our internal control over financial reporting.
+Added: If we fail to remedy these weaknesses or maintain
+Added: an effective system of internal controls, then our ability to produce timely and accurate financial statements or comply with applicable
+Added: regulations could be adversely affected.
+Added: We may identify additional material weaknesses in our internal controls over financing reporting
+Added: which we may not be able to remedy in a timely manner.
+Added: connection with the preparation and audit of the financial statements as of and for the fiscal years ended December 31, 2023 and 2022,
+Added: material weaknesses were identified in our internal control over financial reporting.
+Added: A material weakness is a deficiency, or a combination
+Added: of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement
+Added: of annual or interim financial statements will not be prevented or detected on a timely basis.
+Added: These material weaknesses primarily relate
+Added: to the following matters that are relevant to the preparation of our financial statements:
+Added: have limited segregation of duties.
+Added: For the periods under audit, Old Conduit did not have any internal personnel in the financial
+Added: accounting and reporting department, instead relied upon third party consultants to perform these activities.
+Added: lack a formal process for review and approval of financial statements.
+Added: For the periods under audit, especially prior to the business
+Added: combination, numerous, recurring errors in account balances and disclosures were detected in the financial statements that resulted
+Added: in a reasonable possibility that a material misstatement would not have been detected on a timely basis.
+Added: did not design adequate and appropriate internal controls, including monitoring controls, to review and evaluate the accounting implications
+Added: of all material transactions that occurred in the audit period.
+Added: these material weaknesses are not remediated, it could result in a misstatement of account balances or disclosures that would result
+Added: in a material misstatement to the annual or interim financial statements that would not be prevented or detected.
+Added: We are implementing
+Added: measures designed to improve our internal control over financial reporting to remediate these material weaknesses, although they have
+Added: not been fully remediated as of the date of this filing.
+Added: As a part of these measures, we entered into an employment agreement with Mr.
+Added: Sragovicz, previously MURF’s Chief Financial Officer, which provides that Mr.
+Added: Sragovicz will serve as the Company’s Chief
+Added: Financial Officer.
+Added: In addition, we anticipate hiring additional qualified accounting personnel with experience with complex GAAP and
+Added: SEC rules while, meanwhile, continuing to engage consultants to assist with our financial statement close process, segregating duties
+Added: among accounting personnel to enable adequate review controls, further developing and documenting our accounting policies, and designing,
+Added: implementing, and/or expanding IT systems and application controls in our systems relevant to the preparation of the consolidated financial
+Added: We also expect to engage an external advisor to assist with evaluating and documenting the design and operating effectiveness
+Added: of internal controls and assisting with the remediation of deficiencies, as necessary.
+Added: The primary costs associated with such measures
+Added: are corresponding recruiting and additional salary and consulting costs, which are difficult to estimate but which may be significant.
+Added: These additional resources and procedures are intended to enable us to broaden the scope and quality of our internal review of underlying
+Added: information related to financial reporting and to formalize and enhance our internal control procedures.
+Added: material weaknesses will not be considered remediated until our remediation plan has been fully implemented, the applicable controls
+Added: operate for a sufficient period of time, and we have concluded, through testing, that the newly implemented and enhanced controls are
+Added: operating effectively.
+Added: We currently expect to commence the remediation plan by documenting and implementing such plan, followed with
+Added: testing such controls over time.
+Added: We cannot predict the success of such efforts or the outcome of its assessment of the remediation efforts.
+Added: Our efforts may not remediate these material weaknesses in our internal control over financial reporting, or additional material weaknesses
+Added: may be identified in the future.
+Added: A failure to implement and maintain effective internal control over financial reporting could result
+Added: in errors in our financial statements that could result in a restatement of our financial statements and could cause us to fail to meet
+Added: our reporting obligations, any of which could diminish investor confidence in us and cause a decline in the price of our common stock.
+Added: independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over
+Added: financial reporting until after we are no longer an “emerging growth company,” as defined in the JOBS Act.
+Added: At such time,
+Added: our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level
+Added: at which our internal control over financial reporting is documented, designed, or operating.
+Added: is a risk that we will fail to maintain an effective system of internal controls and our ability to produce timely and accurate financial
+Added: statements or comply with applicable regulations could be adversely affected.
+Added: We may identify material weaknesses in our internal controls
+Added: over financing reporting which we may not be able to remedy in a timely manner.
+Added: a public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley
+Added: Act, the regulations of Nasdaq, the rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements,
+Added: and more complex accounting rules.
+Added: Responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate
+Added: internal control over financial reporting and disclosure controls and procedures.
+Added: Effective internal controls are necessary for us to
+Added: produce reliable financial reports and are important to help prevent financial fraud.
+Added: may discover additional weaknesses in our system of internal financial and accounting controls and procedures that could result in a
+Added: material misstatement of our financial statements.
+Added: Our internal control over financial reporting will not prevent or detect all errors
+Added: and all fraud.
+Added: A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that
+Added: the control system’s objectives will be met.
+Added: Because of the inherent limitations in all control systems, no evaluation of controls
+Added: can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud
+Added: will be detected.
+Added: we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain
+Added: proper and effective internal controls, we may not be able to produce timely and accurate financial statements.
+Added: If we cannot provide
+Added: reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence
+Added: in our reported financial information, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory
+Added: we do not develop and implement all required accounting practices and policies, we may be unable to provide the financial information
+Added: required of a U.S.
+Added: publicly traded company in a timely and reliable manner.
+Added: we fail to develop and maintain effective internal controls and procedures and disclosure procedures and controls, we may be unable to
+Added: provide financial information and required SEC reports that a U.S.
+Added: publicly traded company is required to provide in a timely and reliable
+Added: Any such delays or deficiencies could penalize us, including by limiting our ability to obtain financing, either in the public
+Added: capital markets or from private sources and hurt our reputation and could thereby impede our ability to implement our growth strategy.
+Added: In addition, any such delays or deficiencies could result in our failure to meet the requirements for continued listing of our shares
+Added: of common stock on a national securities exchange.
+Added: may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance
+Added: coverage for those claims is inadequate.
+Added: face an inherent risk of product liability as a result of the clinical testing of our clinical assets and will face an even greater risk
+Added: if we commercialize any products.
+Added: This risk exists even if a product is approved for commercial sale by the FDA and manufactured in facilities
+Added: licensed and regulated by the FDA or an applicable foreign regulatory authority.
+Added: Our products and clinical assets are designed to affect
+Added: important bodily functions and processes.
+Added: Any side effects, manufacturing defects, misuse, or abuse associated with our clinical assets
+Added: could result in injury to a patient or even death.
+Added: We cannot offer any assurance that we will not face product liability suits in the
+Added: future, nor can we assure investors that our insurance coverage will be sufficient to cover our liability under any such cases.
+Added: a liability claim may be brought against us even if our clinical assets merely appear to have caused an injury.
+Added: Product liability claims
+Added: may be brought against us by consumers, health care providers, pharmaceutical companies, or others selling or otherwise coming into contact
+Added: with our clinical assets, among others.
+Added: If we cannot successfully defend ourselves against product liability claims, we will incur substantial
+Added: liabilities and reputational harm.
+Added: currently rely on, and expect to continue to rely on, third-party CROs and other third parties to conduct and oversee our clinical trials
+Added: and other aspects of product development.
+Added: If these third parties do not meet our requirements or otherwise conduct the trials as required,
+Added: we may not be able to satisfy our contractual obligations or obtain regulatory approval for, or commercialize, our clinical assets when
+Added: expected or at all.
+Added: have in the past relied and expect to continue to rely on third-party CROs to conduct and oversee our clinical trials and other aspects
+Added: of product development.
+Added: We also rely upon various medical institutions, clinical investigators, and contract laboratories to conduct
+Added: our trials in accordance with our clinical trial protocols and all applicable regulatory requirements, including the FDA’s regulations
+Added: and GCPs, which are an international standard meant to protect the rights and health of patients and to define the roles of clinical
+Added: trial sponsors, administrators and monitors, and state regulations governing the handling, storage, security, and recordkeeping for drug
+Added: and biologic products.
+Added: These CROs and other third parties play a significant role in the conduct of these trials and the subsequent collection
+Added: and analysis of data from the clinical trials.
+Added: We rely heavily on these parties for the execution of our clinical trials and preclinical
+Added: studies, and control only certain aspects of their activities.
+Added: We, our CROs, and other third-party contractors are required to comply
+Added: with GCP, GLP, and GACP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities
+Added: for products in clinical development.
+Added: Regulatory authorities enforce these GCP, GLP, and GACP requirements through periodic inspections
+Added: of trial sponsors, principal investigators, and trial sites.
+Added: If we or any of these third parties fail to comply with applicable GCP,
+Added: GLP, or GACP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or other regulatory
+Added: authority may require us to perform additional clinical trials before approving our or our partners’ marketing applications.
+Added: cannot assure investors that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our
+Added: clinical or preclinical trials complies with applicable GCP and GLP requirements.
+Added: In addition, our clinical trials must generally be
+Added: conducted with product produced under cGMP regulations.
+Added: Our failure to comply with these regulations and policies may require us to repeat
+Added: clinical trials, which would delay the regulatory approval process.
+Added: CROs are not our employees, and we do not control whether or not they devote sufficient time and resources to our clinical trials.
+Added: CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical
+Added: trials, or other drug development activities, which could harm our competitive position.
+Added: We face the risk of potential unauthorized disclosure
+Added: or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow potential competitors
+Added: to access and exploit our proprietary technology.
+Added: If our CROs do not successfully carry out their contractual duties or obligations,
+Added: fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to
+Added: adhere to our clinical trial protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed,
+Added: or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any clinical asset that we develop.
+Added: As a result, our financial results and the commercial prospects for any clinical asset that we develop would be harmed, our costs could
+Added: increase, and our ability to generate revenue could be delayed.
+Added: any of our CROs or clinical trial sites terminate their involvement in one of our clinical trials for any reason, we may not be able
+Added: to enter into arrangements with alternative CROs or clinical trial sites, or do so on commercially reasonable terms.
+Added: In addition, if
+Added: our relationship with clinical trial sites is terminated, we may experience the loss of follow-up information on patients enrolled in
+Added: our ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site.
+Added: principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and could receive
+Added: cash or equity compensation in connection with such services.
+Added: If these relationships and any related compensation result in perceived
+Added: or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be questioned by the FDA.
+Added: rely completely on third-party contractors to supply, manufacture, and distribute clinical drug supplies for our clinical assets, including
+Added: certain sole-source suppliers and manufacturers.
+Added: We intend to rely on third parties for commercial supply, manufacturing, and distribution
+Added: if any of our clinical assets receive regulatory approval and we expect to rely on third parties for supply, manufacturing, and distribution
+Added: of preclinical, clinical, and commercial supplies of any future clinical assets.
+Added: do not currently have, nor do we plan to acquire, the infrastructure or capability to supply, manufacture, or distribute preclinical,
+Added: clinical, or commercial quantities of drug substances or products.
+Added: Our ability to develop our clinical assets depends and our ability
+Added: to commercially supply our products will depend, in part, on our ability to successfully obtain the raw materials and APIs and other
+Added: substances and materials used in our clinical assets from third parties and to have finished products manufactured by third parties in
+Added: accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing and commercialization.
+Added: fail to develop and maintain supply relationships with these third parties, we may be unable to continue to develop or commercialize
+Added: our clinical assets.
+Added: rely and will continue to rely on certain third parties as the sole source of the materials they supply or the finished products they
+Added: Any of our existing suppliers or manufacturers may:
+Added: to supply us with product on a timely basis or in the requested amount due to unexpected damage to or destruction of facilities or
+Added: equipment or otherwise;
+Added: to increase manufacturing capacity and produce drug product and components in larger quantities and at higher yields in a timely
+Added: or cost-effective manner, or at all, to sufficiently meet our commercial needs;
+Added: unable to meet our production demands due to issues related to their reliance on sole-source suppliers and manufacturers;
+Added: us with product that fails to meet regulatory requirements;
+Added: unavailable through business interruption or financial insolvency;
+Added: regulatory status as an approved source;
+Added: unable or unwilling to renew current supply agreements when such agreements expire on a timely basis, on acceptable terms or at all;
+Added: production or manufacturing of necessary drug substances or products.
+Added: the event of any of the foregoing, if we do not have an alternative supplier or manufacturer in place, we would be required to expend
+Added: substantial management time and expense to identify, qualify, and transfer processes to alternative suppliers or manufacturers.
+Added: technology to other sites may require additional processes, technologies, and validation studies, which are costly, may take considerable
+Added: amounts of time, may not be successful and, in most cases, require review and approval by the FDA.
+Added: Any need to find and qualify new suppliers
+Added: or manufacturers could significantly delay production of our clinical assets, adversely impact our ability to market our clinical assets,
+Added: and adversely affect our business.
+Added: Replacements may not be available to us on a timely basis, on acceptable terms, or at all.
Additionally,
−Removed: in connection with our initial business combination, it is likely that Nasdaq will require us to file a new initial listing application
−Removed: and meet its initial listing requirements as opposed to its more lenient continued listing requirements.
−Removed: We cannot assure you that we
−Removed: will be able to meet those initial listing requirements at that time.
−Removed: Nasdaq delists our securities from trading on its exchange, we could face significant material adverse consequences, including:
−Removed: inability to consummate our initial business combination;
−Removed: limited availability of market quotations for our securities;
−Removed: liquidity with respect to our securities;
−Removed: determination that our shares of common stock are “penny stock” which will require brokers trading in our shares of common
−Removed: stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market
−Removed: for our shares of common stock;
−Removed: limited amount of news and analyst coverage for our company;
−Removed: decreased ability to issue additional securities or obtain additional financing in the future.
−Removed: we seek stockholder approval of our initial business combination and we do not conduct redemptions pursuant to the tender offer rules,
−Removed: and if you or a “group” of stockholders are deemed to hold in excess of 15% of our common stock, you will lose the ability
−Removed: to redeem all such shares in excess of 15% of our common stock.
−Removed: we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business
−Removed: combination pursuant to the tender offer rules, our certificate of incorporation provides that a public stockholder, together with any
−Removed: affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined
−Removed: under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to more than an aggregate of 15%
−Removed: of the shares sold in our initial public offering without our prior consent, which we refer to as the “Excess Shares.” However,
−Removed: we would not be restricting our stockholders’ ability to vote all of their shares (including Excess Shares) for or against our
−Removed: initial business combination.
−Removed: Your inability to redeem the Excess Shares will reduce your influence over our ability to complete our
−Removed: initial business combination and you could suffer a material loss on your investment in us if you sell Excess Shares in open market transactions.
−Removed: Additionally, you will not receive redemption distributions with respect to the Excess Shares if we complete our initial business combination.
−Removed: And as a result, you will continue to hold that number of shares exceeding 15% and, in order to dispose of such shares, would be required
−Removed: to sell your stock in open market transactions, potentially at a loss.
−Removed: have not registered the shares of Class A common stock issuable upon exercise of the warrants under the Securities Act or any state securities
−Removed: laws at this time, and such registration may not be in place when an investor desires to exercise warrants, thus precluding such investor
−Removed: from being able to exercise its warrants except on a cashless basis.
−Removed: If the issuance of the shares upon exercise of warrants is not registered,
−Removed: qualified or exempt from registration or qualification, the holder of such warrant will not be entitled to exercise such warrant and
−Removed: such warrant may have no value and expire worthless.
−Removed: have not registered the shares of common stock issuable upon exercise of the warrants under the Securities Act or any state securities
−Removed: laws at this time.
−Removed: However, under the terms of the warrant agreement, we have agreed that as soon as practicable, but in no event later
−Removed: than 15 business days after the closing of our initial business combination, we will use our best efforts to file with the SEC a registration
−Removed: statement for the registration under the Securities Act of the issuance of the shares of common stock issuable upon exercise of the warrants
−Removed: and thereafter will use our best efforts to cause the same to become effective within 60 business days following our initial business
−Removed: combination and to maintain a current prospectus relating to the common stock issuable upon exercise of the warrants, until the expiration
−Removed: of the warrants in accordance with the provisions of the warrant agreement.
−Removed: We cannot assure you that we will be able to do so if, for
−Removed: example, any facts or events arise which represent a fundamental change in the information set forth in the registration statement or
−Removed: prospectus, the financial statements contained or incorporated by reference therein are not current, complete or correct or the SEC issues
−Removed: a stop order.
−Removed: If the shares of common stock issuable upon exercise of the warrants are not registered under the Securities Act, we will
−Removed: be required to permit holders to exercise their warrants on a cashless basis.
−Removed: However, no warrant will be exercisable for cash or on
−Removed: a cashless basis, and we will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance
−Removed: of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption
−Removed: from registration is available.
−Removed: Notwithstanding the foregoing, if a registration statement covering the issuance of the common stock
−Removed: issuable upon exercise of the warrants is not effective within a specified period following the consummation of our initial business
−Removed: combination, warrant holders may, until such time as there is an effective registration statement and during any period when we shall
−Removed: have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided
−Removed: by Section 3(a)(9) of the Securities Act, provided that such exemption is available.
−Removed: If that exemption, or another exemption, is not
−Removed: available, holders will not be able to exercise their warrants on a cashless basis.
−Removed: We will use our best efforts to register or qualify
−Removed: the shares under applicable blue sky laws to the extent an exemption is not available.
−Removed: In no event will we be required to net cash settle
−Removed: any warrant, or issue securities or other compensation in exchange for the warrants in the event that we are unable to register or qualify
−Removed: the shares underlying the warrants under applicable state securities laws and there is no exemption available.
−Removed: If the issuance of the
−Removed: shares upon exercise of the warrants is not so registered or qualified or exempt from registration or qualification, the holder of such
−Removed: warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless.
−Removed: In such event, holders
−Removed: who acquired their warrants as part of a purchase of units will have paid the full unit purchase price solely for the shares of common
−Removed: stock included in the units.
−Removed: If and when the warrants become redeemable by us, we may not exercise our redemption right if the issuance
−Removed: of shares of common stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue
−Removed: sky laws or we are unable to effect such registration or qualification.
−Removed: We will use our best efforts to register or qualify such shares
−Removed: of common stock under the blue sky laws of the state of residence in those states in which the warrants were offered by us in our initial
−Removed: public offering.
−Removed: you exercise your warrants on a “cashless basis,” you will receive fewer shares of common stock from such exercise than if
−Removed: you were to exercise such warrants for cash.
−Removed: are circumstances in which the exercise of the warrants may be required or permitted to be made on a cashless basis.
−Removed: First, if a registration
−Removed: statement covering the issuance of the shares of common stock issuable upon exercise of the warrants is not effective by the 60 th
−Removed: business day after the closing of our initial business combination, warrant holders may, until such time as there is an effective
−Removed: registration statement, exercise warrants on a cashless basis in accordance with Section 3(a)(9) of the Securities Act or another exemption.
−Removed: Second, if a registration statement covering the common stock issuable upon exercise of the warrants is not effective within a specified
−Removed: period following the consummation of our initial business combination, warrant holders may, until such time as there is an effective
−Removed: registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants
−Removed: on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available;
−Removed: if that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.
−Removed: if we call the warrants for redemption, our management will have the option to require all holders that wish to exercise warrants to
−Removed: do so on a cashless basis.
−Removed: In the event of an exercise on a cashless basis, a holder would pay the warrant exercise price by surrendering
−Removed: the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares
−Removed: of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair
−Removed: market value” (as defined in the next sentence) by (y) the fair market value.
−Removed: The “fair market value” for this purpose
−Removed: shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to
−Removed: the date on which the notice of exercise is received by the warrant agent or on which the notice of redemption is sent to the holders
−Removed: of warrants, as applicable.
−Removed: As a result, you would receive fewer shares of common stock from such exercise than if you were to exercise
−Removed: such warrants for cash.
−Removed: may issue additional common stock or preferred stock to complete our initial business combination or under an employee incentive plan
−Removed: after completion of our initial business combination.
−Removed: Any such issuances would dilute the interest of our stockholders and likely present
−Removed: certificate of incorporation authorizes the issuance of up to 110,000,000 shares of common stock, consisting of (i) 100,000,000 shares
−Removed: of Class A common stock, $0.0001 par value, (ii) 10,000,000 shares of Class B common stock, $0.0001 par value, and (iii) 1,000,000 shares
−Removed: of undesignated preferred stock, $0.0001 par value per share.
−Removed: Immediately after our initial public offering and the sale of the placement
−Removed: units, there was 86,021,000 authorized but unissued shares of Class A common stock, which amount does not take into account the shares
−Removed: of common stock reserved for issuance upon exercise of outstanding warrants.
−Removed: may issue a substantial number of additional shares of common or preferred stock to complete our initial business combination or under
−Removed: an employee incentive plan after completion of our initial business combination (although our certificate of incorporation provides that
−Removed: we may not issue securities that can vote with common stockholders on matters related to our pre-initial business combination activity).
−Removed: However, our certificate of incorporation provides, among other things, that prior to our initial business combination, we may not issue
−Removed: additional shares of capital stock that would entitle the holders thereof to (i) receive funds from the Trust Account or (ii) vote on
−Removed: any initial business combination.
−Removed: These provisions of our certificate of incorporation, like all provisions of our certificate of incorporation,
−Removed: may be amended with the approval of our stockholders.
−Removed: However, our executive officers, directors and director nominees have agreed, pursuant
−Removed: to a written agreement with us, that they will not propose any amendment to our certificate of incorporation (A) to modify the substance
−Removed: or timing of our obligation to allow redemption in connection with our initial business combination or certain amendments to our charter
−Removed: prior thereto or to redeem 100% of our public shares if we do not complete our initial business combination within 12 months from the
−Removed: consummation of our initial public offering (or up to February 7, 2024 at the election of the Company subject to satisfaction of certain
−Removed: conditions) or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity,
−Removed: unless we provide our public stockholders with the opportunity to redeem their shares of common stock upon approval of any such amendment
−Removed: at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which
−Removed: interest shall be net of taxes payable), divided by the number of then outstanding public shares.
−Removed: issuance of additional shares of common or preferred stock:
−Removed: significantly dilute the equity interest of investors in our initial public offering;
−Removed: subordinate the rights of holders of our common stock if preferred stock is issued with rights senior to those afforded our common
+Added: we and our manufacturers do not currently maintain significant inventory of drug substances and other materials.
+Added: Any interruption in
+Added: the supply of a drug substance or other material or in the manufacture of our clinical assets could have a material adverse effect on
+Added: our business, financial condition, operating results, and prospects.
+Added: do not have direct control over the ability of our contract suppliers and manufacturers to maintain adequate capacity and capabilities
+Added: to serve our needs, including quality control, quality assurance, and qualified personnel.
+Added: Although we are ultimately responsible for
+Added: ensuring compliance with regulatory requirements such as cGMPs and GACP, we are dependent on our contract suppliers and manufacturers
+Added: for day-to-day compliance with cGMPs or GACP for production of raw materials, APIs, and finished products.
+Added: Facilities used by our contract
+Added: suppliers and manufacturers to produce the APIs and other substances and materials or finished products for commercial sale must pass
+Added: inspection and be approved by the FDA and other relevant regulatory authorities.
+Added: Our contract suppliers and manufacturers must comply
+Added: with cGMP and GACP requirements enforced by the FDA through its facilities inspection program and review of submitted technical information.
+Added: If the safety of any product or clinical asset or component is compromised due to a failure to adhere to applicable laws or for other
+Added: reasons, we may not be able to successfully commercialize or obtain regulatory approval for the affected product or clinical asset, and
+Added: we may be held liable for injuries sustained as a result.
+Added: Any of these factors could cause a delay or termination of preclinical studies,
+Added: clinical trials, or regulatory submissions or approvals of our clinical assets, and could entail higher costs or result in us being unable
+Added: to effectively commercialize our approved products on a timely basis, or at all.
+Added: addition, these contract manufacturers are engaged with other companies to supply and manufacture materials or products for such companies,
+Added: which also exposes our suppliers and manufacturers to regulatory risks for the production of such materials and products.
+Added: failure to meet the regulatory requirements for the production of those materials and products may also affect the regulatory clearance
+Added: of a contract supplier’s or manufacturer’s facility.
+Added: If the FDA or a comparable foreign regulatory agency does not approve
+Added: these facilities for the supply or manufacture of our clinical assets, or if it withdraws its approval in the future, we may need to
+Added: find alternative supply or manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval
+Added: of, or market our clinical assets, if approved.
+Added: any of our third-party contractors terminate their involvement in the supply, manufacture, or distribution of clinical drug supplies
+Added: for us for any reason, we may not be able to enter into arrangements with alternative third party-contractors, or do so on commercially
+Added: reasonable terms.
+Added: In addition, if our relationship with such third-party contractors is terminated, we may experience a negative impact
+Added: to the respective licenses on which we rely and, therefore, on our ability to obtain regulatory approval for, or commercialize, our clinical
+Added: assets when expected or at all.
+Added: reliance on contract manufacturers and suppliers further exposes us to the possibility that they, or third parties with access to their
+Added: facilities, will have access to and may misappropriate our trade secrets or other proprietary information.
+Added: addition, the manufacturing facilities of certain of our suppliers are located outside of the U.S.
+Added: This may give rise to difficulties
+Added: in importing our products or clinical assets or their components into the U.S.
+Added: or other countries as a result of, among other things,
+Added: regulatory agency approval requirements or import inspections, incomplete or inaccurate import documentation, or defective packaging.
+Added: currently rely on agreements with third parties for the purpose of licensing our clinical assets.
+Added: In the near-term, we intend to rely
+Added: on third parties for the licensing of clinical assets and those which may arise through future partnerships.
+Added: currently rely on agreements with third parties for the purpose of licensing clinical assets from large pharmaceutical companies.
+Added: example, we have agreements with St George Street pursuant to which we license clinical assets from St George Street and, in turn, St
+Added: George Street licenses such assets from AstraZeneca.
+Added: If we are in breach of the agreements, the termination of such agreement(s) could
+Added: materially adversely affect our business, financial condition, operating results, and prospects.
+Added: Our business strategy heavily depends
+Added: on our ability to commercialize our clinical assets and our ability to enter into license agreements relating to such clinical assets
+Added: is critical to the success of our operations.
+Added: In addition, we are not a party to the license agreements between St George Street and
+Added: AstraZeneca, and St George Street may have other agreements with third parties relating to the development of the clinical assets that
+Added: A termination of such third-party agreements could have a material impact on or materially disrupt our operations.
+Added: we hold our own intellectual property outside of the scope of our agreements with third parties, a termination of the agreement could
+Added: adversely affect our business and ability to commercialize our clinical assets.
+Added: These third parties play a significant role in the conduct
+Added: of these trials and the subsequent collection and analysis of data from the clinical trials.
+Added: We rely heavily on these parties for the
+Added: execution of our clinical trials and preclinical studies, and control only certain aspects of their activities.
+Added: may choose not to continue developing or commercializing any of our clinical assets at any time during development or after approval,
+Added: which would reduce or eliminate our potential return on investment for those clinical assets.
+Added: may decide to discontinue the development of any of our clinical assets or not to continue commercializing one or more of our approved
+Added: clinical assets for a variety of reasons, including the appearance of new technologies that make a product obsolete, competition from
+Added: a competing product, or changes in or failure to comply with applicable regulatory requirements at any time.
+Added: If we terminate a program
+Added: in which we have invested significant resources, we will not receive any return on our investment and we will have missed the opportunity
+Added: to have allocated those resources to potentially more productive uses.
+Added: we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize
+Added: our clinical assets or otherwise implement our business plan.
+Added: ability to compete in the highly competitive pharmaceuticals industry depends upon its ability to attract and retain highly qualified
+Added: managerial, scientific, medical, sales, marketing, and other personnel.
+Added: We are highly dependent on our management, including our Chief
+Added: Executive Officer, David Tapolczay.
+Added: The loss of the services of any of these individuals could impede, delay, or prevent the successful
+Added: development of our product pipeline, completion of our planned clinical trials, commercialization of our clinical assets, or in-licensing
+Added: or acquisition of new assets and could negatively impact our ability to successfully implement our business plan.
+Added: If we lose the services
+Added: of any of these individuals, we might not be able to find suitable replacements on a timely basis or at all,
+Added: our business could be harmed as a result.
+Added: We do not maintain “key man” insurance policies on the lives of these individuals
+Added: or the lives of any of our other employees.
+Added: In order to retain valuable employees, in addition to salary and cash incentives, we provide
+Added: stock options that vest over time.
+Added: might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for
+Added: qualified personnel among biotechnology, pharmaceutical, and other businesses.
+Added: We could have difficulty attracting experienced personnel
+Added: to the Company and may be required to expend significant financial resources in our employee recruitment and retention efforts.
+Added: of the other pharmaceutical companies with whom we compete for qualified personnel have greater financial and other resources, different
+Added: risk profiles, and longer histories in the industry than we do.
+Added: They also may provide more diverse opportunities and better chances for
+Added: career advancement.
+Added: If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience
+Added: constraints that will harm our ability to implement our business strategy and achieve our business objectives.
+Added: addition, we have scientific and clinical advisors who assist us in formulating our development and clinical strategies.
+Added: These advisors
+Added: are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability
+Added: In addition, our advisors may have arrangements with other companies to assist those companies in developing products or technologies
+Added: that may compete with those of the Company.
+Added: currently have limited marketing capabilities and no sales organization.
+Added: If we do not establish sales and marketing capabilities on our
+Added: own or through third parties, we will be limited in our commercialization to license deals with third parties following successful Phase
+Added: currently have limited marketing capabilities and no sales organization.
+Added: If we do not establish sales and marketing capabilities on our
+Added: own or through third parties, we will be limited in our commercialization to license deals with third parties following successful Phase
+Added: To commercialize our clinical assets, if approved, in the U.S., Canada, the European Union, and other jurisdictions that we
+Added: seek to enter, we must build our marketing, sales, distribution, managerial, and other non-technical capabilities or make arrangements
+Added: with third parties to perform these services, and we may not be successful in doing so.
+Added: Although our management team has experience in
+Added: the marketing, sale, and distribution of pharmaceutical products from prior employment at other companies, we as a company have no prior
+Added: experience in the marketing, sale, and distribution of pharmaceutical products and there are significant risks involved in building and
+Added: managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate sufficient sales
+Added: leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing
+Added: Any failure or delay in the development of our internal sales, marketing, and distribution capabilities would adversely impact
+Added: the commercialization of these products.
+Added: We may choose to collaborate with additional third parties that have direct sales forces and
+Added: established distribution systems, either to augment our own sales force and distribution systems or in lieu of its own sales force and
+Added: distribution systems.
+Added: If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully
+Added: commercialize our clinical assets.
+Added: If we are unable to successfully commercialize our clinical assets, either on our own or through collaborations
+Added: with one or more third parties, our business, financial condition, operating results, and prospects would suffer.
+Added: failure to successfully in-license, acquire, develop, and market additional clinical assets or approved products would impair our ability
+Added: to grow our business.
+Added: intend to in-license, acquire, develop, and market additional products and clinical assets and we may in-license or acquire commercial-stage
+Added: products or engage in other strategic transactions.
+Added: Because our internal research and development capabilities are limited, we may be
+Added: dependent upon pharmaceutical companies, academic scientists, and other researchers to sell or license products or technology to us.
+Added: The success of this strategy depends partly upon our ability to identify and select promising pharmaceutical clinical assets and products,
+Added: negotiate licensing or acquisition agreements with their current owners, and finance these arrangements.
+Added: process of proposing, negotiating, and implementing a license or acquisition of a clinical asset or approved product is lengthy and complex.
+Added: Other companies, including some with substantially greater financial, marketing, sales, and other resources, may compete with us for
+Added: the license or acquisition of clinical assets and approved products.
+Added: We have limited resources to identify and execute the acquisition
+Added: or in-licensing of third-party products, businesses, and technologies and integrate them into our current infrastructure.
+Added: may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated
+Added: benefits of such efforts.
+Added: We may not be able to acquire the rights to additional clinical assets on terms that we find acceptable, or
+Added: any clinical asset that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical
+Added: testing and approval by the FDA and applicable foreign regulatory authorities.
+Added: All clinical assets are prone to risks of failure typical
+Added: of pharmaceutical product development, including the possibility that a clinical asset will not be shown to be sufficiently safe and
+Added: effective for approval by regulatory authorities.
+Added: In addition, we cannot provide assurance that any approved products that we acquire
+Added: will be manufactured or sold profitably or achieve market acceptance.
+Added: potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships,
+Added: joint ventures, restructurings, divestitures, business combinations, and investments.
+Added: Any such transaction may require us to incur non-recurring
+Added: or other charges, may increase our near- and long-term expenditures, and may pose significant integration challenges or disrupt our management
+Added: or business, which could adversely affect our operations and financial results.
+Added: For example, these transactions entail numerous potential
+Added: operational and financial risks, including:
+Added: to unknown liabilities;
+Added: of our business and diversion of our management’s time and attention in order to develop acquired products, clinical assets,
+Added: or technologies;
+Added: of substantial debt or dilutive issuances of equity securities to pay for acquisitions;
+Added: acquisition and integration costs;
+Added: of assets or impairment charges;
+Added: amortization expenses;
+Added: and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;
+Added: of relationships with key suppliers, partners, or customers of any acquired businesses due to changes in management and ownership;
+Added: to retain our key employees or those of any acquired businesses.
+Added: there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, and any transaction
+Added: that we do complete could harm our business, financial condition, operating results, and prospects.
+Added: Manufacturing
+Added: and supply of the APIs and other substances and materials used in our clinical assets is a complex and technically challenging undertaking,
+Added: and there is potential for failure at many points in the manufacturing, testing, quality assurance, and distribution supply chain, as
+Added: well as the potential for latent defects after products have been manufactured and distributed.
+Added: Manufacturing
+Added: and supply of APIs, other substances, and materials and finished drug products is technically challenging.
+Added: Changes beyond our direct
+Added: control can impact the quality, volume, price, and successful delivery of our clinical assets and can impede, delay, limit, or prevent
+Added: the successful development and commercialization of our clinical assets.
+Added: Mistakes and mishandling are not uncommon and can affect successful
+Added: production and supply.
+Added: Some of these risks include:
+Added: of our manufacturers to follow cGMP or GACP requirements or mishandling of product while in production or in preparation for transit;
+Added: of our contract suppliers and manufacturers to efficiently and cost-effectively increase and maintain high yields and batch quality,
+Added: consistency, and stability;
+Added: inability to develop an FDA-approved bioassay for release of any future product;
+Added: in establishing optimal drug delivery substances and techniques, production, and storage methods and packaging and shipment processes;
+Added: transportation
+Added: and import/export risk, particularly given the global nature of our supply chain;
+Added: in analytical results or failure of analytical techniques that we depend on for quality control and release of any future product;
+Added: disasters, pandemics, labor disputes, financial distress, lack of raw material supply, issues with facilities and equipment, or other
+Added: forms of disruption to business operations of our contract manufacturers and suppliers;
+Added: defects that may become apparent after the product has been released and which may result in recall and destruction of product.
+Added: of these factors could result in delays or higher costs in connection with our clinical trials, regulatory submissions, required approvals,
+Added: or commercialization of our clinical assets, which could harm our business, financial condition, operating results, and prospects.
+Added: operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating
+Added: results to fall below expectations.
+Added: operations of the Company since the Business Combination and of Old Conduit prior to the Business Combination have been primarily limited
+Added: to researching and developing our clinical assets and undertaking preclinical studies and clinical trials of our clinical assets.
+Added: have not yet obtained regulatory approvals for any of our clinical assets.
+Added: Consequently, any predictions investors make about our future
+Added: success or viability may not be as accurate as they could be if we had a longer operating history or approved products on the market.
+Added: Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may
+Added: be difficult to predict, including the following:
+Added: in the commencement, enrollment, and the timing of clinical testing for our clinical assets;
+Added: timing and success or failure of clinical trials for our clinical assets or competing clinical assets, or any other change in the
+Added: competitive landscape of our industry, including consolidation among our competitors or partners;
+Added: delays in regulatory review and approval of clinical assets in clinical development;
+Added: timing and cost of, and level of investment in, research and development activities relating to our clinical assets, which may change
+Added: from time to time;
+Added: cost of manufacturing our clinical assets, which may vary depending on FDA guidelines and requirements, and the quantity of production;
+Added: ability to obtain additional funding to develop our clinical assets;
+Added: that we will or may incur to acquire or develop additional clinical assets and technologies;
+Added: level of demand for our clinical assets, should they receive approval, which may vary significantly;
+Added: side effects of our clinical assets that could delay or prevent commercialization or cause an approved drug to be taken off the market;
+Added: ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for our clinical assets, if approved;
+Added: dependency on third-party manufacturers to supply or manufacture our clinical assets;
+Added: ability to establish an effective sales, marketing, and distribution infrastructure in a timely manner;
+Added: acceptance of our clinical assets, if approved, and our ability to forecast demand for those clinical assets;
+Added: ability to receive approval and commercialize our clinical assets outside of the U.S.;
+Added: ability to establish and maintain collaborations, licensing, or other arrangements;
+Added: ability and third parties’ abilities to protect intellectual property rights;
+Added: related to and outcomes of potential litigation or other disputes;
+Added: ability to adequately support future growth;
+Added: ability to attract and retain key personnel to manage our business effectively;
+Added: liabilities associated with hazardous materials;
+Added: ability to maintain adequate insurance policies;
+Added: accounting pronouncements or changes in our accounting policies.
+Added: Concentration
+Added: of ownership of our equity securities may have the effect of delaying or preventing a change in control.
+Added: of April 16, 2024, Corvus Capital Limited (of which Dr.
+Added: Regan, a director on our board of directors, is the Chief Executive Officer),
+Added: Algo Holdings, Inc., and Dr.
+Added: Regan personally, together hold an ownership interest of 45,593,799 shares of our common stock or approximately
+Added: 61.8% of our outstanding common stock, St George Street Capital holds an ownership interest of 4,749,816 shares of our common stock or
+Added: approximately 6.4% of our outstanding common stock, and the Sponsor holds an ownership interest of 4,105,250 shares of our common stock
+Added: or approximately 6.4% of our outstanding common stock.
+Added: As a result, a small number of our equity holders may have the ability to determine
+Added: the outcome of corporate actions of the Company requiring stockholder approval, including the election all of the directors of the board
+Added: of directors and the approval of significant corporate matters.
+Added: This concentration of ownership may have the effect of delaying or preventing
+Added: a change in control and might adversely affect the market price of our common stock.
+Added: Capital Limited, Algo Holdings, Inc., and Andrew Regan, our principal stockholders, beneficially own greater than 50% of our outstanding
+Added: shares of common stock, which will cause us to be deemed a “controlled company” under the rules of Nasdaq.
+Added: of April 16, 2024, Corvus Capital Limited, Algo Holdings, Inc.
+Added: and Andrew Regan (one of our directors) beneficially own 61.7% of the
+Added: voting power of our capital stock.
+Added: Because Corvus Capital Limited, Algo Holdings, Inc.
+Added: Regan beneficially own more than 50% of
+Added: our outstanding shares, we are a “controlled company” under the rules of Nasdaq.
+Added: Under these rules, a company of which more
+Added: than 50% of the voting power is held by an individual, a group or another company is a “controlled company” and, as such,
+Added: can elect to be exempt from certain corporate governance requirements, including requirements that:
+Added: majority of the board of directors consist of independent directors;
+Added: board of directors maintain a nominations committee with prescribed duties and a written charter;
+Added: board of directors maintains a compensation committee with prescribed duties and a written charter and comprised solely of independent
+Added: a “controlled company,” we may elect to rely on some or all of these exemptions, however, we do not intend take advantage
+Added: of any of these exemptions.
+Added: Despite the fact we do not intend to take advantage of these exemptions, our status as a controlled company
+Added: could make our common stock less attractive to some investors or otherwise harm our stock price.
+Added: in foreign currency could have an effect on our reported results of operations.
+Added: exposure to fluctuations in foreign currency rates results primarily from the translation exposure associated with the preparation of
+Added: our consolidated financial statements, as well as from transaction exposure associated with transactions in currencies other than our
+Added: functional currency.
+Added: While our consolidated financial statements are reported in U.S.
+Added: dollars, our financial statements of foreign subsidiaries
+Added: are prepared using the British pound sterling as the functional currency and then translated into U.S.
+Added: We cannot accurately
+Added: predict the nature or extent of future exchange rate variability of the British pound sterling or the exchange rate relative to the U.S.
+Added: Foreign exchange rates are sensitive to factors beyond our control.
+Added: In addition, Brexit has caused, and may continue to cause,
+Added: significant volatility in currency exchange rates, especially between the U.S.
+Added: dollar and the British pound sterling.
+Added: These fluctuations
+Added: in foreign currency exchange rates could negatively affect our results of operations and impact reported financial results.
+Added: operating results and liquidity needs could be negatively affected by market fluctuations and economic downturn.
+Added: operating results and liquidity could be negatively affected by economic conditions generally, both in the U.S.
+Added: and elsewhere around
+Added: The market for discretionary medical products and procedures may be particularly vulnerable to unfavorable economic conditions.
+Added: Some patients may consider certain of our clinical assets to be discretionary, and if full reimbursement for such products is not available,
+Added: demand for these products may be tied to the discretionary spending levels of our targeted patient populations.
+Added: Domestic and international
+Added: equity and debt markets have experienced and may continue to experience heightened volatility and turmoil based on domestic and international
+Added: economic conditions and concerns.
+Added: In the event these economic conditions and concerns continue or worsen and the markets continue to
+Added: remain volatile, our operating results and liquidity could be adversely affected by those factors in many ways, including weakening demand
+Added: for certain of our products and making it more difficult for us to raise funds if necessary.
+Added: Additionally, although we plan to market
+Added: our products primarily in the U.S., we could in the future have partners with extensive global operations, indirectly exposing us to
+Added: maintain our cash and cash equivalents with high quality, accredited financial institutions.
+Added: However, some of these accounts exceed the
+Added: government-insured limits, and, while we believe that we are not exposed to significant credit risk due to the financial strength of
+Added: these depository institutions or investments, the failure or collapse of one or more of these depository institutions or default on these
+Added: investments could materially adversely affect our ability to recover these assets and/or materially harm our financial condition.
+Added: are increasingly dependent on information technology, and our systems and infrastructure face certain risks, including cybersecurity
+Added: and data leakage risks.
+Added: disruptions to our information technology systems or breaches of information security could adversely affect our business.
+Added: In the ordinary
+Added: course of business, we collect, store, and transmit large amounts of confidential information, and it is critical that we do so in a
+Added: secure manner to maintain the confidentiality and integrity of such confidential information.
+Added: The size and complexity of our information
+Added: technology systems, and those of our third-party vendors with whom we contract, make such systems potentially vulnerable to service interruptions
+Added: and security breaches from inadvertent or intentional actions by our employees, partners, or vendors, from attacks by malicious third
+Added: parties, or from intentional or accidental physical damage to our systems infrastructure maintained by us or by third parties.
+Added: the secrecy of this confidential, proprietary, or trade secret information is important to our competitive business position.
+Added: have taken steps to protect such information and invested in information technology, there can be no assurance that our efforts will
+Added: prevent service interruptions or security breaches in our systems or the unauthorized or inadvertent wrongful use or disclosure of confidential
+Added: information that could adversely affect our business operations or result in the loss, dissemination, or misuse of critical or sensitive
+Added: A breach of our security measures or the accidental loss, inadvertent disclosure, unapproved dissemination, misappropriation
+Added: or misuse of trade secrets, proprietary information, or other confidential information, whether as a result of theft, hacking, fraud,
+Added: trickery, or other forms of deception, or for any other reason, could enable others to produce competing products, use our proprietary
+Added: technology or information, or adversely affect our business or financial condition.
+Added: Further, any such interruption, security breach,
+Added: loss, or disclosure of confidential information could result in financial, legal, business, and reputational harm to us and could have
+Added: a material adverse effect on our business, financial position, results of operations, or cash flow.
+Added: business and operations would suffer in the event of failures in our internal computer systems.
+Added: the implementation of security measures, our computer systems and those of our current and any future partners, contractors, and consultants
+Added: are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical
+Added: While we have not experienced any such material system failure, accident, or security breach to date, if such an event were
+Added: to occur and cause interruptions in our operations, it could result in a material disruption of our manufacturing activities, development
+Added: programs, and business operations.
+Added: For example, the loss of manufacturing records or clinical trial data from completed or future clinical
+Added: trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.
+Added: If we experienced a security breach, our online sources were hacked, or we experienced a data leak, it could result in confidential clinical
+Added: trial data being leaked to competitors and the market.
+Added: To the extent that any disruption or security breach were to result in a loss
+Added: of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability
+Added: and the further commercialization and development of our products and clinical assets could be delayed.
+Added: Related to Intellectual Property
+Added: to adequately protect our intellectual property could adversely affect our business, financial condition, and operating results.
+Added: business depends on our intellectual property and proprietary technology, the protection of which is crucial to the success of our business.
+Added: We rely on a combination of trademark, copyright, and trade secret laws, license agreements, intellectual property assignment agreements,
+Added: and confidentiality procedures to protect our intellectual property.
+Added: Additionally, we rely on proprietary information (such as trade
+Added: secrets, know-how, and confidential information) to protect intellectual property that may not be patentable, or that we believe is best
+Added: protected by means that do not require public disclosure.
+Added: We generally attempt to protect our intellectual property, technology, and
+Added: confidential information by requiring our employees and consultants who develop intellectual property on our behalf to enter into confidentiality
+Added: and invention assignment agreements and third parties that we share information with to enter into nondisclosure agreements.
+Added: These agreements
+Added: may not effectively prevent unauthorized use or disclosure of our confidential information, intellectual property, or technology and
+Added: may not provide an adequate remedy in the event of unauthorized use or disclosure of our confidential information or technology, or infringement
+Added: of our intellectual property.
+Added: For example, we may fail to enter into the necessary agreements, and even if entered into, these agreements
+Added: may be willfully breached or may otherwise fail to prevent disclosure, third-party infringement, or misappropriation of our proprietary
+Added: information, may be limited as to their term, and may not provide an adequate remedy in the event of unauthorized disclosure or use of
+Added: proprietary information.
+Added: In addition, our proprietary information may otherwise become known or be independently developed by our competitors
+Added: or other third parties.
+Added: To the extent that our employees, consultants, contractors, and other third parties use intellectual property
+Added: owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.
+Added: time-consuming litigation could be necessary to enforce and determine the scope of our intellectual property rights and other proprietary
+Added: rights, and failure to obtain or maintain protection for our proprietary information could adversely affect our competitive business
+Added: our efforts to protect our proprietary rights, other parties may unintentionally or willfully disclose, obtain, or use our technologies
+Added: or systems, which may allow unauthorized parties to copy aspects of our platform or other software, technology, and functionality or
+Added: obtain and use information that we consider proprietary.
+Added: In addition, unauthorized parties may also attempt, or successfully endeavor,
+Added: to obtain our intellectual property, confidential information, and trade secrets through various methods, including through scraping
+Added: of public data or other content from our website or mobile applications, cybersecurity attacks, and legal or other methods of protecting
+Added: this data may be inadequate.
+Added: Monitoring unauthorized use and disclosures of our intellectual property, proprietary technology, or confidential
+Added: information can be difficult and expensive and we cannot be sure that the steps we have taken will prevent misappropriation or infringement
+Added: of our intellectual property or proprietary rights.
+Added: have registered the domain name for the website that we use in our business, which is www.conduitpharma.com.
+Added: The inclusion of the website
+Added: address in this Annual Report does not include or incorporate by reference the information on the Company’s website into this document.
+Added: have and may continue to adopt service names similar to ours, thereby harming our ability to build brand identity and possibly leading
+Added: to user confusion.
+Added: In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks
+Added: that are similar to our trademarks.
+Added: Further, litigation or proceedings before the U.S.
+Added: Patent and Trademark Office or other governmental
+Added: authorities and administrative bodies in the U.S.
+Added: and abroad may be necessary in the future to enforce our intellectual property rights
+Added: and to determine the validity and scope of the proprietary rights of others.
+Added: Any litigation initiated by us concerning the violation
+Added: by third parties of our intellectual property rights is likely to be expensive and time-consuming and could lead to the invalidation
+Added: of, or render unenforceable, our intellectual property, or could otherwise have negative consequences for us.
+Added: Even when we sue other
+Added: parties for such infringement, that suit may have adverse consequences for our business.
+Added: In addition, we may not timely or successfully
+Added: apply for a patent or register our trademarks or otherwise secure our intellectual property, which could result in negative effects to
+Added: our market share, financial condition, and results of operations.
+Added: Our efforts to protect, maintain, or enforce our proprietary rights
+Added: may not be respected in the future or may be invalidated, circumvented, or challenged, and could result in substantial costs and diversion
+Added: of resources, which could adversely affect our business, financial condition, and operating results.
+Added: may be unable to continue to use the domain name that we use in our business or prevent third parties from acquiring and using domain
+Added: names that infringe on, are similar to, or otherwise decrease the value of our brand, trademarks, or service marks.
+Added: have registered the domain name that we use in our business.
+Added: If we lose the ability to use that domain name, whether due to trademark
+Added: claims, failure to renew the applicable registration, or any other cause, we may be forced to market our business under a new domain
+Added: name, which could cause us substantial harm, or to incur significant expense in order to purchase rights to the domain name in question.
+Added: We may not be able to obtain preferred domain names outside the U.S.
+Added: due to a variety of reasons, including because they are already
+Added: held by others.
+Added: In addition, our competitors and others could attempt to capitalize on our brand recognition by using domain names similar
+Added: to our domain name.
+Added: We may be unable to prevent third parties from acquiring and using domain names that infringe on, are similar to,
+Added: or otherwise decrease the value of our brand or our trademarks or service marks.
+Added: Protecting, maintaining, and enforcing our rights in
+Added: our domain names may require litigation, which could result in substantial costs and diversion of resources, which could in turn adversely
+Added: affect our business, financial condition, and operating results.
+Added: may not be able to protect our intellectual property rights throughout the world.
+Added: prosecuting, and defending patents on our clinical assets in all countries throughout the world would be prohibitively expensive.
+Added: requirements for patentability may differ in certain countries, particularly developing countries.
+Added: In addition, the laws of some foreign
+Added: countries do not protect intellectual property rights to the same extent as laws in the U.S.
+Added: Consequently, we may not be able to prevent
+Added: third parties from practicing our inventions in all countries outside the U.S.
+Added: Competitors may use our technologies in jurisdictions
+Added: where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to
+Added: territories where we have patent protection, but enforcement on infringing activities is inadequate.
+Added: These products may compete with
+Added: our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
+Added: companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.
+Added: legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual
+Added: property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of
+Added: our patents or marketing of competing products in violation of our proprietary rights generally.
+Added: Proceedings to enforce our patent rights
+Added: in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could
+Added: put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke
+Added: third parties to assert claims against us.
+Added: We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded,
+Added: if any, may not be commercially meaningful.
+Added: In addition, certain countries in Europe and certain developing countries have compulsory
+Added: licensing laws under which a patent owner may be compelled to grant licenses to third parties.
+Added: In those countries, we may have limited
+Added: remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially
+Added: diminish the value of those patents.
+Added: This could limit our potential revenue opportunities.
+Added: Accordingly, our efforts to enforce our intellectual
+Added: property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we
+Added: own or license.
+Added: Our ability to protect and enforce our intellectual property rights may also be adversely affected by unforeseen changes
+Added: in foreign intellectual property laws.
+Added: and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements
+Added: imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
+Added: maintenance and annuity fees on any issued patent are due to be paid to the United States Patent and Trademark Office (“USPTO”)
+Added: and foreign patent agencies in several stages over the lifetime of the patent.
+Added: The USPTO and various foreign governmental patent agencies
+Added: require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application
+Added: While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable
+Added: rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting
+Added: in partial or complete loss of patent rights in the relevant jurisdiction.
+Added: Non-compliance events that could result in abandonment or
+Added: lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of
+Added: fees, and failure to properly legalize and submit formal documents.
+Added: If we or our licensors fail to maintain the patents and patent applications
+Added: covering our clinical assets, our competitors might be able to enter the market, which would have an adverse effect on our business.
+Added: we fail to comply with our obligations under our intellectual property license agreements, we could lose license rights that are important
+Added: to our business.
+Added: are a party to certain license agreements that impose various diligence, milestone, royalty, insurance, and other obligations on us.
+Added: If we fail to comply with these obligations, the respective licensors may have the right to terminate the license, in which event we
+Added: may not be able to develop or market the affected clinical asset.
+Added: Our business strategy depends on our ability to commercialize our clinical
+Added: assets and our ability to enter into license agreements relating to such clinical assets is critical to the success of our operations.
+Added: The loss of such rights could materially adversely affect our business, financial condition, operating results, and prospects.
+Added: information about these license arrangements, see “Business — Strategic Alliances and Arrangements.”
+Added: we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome
+Added: in that litigation could have a material adverse effect on our business.
+Added: commercial success depends upon its ability to develop, manufacture, market, and sell our clinical assets and use our proprietary technologies
+Added: without infringing the proprietary rights of third parties.
+Added: We cannot guarantee that marketing and selling such candidates and using
+Added: such technologies will not infringe existing or future patents.
+Added: Numerous U.S.
+Added: and foreign issued patents and pending patent applications
+Added: owned by third parties exist in the fields relating to our clinical assets.
+Added: As the biotechnology and pharmaceutical industries expand
+Added: and more patents are issued, the risk increases that others may assert that our clinical assets, technologies, or methods of delivery
+Added: or use infringe their patent rights.
+Added: Moreover, it is not always clear to industry participants, including us, which patents cover various
+Added: drugs, biologics, drug delivery systems, or their methods of use, and which of these patents may be valid and enforceable.
+Added: Thus, because
+Added: of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege
+Added: they have patent rights encompassing our clinical assets, technologies, or methods.
+Added: addition, there may be issued patents of third parties that are infringed or are alleged to be infringed by our clinical assets or proprietary
+Added: technologies.
+Added: We cannot be certain that others have not filed patent applications for technology covered by our own and in-licensed issued
+Added: patents or our pending applications because some patent applications in the U.S.
+Added: may be maintained in secrecy until the patents are issued,
+Added: patent applications in the U.S.
+Added: and many foreign jurisdictions are typically not published until eighteen months after filing, and publications
+Added: in the scientific literature often lag behind actual discoveries.
+Added: Our competitors may have filed, and may in the future file, patent
+Added: applications covering our clinical assets or technology similar to ours.
+Added: Any such patent application may have priority over our own and
+Added: in-licensed patent applications or patents, which could further require us to obtain rights to issued patents covering such technologies.
+Added: If another party has filed a U.S.
+Added: patent application on inventions similar to those owned or in-licensed to us, we or, in the case of
+Added: in-licensed technology, the licensor may have to participate, in the U.S., in an interference proceeding to determine priority of invention.
+Added: may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging
+Added: that our clinical assets or proprietary technologies infringe such third parties’ intellectual property rights, including litigation.
+Added: These lawsuits could claim that there are existing patent rights for such drug and this type of litigation can be costly and could adversely
+Added: affect our operating results and divert the attention of managerial and technical personnel, even if we do not infringe such patents
+Added: or the patents asserted against us are ultimately established as invalid.
+Added: There is a risk that a court would decide that we are infringing
+Added: the third party’s patents and would order us to stop the activities covered by the patents.
+Added: In addition, there is a risk that a
+Added: court will order us to pay the other party damages for having violated the other party’s patents.
+Added: a result of patent infringement claims, or to avoid potential claims, we may choose or be required to seek licenses from third parties.
+Added: These licenses may not be available on commercially acceptable terms, or at all.
+Added: Even if we are able to obtain a license, the license
+Added: would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result
+Added: in our competitors gaining access to the same intellectual property, or such rights might be restrictive and limit our present and future
+Added: Ultimately, we or a licensee could be prevented from commercializing a product or be forced to cease some aspect of our business
+Added: operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.
+Added: addition to possible infringement claims against us, we may become a party to other patent litigation and other proceedings, including
+Added: interference, derivation, re-examination, or other post-grant proceedings declared or granted by the USPTO, and similar proceedings in
+Added: foreign countries, regarding intellectual property rights with respect to our current or future products.
+Added: is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical
+Added: industries generally.
+Added: To date, no litigation asserting infringement claims has ever been brought against us.
+Added: If a third-party claims
+Added: that we infringe its intellectual property rights, we may face a number of issues, including:
+Added: and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert
+Added: our management’s attention from our core business;
+Added: damages for infringement, which we may have to pay if a court decides that the product or technology at issue infringes or violates
+Added: the third party’s rights, and if the court finds that the infringement was willful, we could be ordered to pay treble damages
+Added: and the patent owner’s attorneys’ fees;
+Added: court prohibiting us from selling or licensing the product or using the technology unless the third party licenses its intellectual
+Added: property rights to us, which it is not required to do;
+Added: a license is available from a third party, we may have to pay substantial royalties or upfront fees or grant cross-licenses to intellectual
+Added: property rights for our products or technologies;
+Added: our products or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and
+Added: of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially
+Added: greater resources.
+Added: In addition, any uncertainties resulting from the initiation and continuation of any litigation could harm our ability
+Added: to raise additional funds or otherwise adversely affect our business, financial condition, operating results, and prospects.
+Added: we rely on certain third-party licensors and partners, and will continue to do so in the future, if one of our licensors or partners
+Added: is sued for infringing a third party’s intellectual property rights, our business, financial condition, operating results, and
+Added: prospects could suffer in the same manner as if we were sued directly.
+Added: In addition to facing litigation risks, we have agreed to indemnify
+Added: certain third-party licensors and partners against claims of infringement caused by our proprietary technologies, and we have entered
+Added: or may enter into cost-sharing agreements with some our licensors and partners that could require us to pay some of the costs of patent
+Added: litigation brought against those third parties whether or not the alleged infringement is caused by our proprietary technologies.
+Added: certain instances, these cost-sharing agreements could also require us to assume greater responsibility for infringement damages than
+Added: would be assumed just on the basis of our technology.
+Added: occurrence of any of the foregoing could adversely affect our business, financial condition, or operating results.
+Added: may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, or
+Added: other claims may be made against us, which could be expensive and time-consuming.
+Added: may infringe our intellectual property, including our patents or the patents of our licensors.
+Added: As a result, we may be required to file
+Added: infringement claims to stop third-party infringement or unauthorized use.
+Added: This can be expensive and time-consuming, particularly for
+Added: a company of our size.
+Added: In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable
+Added: or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology
+Added: or that the factors necessary to grant an injunction against an infringer are not satisfied.
+Added: An adverse determination of any litigation
+Added: or other proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly, or amended such that they
+Added: do not cover our clinical assets.
+Added: Moreover, such adverse determinations could put our patent applications at risk of not issuing or issuing
+Added: with limited and potentially inadequate scope to cover our clinical assets or to prevent others from marketing similar products.
+Added: Interference,
+Added: derivation, or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with
+Added: respect to our patent applications or those of our licensors or potential partners.
+Added: Litigation or USPTO proceedings brought by us may
+Added: fail or may be invoked against us by third parties.
+Added: Even if we are successful, domestic or foreign litigation or USPTO or foreign patent
+Added: office proceedings may result in substantial costs and distraction to our management.
+Added: We may not be able, alone or with our licensors
+Added: or potential partners, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect
+Added: such rights as fully as in the U.S.
+Added: because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there
+Added: is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.
+Added: In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings,
+Added: motions, or other interim proceedings or developments or public access to related documents.
+Added: addition, in August 2023, prior to the Business Combination, our now wholly-owned subsidiary, Conduit Pharmaceuticals Limited, received
+Added: a letter from Strand Hanson Limited (“Strand”) claiming it was owed advisory fees pursuant to a previously executed letter.
+Added: Conduit rejected and disputes the substance of the letter in full.
+Added: Following such rejection, on September 7, 2023, Strand filed a claim
+Added: in the Business and Property Courts of England and Wales claiming it is entitled to be paid the sum of $2 million and, as a result of
+Added: the event the Business Combination is completed, to be issued 6.5 million shares of common stock.
+Added: We intend to vigorously defend against
+Added: these claims.
+Added: Regardless of its outcome, the litigation may impact our business due to, among other things, defense legal cost and the
+Added: diversion of the attention of our management.
+Added: reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated
+Added: or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets
+Added: and protect other proprietary information.
+Added: consider proprietary trade secrets or confidential know-how and unpatented know-how to be important to our business.
+Added: We may rely on trade
+Added: secrets or confidential know-how to protect our technology, especially where we believe that patent protection is of limited value.
+Added: protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants,
+Added: collaborators, contractors, and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting
+Added: agreements, or other similar agreements with us prior to beginning research or disclosing proprietary information.
+Added: These agreements typically
+Added: limit the rights of the third parties to use or disclose our confidential information, including our trade secrets.
+Added: However, current
+Added: or former employees, consultants, collaborators, contractors, and advisors may unintentionally or willfully disclose our confidential
+Added: information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure
+Added: of confidential information.
+Added: The need to share trade secrets and other confidential information increases the risk that such trade secrets
+Added: become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation
+Added: of these agreements.
+Added: Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery
+Added: of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on
+Added: our business and results of operations.
+Added: Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential
+Added: know-how is expensive, time consuming, and unpredictable.
+Added: The enforceability of confidentiality agreements may vary from jurisdiction
+Added: to jurisdiction.
+Added: addition, these agreements typically restrict the ability of our employees, consultants, collaborators, contractors, and advisors to
+Added: publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights.
+Added: our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with
+Added: third parties, independent development, or publication of information by any of our third-party collaborators.
+Added: A competitor’s discovery
+Added: of our trade secrets would impair our competitive position and have an adverse impact on our business.
+Added: may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed to us alleged
+Added: trade secrets of their former employers or their former or current customers.
+Added: is common in the biotechnology and pharmaceutical industries, certain of our employees were formerly employed by other biotechnology
+Added: or pharmaceutical companies, including our competitors or potential competitors.
+Added: Moreover, we engage the services of consultants to assist
+Added: it in the development of our products and clinical assets, many of whom were previously employed at or may have previously been or are
+Added: currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
+Added: We may be subject to claims that these employees and consultants or we have inadvertently or otherwise used or disclosed trade secrets
+Added: or other proprietary information of their former employers or their former or current customers.
+Added: Although we have no knowledge of any
+Added: such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims.
+Added: if we are successful in defending against any such claims, any such litigation could be protracted, expensive, a distraction to our management
+Added: team, not viewed favorably by investors and other third parties, and may potentially result in an unfavorable outcome.
+Added: our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
+Added: and our business may be adversely affected.
+Added: unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing
+Added: on other marks.
+Added: We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition
+Added: among potential collaborators or customers in our markets of interest.
+Added: At times, competitors may adopt trade names or trademarks similar
+Added: to those of ours, thereby impeding our ability to build brand identity and possibly leading to market confusion.
+Added: In addition, there could
+Added: be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate
+Added: variations of our unregistered trademarks or trade names.
+Added: Over the long term, if we are unable to successfully register its trademarks
+Added: and trade names and establish name recognition based on its trademarks and trade names, then we may not be able to compete effectively,
+Added: and our business may be adversely affected.
+Added: Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets,
+Added: domain names, copyrights, or other intellectual property may be ineffective and could result in substantial costs and diversion of resources
+Added: and could adversely impact our financial condition or results of operations.
+Added: proprietary information may be lost, or we may suffer security breaches.
+Added: the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary
+Added: business information, personal data, and personally identifiable information of our clinical trial subjects and employees, in our data
+Added: centers and on our networks.
+Added: The secure processing, maintenance, and transmission of this information is critical to our operations.
+Added: Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due
+Added: to employee error, malfeasance, or other disruptions.
+Added: Although, to our knowledge, we have not experienced any such material security
+Added: breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed,
+Added: lost, or stolen.
+Added: Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under
+Added: laws that protect the privacy of personal information, significant regulatory penalties, disrupt our operations, damage our reputation,
+Added: and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay
+Added: our clinical development of our clinical assets.
+Added: Related to Securities Markets and Investment in Our Stock
+Added: may delist our securities from trading on its exchange.
+Added: common stock is listed on The Nasdaq Global Market and our redeemable warrants are listed on The Nasdaq Capital Market.
+Added: Although we met
+Added: the minimum initial listing standards of Nasdaq, which generally only requires that we meet certain requirements relating to stockholders’
+Added: equity, market capitalization, aggregate market value of publicly held shares, and distribution requirements, we cannot assure investors
+Added: that our securities will continue to be listed on Nasdaq in the future.
+Added: The inability to comply with Nasdaq’s continued requirements
+Added: or standards could result in the delisting of our common stock, which could have a material adverse effect on our financial condition
+Added: and could cause the value of the common stock to decline.
+Added: our common stock were to be delisted from trading on The Nasdaq Global Market and the trading price of our common stock were below $5.00
+Added: per share on the date the common stock is delisted, trading in our common stock would also be subject to the requirements of certain
+Added: rules promulgated under the Exchange Act.
+Added: These rules require additional disclosure by broker-dealers in connection with any trades involving
+Added: a stock defined as a “penny stock” and impose various sales practice requirements on broker-dealers who sell penny stocks
+Added: to persons other than established customers and accredited investors, generally institutions.
+Added: These additional requirements may discourage
+Added: broker-dealers from effecting transactions in securities that are classified as penny stocks, which could severely limit the market price
+Added: and liquidity of such securities and the ability of purchasers to sell such securities in the secondary market.
+Added: A penny stock is defined
+Added: generally as any non-exchange listed equity security that has a market price of less than $5.00 per share, subject to certain exceptions.
+Added: do not anticipate paying any dividends in the foreseeable future.
+Added: current expectation is that we will retain our future earnings to fund the development and growth of our business.
+Added: As a result, capital
+Added: appreciation, if any, of the shares of our common stock will stockholders’ sole source of gain, if any, for the foreseeable future.
+Added: Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) provides, subject to limited
+Added: exceptions, that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain stockholder litigation
+Added: matters, which could limit our stockholders’ ability to obtain a chosen judicial forum for disputes with us or our directors, officers,
+Added: employees, or stockholders.
+Added: Certificate of Incorporation requires to the fullest extent permitted by law, that derivative actions brought in our name, actions against
+Added: directors, officers and employees for breach of fiduciary duty and other similar actions may be brought in the Court of Chancery in the
+Added: State of Delaware or, if that court lacks subject matter jurisdiction, another federal or state court situated in the State of Delaware.
+Added: Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of
+Added: and consented to the forum provisions in our Certificate of Incorporation.
+Added: In addition, our Certificate of Incorporation and Bylaws provide
+Added: that the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause
+Added: of action under the Securities Act and the Exchange Act.
+Added: Neither the exclusive forum provisions nor the federal securities laws (and
+Added: the rules and regulations thereunder) may be waived by a stockholder.
+Added: March 2020, the Delaware Supreme Court issued a decision in Salzburg et al.
+Added: Sciabacucchi , which found that an exclusive forum
+Added: provision providing for claims under the Securities Act to be brought in federal court is facially valid under Delaware law.
+Added: to enforce this provision, but we do not know whether courts in other jurisdictions will agree with this decision or enforce it.
+Added: choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum of its choosing for disputes with
+Added: us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims and,
+Added: if a stockholder were to bring such a claim, the choice of forum provision may result in the stockholder incurring increased costs in
+Added: connection with bring such a claim as such stockholder will be required to bring the claim in the state or federal courts located in
+Added: the State of Delaware.
+Added: Alternatively, if a court were to find the choice of forum provision contained in our Certificate of Incorporation
+Added: to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions,
+Added: which could harm its business, operating results, and financial condition.
+Added: charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price
+Added: of our common stock.
+Added: Certificate of Incorporation and Bylaws contain provisions that could delay or prevent a change in control of the Company.
+Added: These provisions
+Added: could also make it more difficult for stockholders to elect directors and take other corporate actions.
+Added: These provisions include:
+Added: our board of directors to issue preferred stock with voting or other rights or preferences that could discourage a takeover attempt
+Added: or delay changes in control;
+Added: cumulative voting in the election of directors;
+Added: that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;
+Added: stockholder action by written consent;
+Added: the persons who may call special meetings of stockholders;
+Added: advance notification of stockholder nominations and proposals.
+Added: provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult
+Added: for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.
+Added: and other provisions in our Certificate of Incorporation and Bylaws and under Delaware law could discourage potential takeover attempts,
+Added: reduce the price investors might be willing to pay in the future for shares of common stock and result in the market price of common
+Added: stock being lower than it would be without these provisions.
+Added: securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or if they
+Added: adversely change their recommendations or publish negative reports regarding our business or our common stock, our share price and trading
+Added: volume could decline.
+Added: trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us, our
+Added: business, or our market.
+Added: Currently, we do not have any analyst coverage and may not obtain analyst coverage in the future.
+Added: we obtain analyst coverage, we will not have any control over such analysts.
+Added: If one or more of the analysts who cover us downgrade the
+Added: common stock or change their opinion of such shares, the share price of the common stock would likely decline.
+Added: If one or more of these
+Added: analysts cease coverage of the Company or fail to regularly publish reports on the Company, we could lose visibility in the financial
+Added: markets, which could cause the share price or trading volume of the common stock to decline.
+Added: are an “emerging growth company” and we cannot be certain if the reduced disclosure requirements applicable to emerging growth
+Added: companies will make our securities less attractive to investors.
+Added: are an “emerging growth company,” as defined in the JOBS Act.
+Added: Emerging growth companies can delay adopting new or revised
+Added: accounting standards until such time as those standards apply to private companies.
+Added: As an emerging growth company, we are not required
+Added: to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, we have reduced disclosure obligations
+Added: regarding executive compensation in our periodic reports and proxy statements, and we are exempt from the requirements of holding a nonbinding
+Added: advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
+Added: predict if investors will find our stock less attractive because we may rely on these provisions.
+Added: If some investors find our stock less
+Added: attractive as a result, there may be a less active trading market for our shares and our stock price may be more volatile.
+Added: will remain an emerging growth company until the earliest of (i) the end of the fiscal year in which the market value of our common stock
+Added: that is held by non-affiliates exceeds $700 million as of the end of the second fiscal quarter, (ii) the end of the fiscal year in which
+Added: we have total annual gross revenues of $1.235 billion or more during such fiscal year, (iii) the date on which we issue more than $1
+Added: billion in non-convertible debt in a three-year period, or (iv) the end of the fiscal year following the fifth anniversary of the date
+Added: of the first sale of our common stock pursuant to an effective registration statement filed under the Securities Act.
+Added: for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us
+Added: and may reduce the amount of money available to us.
+Added: Certificate of Incorporation and Bylaws provides that we will indemnify our directors and officers, in each case to the fullest extent
+Added: permitted by Delaware law.
+Added: addition, as permitted by Section 145 of the DGCL, our Bylaws and our indemnity agreements that we entered into with our directors and
+Added: officers provide that:
+Added: will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request,
+Added: to the fullest extent permitted by Delaware law.
+Added: Delaware law provides that a corporation may indemnify such person if such person
+Added: acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant
+Added: and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful;
+Added: may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;
+Added: will be required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except
+Added: that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled
+Added: to indemnification;
+Added: will not be obligated pursuant to our Bylaws to indemnify a person with respect to proceedings initiated by that person against us
+Added: or our other indemnitees, except with respect to proceedings authorized by our board of directors;
+Added: rights conferred in our Bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors,
+Added: officers, employees and agents and to obtain insurance to indemnify such persons;
+Added: may not retroactively amend our Bylaw provisions to reduce our indemnification obligations to directors, officers, employees and
+Added: Related to Finances and Capital Requirements
+Added: will require substantial additional funding in the future, which may not be available to us on acceptable terms, or at all, and, if not
+Added: so available, may require us to delay, limit, reduce, or cease our operations.
+Added: operations have consumed substantial amounts of cash since our inception.
+Added: As of December 31, 2023, we had an accumulated deficit of $11.3
+Added: million and our net loss was $0.5 million for the fiscal year ended December 31, 2023.
+Added: We expect to continue to incur significant expenses
+Added: and increasing operating losses for the foreseeable future.
+Added: Our business will require substantial additional capital for implementation
+Added: of our long-term business plan and development of clinical assets.
+Added: Our ability to raise additional funds may be adversely impacted by
+Added: potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in
+Added: As we require additional funds, we may seek to fund our operations through the sale of additional equity securities, debt financing,
+Added: and/or strategic collaboration agreements.
+Added: We cannot be sure that additional financing from any of these sources will be available when
+Added: needed or that, if available, the additional financing will be obtained on favorable terms.
+Added: future funding requirements will depend on many factors, including, but not limited to:
+Added: progress, timing, scope, and costs of our clinical trials, including the ability to timely enroll patients in our potential future
+Added: clinical trials;
+Added: outcome, timing, and cost of regulatory approvals by the FDA and comparable regulatory authorities, including the potential that
+Added: the FDA or comparable regulatory authorities may require that we perform more studies than those that we currently expect;
+Added: amount of revenues, if any, from our current clinical assets or any future clinical assets;
+Added: terms and timing of any potential future collaborations, licensing, or other arrangements that we may establish;
+Added: requirements of any future acquisitions and/or the development of other clinical assets;
+Added: costs of operating as a public company;
+Added: time and cost necessary to respond to technological and market developments;
+Added: disputes which may occur between us, employees, collaborators, or other prospective business partners;
+Added: costs of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights
+Added: we raise additional funds by selling shares of our common stock or other equity-linked securities, the ownership interest of our current
+Added: stockholders will be diluted.
+Added: We may seek to access the public or private capital markets whenever conditions are favorable, even if
+Added: we do not have an immediate need for additional capital at that time.
+Added: If we raise additional funds through collaborations, strategic
+Added: alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our
+Added: technologies, future revenue streams, or clinical assets or to grant licenses on terms that may not be acceptable to us.
+Added: additional funds through debt financing, we may have to grant a security interest on our assets to the future lenders, our debt service
+Added: costs may be substantial, and the lenders may have a preferential position in connection with any future bankruptcy or liquidation involving
+Added: April 12, 2024, the last quoted sale price for our common stock as reported on Nasdaq was $3.18 per share.
+Added: Currently, the exercise prices
+Added: of the Company’s warrants are greater than the current market price of our common stock.
+Added: Accordingly, such warrants are unlikely
+Added: to be exercised and therefore the Company does not expect to receive any proceeds from such exercise of the warrants in the near term.
+Added: Whether any holders of Warrants determine to exercise such warrants, which would result in cash proceeds to the Company, will likely
+Added: depend upon the market price of our common stock at the time of any such holder’s determination.
+Added: we are unable to raise additional capital when needed, we may be required to curtail the development of our technology or materially
+Added: curtail or reduce our operations.
+Added: We could be forced to sell or dispose of our rights or assets.
+Added: Any inability to raise adequate funds
+Added: on commercially reasonable terms could have a material adverse effect on our business, results of operations, and financial condition,
+Added: including the possibility that a lack of funds could cause our business to fail and our Company to dissolve and liquidate with little
+Added: or no return to investors.
+Added: will continue to incur significant increased costs as a result of operating as a public company, and our management will be required
+Added: to devote substantial time to new compliance initiatives.
+Added: a publicly traded company, we will incur significant legal, accounting, and other expenses under the Exchange Act, the Sarbanes-Oxley
+Added: Act, and other applicable securities rules and regulations.
+Added: In addition, new and changing laws, regulations, and standards relating to
+Added: corporate governance and public disclosure, including the Dodd Frank Wall Street Reform and Consumer Protection Act and the rules and
+Added: regulations promulgated and to be promulgated thereunder, as well as under the Sarbanes-Oxley Act, the JOBS Act, and the rules and regulations
+Added: of the SEC and national securities exchanges have created uncertainty for public companies and increased the costs and the time that
+Added: our board of directors and management must devote to complying with these rules and regulations.
+Added: We expect these rules and regulations
+Added: to increase our legal and financial compliance costs and will divert management time and attention from revenue generating activities.
+Added: the need to establish the corporate infrastructure demanded of a public company may divert management’s attention from implementing
+Added: our growth strategy, which could prevent us from improving our business, results of operations, and financial condition.
+Added: We have made,
+Added: and will continue to make, changes to our internal controls and procedures for financial reporting and accounting systems to meet our
+Added: reporting obligations as a publicly traded company.
+Added: However, the measures we take may not be sufficient to satisfy our obligations as
+Added: a publicly traded company.
+Added: as long as we remain an “emerging growth company” as defined in the JOBS Act, we may take advantage of certain exemptions
+Added: from various reporting requirements that are applicable to other public companies that are not “emerging growth companies.”
+Added: We may remain an “emerging growth company” until the earliest of (i) the last day of our fiscal year following February 7,
+Added: 2027 (the fifth anniversary of the consummation of the SPAC IPO), (ii) the last day of the fiscal year in which the market value of our
+Added: shares of common stock that are held by non-affiliates exceeds $700 million as of June 30 of that fiscal year, (iii) the last day of
+Added: the fiscal year in which we have total annual gross revenue of $1.235 billion or more during such fiscal year (as indexed for inflation)
+Added: or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt in the prior three-year period.
+Added: Further, there
+Added: is no guarantee that the exemptions available to us under the JOBS Act will result in significant savings.
+Added: To the extent we choose not
+Added: to use exemptions from various reporting requirements under the JOBS Act, we will incur additional compliance costs, which may impact
+Added: may issue additional shares of common stock or preferred stock under an employee incentive plan, which would dilute the interest of our
+Added: stockholders.
+Added: may issue a substantial number of additional shares of common or preferred stock under an employee incentive plan.
+Added: The issuance of additional
+Added: shares of common or preferred stock:
+Added: significantly dilute the equity interest of investors;
+Added: subordinate the rights of holders of common stock if preferred stock is issued with rights senior to those afforded our common stock;
cause a change of control if a substantial number of shares of our common stock are issued, which may affect, among other things,
1 unchanged sentence
and directors;
−Removed: have the effect of delaying or preventing a change of control of us by diluting the stock ownership or voting rights of a person
−Removed: seeking to obtain control of us;
−Removed: adversely affect prevailing market prices for our units, common stock and/or warrants.
−Removed: many other similarly structured special purpose acquisition companies, our initial stockholders will receive additional shares of Class
−Removed: A common stock if we issue shares to consummate an initial business combination.
−Removed: the case that additional shares of Class A common stock, or equity-linked securities convertible or exercisable for Class A common stock,
−Removed: are issued or deemed issued in excess of the amounts offered in our initial public offering and related to the closing of the initial
−Removed: business combination, the number of founder shares held by the sponsor will be adjusted so that it will equal, in the aggregate, 20%
−Removed: of the total number of all outstanding shares of Class A common stock upon completion of the initial business combination, excluding
−Removed: the shares of Class A common stock underlying the placement units, and any shares or equity-linked securities issued, or to be issued,
−Removed: to any seller in the business combination and any private placement-equivalent units and their underlying securities issued to our sponsor
−Removed: or its affiliates upon conversion of loans made to us.
−Removed: This is different from most other similarly structured blank check companies in
−Removed: which the initial stockholder will only be issued an aggregate of 20% of the total number of shares to be outstanding prior to the initial
−Removed: business combination.
−Removed: Additionally, the aforementioned adjustment will not take into account any shares of Class A common stock redeemed
−Removed: in connection with the business combination.
−Removed: Accordingly, the holders of the founder shares could receive additional shares of Class
−Removed: A common stock even if the additional shares of Class A common stock, or equity-linked securities convertible or exercisable for Class
−Removed: A common stock, are issued or deemed issued solely to replace those shares that were redeemed in connection with the business combination.
−Removed: The foregoing may make it more difficult and expensive for us to consummate an initial business combination.
−Removed: may amend the terms of the warrants in a manner that may be adverse to holders of public warrants with the approval by the holders of
−Removed: at least a majority of the then outstanding public warrants.
−Removed: As a result, the exercise price of your warrants could be increased, the
−Removed: exercise period could be shortened and the number of shares of our Class A common stock purchasable upon exercise of a warrant could
−Removed: be decreased, all without your approval.
−Removed: warrants were issued in registered form under a warrant agreement between Vstock Transfer, LLC, as warrant agent, and us.
−Removed: agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any
−Removed: mistake, including to conform the provisions of the warrant agreement to the description of the terms of the warrants and the warrant
−Removed: agreement set forth in our prospectus for our initial public offering, or defective provision, but requires the approval by the holders
−Removed: of at least a majority of the then outstanding public warrants to make any change that adversely affects the interests of the registered
−Removed: holders of public warrants (which may include public warrants acquired by our sponsor or its affiliates in our initial public offering
−Removed: or thereafter in the open market).
−Removed: Accordingly, we may amend the terms of the public warrants in a manner adverse to a holder if holders
−Removed: of at least a majority of the then outstanding public warrants approve of such amendment.
−Removed: Although our ability to amend the terms of
−Removed: the public warrants with the consent of at least a majority of the then outstanding public warrants is unlimited, examples of such amendments
−Removed: could be amendments to, among other things, increase the exercise price of the warrants, convert the warrants into cash or stock, shorten
−Removed: the exercise period or decrease the number of shares of our Class A common stock purchasable upon exercise of a warrant.
−Removed: warrant agreement will designate the courts of the State of New York or the United States District Court for the Southern District of
−Removed: New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our warrants,
−Removed: which could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with our company.
−Removed: warrant agreement provides that, subject to applicable law, (i) any action, proceeding or claim against us arising out of or relating
−Removed: in any way to the warrant agreement, including under the Securities Act, will be brought and enforced in the courts of the State of New
−Removed: York or the United States District Court for the Southern District of New York, and (ii) that we irrevocably submit to such jurisdiction,
−Removed: which jurisdiction shall be the exclusive forum for any such action, proceeding or claim.
−Removed: We will waive any objection to such exclusive
−Removed: jurisdiction and that such courts represent an inconvenient forum.
−Removed: Notwithstanding
−Removed: the foregoing, these provisions of the warrant agreement will not apply to suits brought to enforce any liability or duty created by
−Removed: the Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive
−Removed: Any person or entity purchasing or otherwise acquiring any interest in any of our warrants shall be deemed to have notice of and
−Removed: to have consented to the forum provisions in our warrant agreement.
−Removed: If any action, the subject matter of which is within the scope of
−Removed: the forum provisions of the warrant agreement, is filed in a court other than a court of the State of New York or the United States District
−Removed: Court for the Southern District of New York (a “foreign action”) in the name of any holder of our warrants, such holder shall
−Removed: be deemed to have consented to:
−Removed: (x) the personal jurisdiction of the state and federal courts located in the State of New York in connection
−Removed: with any action brought in any such court to enforce the forum provisions (an “enforcement action”), and (y) having service
−Removed: of process made upon such warrant holder in any such enforcement action by service upon such warrant holder’s counsel in the foreign
−Removed: action as agent for such warrant holder.
−Removed: choice-of-forum provision may limit a warrant holder’s ability to bring a claim in a judicial forum that it finds favorable for
−Removed: disputes with our company, which may discourage such lawsuits.
−Removed: Alternatively, if a court were to find this provision of our warrant agreement
−Removed: inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs
−Removed: associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business, financial condition
−Removed: and results of operations and result in a diversion of the time and resources of our management and board of directors.
−Removed: may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.
−Removed: have the ability to redeem outstanding warrants at any time after they become exercisable and prior to their expiration, at a price of
−Removed: $0.01 per warrant, provided that the reported last sale price of our Class A common stock equals or exceeds $18.00 per share (as adjusted
−Removed: for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 trading-day period
−Removed: commencing once the warrants become exercisable and ending on the third trading day prior to the date on which we give proper notice
−Removed: of such redemption and provided certain other conditions are met.
−Removed: If and when the warrants become redeemable by us, we may not exercise
−Removed: our redemption right if the issuance of shares of common stock upon exercise of the warrants is not exempt from registration or qualification
−Removed: under applicable state blue sky laws or we are unable to effect such registration or qualification.
−Removed: We will use our best efforts to register
−Removed: or qualify such shares of common stock under the blue sky laws of the state of residence in those states in which the warrants were offered
−Removed: by us in our initial public offering.
−Removed: Redemption of the outstanding warrants could force you (i) to exercise your warrants and pay the
−Removed: exercise price therefor at a time when it may be disadvantageous for you to do so, (ii) to sell your warrants at the then-current market
−Removed: price when you might otherwise wish to hold your warrants or (iii) to accept the nominal redemption price which, at the time the outstanding
−Removed: warrants are called for redemption, is likely to be substantially less than the market value of your warrants.
−Removed: warrants and founder shares may have an adverse effect on the market price of our common stock and make it more difficult to effectuate
−Removed: our initial business combination.
−Removed: have issued warrants to purchase 13,225,000 shares of common stock as part of the units offered in our initial public offering and, simultaneously
−Removed: with the closing of our initial public offering, we issued placement units, in a private placement, consisting of an aggregate of 754,000
−Removed: placement units.
−Removed: Our initial stockholders currently own an aggregate of 3,306,250 founder shares.
−Removed: In addition, if our sponsor makes any
−Removed: working capital loans, up to $1,500,000 of such loans may be converted into units, at a price of $10.00 per unit at the option of the
−Removed: lender, upon consummation of our initial business combination.
−Removed: The units would be identical to the placement units.
−Removed: To the extent we
−Removed: issue shares of common stock to effectuate an initial business combination, the potential for the issuance of a substantial number of
−Removed: additional shares of common stock upon exercise of these warrants could make us a less attractive business combination vehicle to a target
−Removed: Any such issuance will increase the number of issued and outstanding shares of our common stock and reduce the value of the
−Removed: shares of common stock issued to complete the initial business combination.
−Removed: Therefore, our warrants and founder shares may make it more
−Removed: difficult to effectuate an initial business combination or increase the cost of acquiring the target business.
−Removed: placement units are identical to the units sold as part of the units in our initial public offering except that that the placement units
−Removed: and their component securities will not be transferable, assignable or saleable until 30 days after the consummation of our initial business
−Removed: combination except to permitted transferees, the purchasers of the placement units waive any and all rights and claims that they may
−Removed: have to any proceeds, and any interest thereon, held in the Trust Account in respect of the common stock underlying such placement units
−Removed: in the event that a business combination is not consummated.
−Removed: The placement units also have registration rights.
−Removed: Additionally, the warrants
−Removed: underlying the placement units shall contain a cashless exercise provision and shall be non-redeemable while held by the initial purchasers
−Removed: thereof or their permitted assignees.
−Removed: There will be no underwriting fees or commissions due with the respect to the private placement.
−Removed: provision of our warrant agreement may make it more difficult for us to consummate an initial business combination.
−Removed: most blank check companies, if
−Removed: issue additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing
−Removed: of our initial business combination at a Newly Issued Price of less than $9.20 per share;
−Removed: aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available
−Removed: for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions),
−Removed: Market Value is below $9.20 per share,
−Removed: the exercise price of the warrants will be adjusted to be equal to 115% of the greater of the Market Value and the Newly Issued Price,
−Removed: and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market
−Removed: Value and the Newly Issued Price.
−Removed: This may make it more difficult for us to consummate an initial business combination with a target
−Removed: in our certificate of incorporation and Delaware law may inhibit a takeover of us, which could limit the price investors might be willing
−Removed: to pay in the future for our Class A common stock and could entrench management.
−Removed: certificate of incorporation will contain provisions that may discourage unsolicited takeover proposals that stockholders may consider
−Removed: to be in their best interests.
−Removed: are also subject to anti-takeover provisions under Delaware law, which could delay or prevent a change of control.
−Removed: Together these provisions
−Removed: may make the removal of management more difficult and may discourage transactions that otherwise could involve payment of a premium over
−Removed: prevailing market prices for our securities.
−Removed: certificate of incorporation will require, to the fullest extent permitted by law, that derivative actions brought in our name, actions
−Removed: against our directors, officers, other employees or stockholders for breach of fiduciary duty and certain other actions may be brought
−Removed: only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the stockholder bringing the suit will, subject
−Removed: to certain exceptions, be deemed to have consented to service of process on such stockholder’s counsel, which may have the effect
−Removed: of discouraging lawsuits against our directors, officers, other employees or stockholders.
−Removed: certificate of incorporation will require, to the fullest extent permitted by law, that derivative actions brought in our name, actions
−Removed: against our directors, officers, other employees or stockholders for breach of fiduciary duty and certain other actions may be brought
−Removed: only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the stockholder bringing the suit will be
−Removed: deemed to have consented to service of process on such stockholder’s counsel except any action (A) as to which the Court of Chancery
−Removed: in the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and
−Removed: the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination),
−Removed: (B) which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or (C) for which the Court of
−Removed: Chancery does not have subject matter jurisdiction.
−Removed: Any person or entity purchasing or otherwise acquiring any interest in shares of
−Removed: our capital stock shall be deemed to have notice of and consented to the forum provisions in our certificate of incorporation.
−Removed: of forum provision may limit or make more costly a stockholder’s ability to bring a claim in a judicial forum that it finds favorable
−Removed: for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to
−Removed: Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to be
−Removed: inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions,
−Removed: which could harm our business, operating results and financial condition.
−Removed: certificate of incorporation provides that the exclusive forum provision will be applicable to the fullest extent permitted by applicable
−Removed: law, subject to certain exceptions.
−Removed: Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce
−Removed: any duty or liability created by the Exchange Act or the rules and regulations thereunder.
−Removed: As a result, the exclusive forum provision
−Removed: will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal
−Removed: courts have exclusive jurisdiction.
−Removed: In addition, our certificate of incorporation provides that, unless we consent in writing to the
−Removed: selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted
−Removed: by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, or the
−Removed: rules and regulations promulgated thereunder.
−Removed: We note, however, that there is uncertainty as to whether a court would enforce this provision
−Removed: and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.
−Removed: Section 22 of the
−Removed: Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created
−Removed: by the Securities Act or the rules and regulations thereunder.
−Removed: are a newly formed company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve
−Removed: our business objective.
−Removed: are a newly formed company with very limited operating results to date.
−Removed: Since we do not have a substantial operating history, you will
−Removed: have a very limited basis upon which to evaluate our ability to achieve our business objective, which is to acquire an operating business.
−Removed: We will not generate any revenues until, at the earliest, after the consummation of a business combination.
−Removed: in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, including our ability
−Removed: to negotiate and complete our initial business combination and results of operations.
−Removed: are subject to laws and regulations enacted by national, regional and local governments.
−Removed: In particular, we will be required to comply
−Removed: with certain SEC and other legal requirements.
−Removed: Compliance with, and monitoring of, applicable laws and regulations may be difficult,
−Removed: time consuming and costly.
−Removed: laws and regulations and their interpretation and application may also change from time to time and those changes could have a material
−Removed: adverse effect on our business, investments and results of operations.
−Removed: In addition, a failure to comply with applicable laws or regulations,
−Removed: as interpreted and applied, could have a material adverse effect on our business, including our ability to negotiate and complete our
−Removed: initial business combination and results of operations.
−Removed: performance by our management team may not be indicative of future performance of an investment in us.
−Removed: performance by our management team is not a guarantee either (i) of success with respect to any business combination we may consummate
−Removed: or (ii) that we will be able to locate a suitable candidate for our initial business combination.
−Removed: You should not rely on the historical
−Removed: record of our management team’s performance as indicative of our future performance of an investment in the company or the returns
−Removed: the company will, or is likely to, generate going forward.
−Removed: None of our directors has experience with blank check companies or special
−Removed: purpose acquisition companies.
−Removed: Additionally, in the course of their respective careers, members of our management team have been involved
−Removed: in businesses and deals that were unsuccessful.
−Removed: incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss.
−Removed: depend on digital technologies, including information systems, infrastructure and cloud applications and services, including those of
−Removed: third parties with which we may deal.
−Removed: Sophisticated and deliberate attacks on, or security breaches in, our systems or infrastructure,
−Removed: or the systems or infrastructure of third parties or the cloud, could lead to corruption or misappropriation of our assets, proprietary
−Removed: information and sensitive or confidential data.
−Removed: As an early stage company without significant investments in data security protection,
−Removed: we may not be sufficiently protected against such occurrences.
−Removed: We may not have sufficient resources to adequately protect against, or
−Removed: to investigate and remediate any vulnerability to, cyber incidents.
−Removed: It is possible that any of these occurrences, or a combination of
−Removed: them, could have adverse consequences on our ability to consummate a business combination and lead to financial loss.
−Removed: are an emerging growth company and a smaller reporting company within the meaning of the rules adopted by the Securities and Exchange
−Removed: Commission, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies and smaller
−Removed: reporting companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance
−Removed: with other public companies.
−Removed: are an “emerging growth company” within the meaning of the rules adopted by the Securities and Exchange Commission, as modified
−Removed: by the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public
−Removed: companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor internal
−Removed: controls attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
−Removed: in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
−Removed: compensation and stockholder approval of any golden parachute payments not previously approved.
−Removed: As a result, our stockholders may not
−Removed: have access to certain information they may deem important.
−Removed: We could be an emerging growth company for up to five years, although circumstances
−Removed: could cause us to lose that status earlier, including if the market value of our Class A common stock held by non-affiliates exceeds
−Removed: $700 million as of any June 30 before that time, in which case we would no longer be an emerging growth company as of the following December
−Removed: We cannot predict whether investors will find our securities less attractive because we will rely on these exemptions.
−Removed: If some investors
−Removed: find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower
−Removed: than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities may
−Removed: be more volatile.
−Removed: Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
−Removed: standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do
−Removed: not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
−Removed: The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
−Removed: that apply to non-emerging growth companies but any such an election to opt out is irrevocable.
−Removed: We have elected not to opt out of such
−Removed: extended transition period, which means that when a standard is issued or revised and it has different application dates for public or
−Removed: private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new
−Removed: or revised standard.
−Removed: This may make comparison of our financial statements with another public company which is neither an emerging growth
−Removed: company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of
−Removed: the potential differences in accounting standards used.
−Removed: Additionally,
−Removed: we are a “smaller reporting company” as defined in Rule 10(f)(1) of Regulation S-K.
−Removed: Smaller reporting companies may take
−Removed: advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements.
−Removed: We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our Class A common
−Removed: stock held by non-affiliates equals or exceeds $250 million as of the end of the prior June 30 th , or (2) our annual revenues
−Removed: equaled or exceeded $100 million during such completed fiscal year and the market value of our Class A common stock held by non-affiliates
−Removed: exceeds $700 million as of the prior June 30 th .
−Removed: To the extent we take advantage of such reduced disclosure obligations, it
−Removed: may also make comparison of our financial statements with other public companies difficult or impossible.
−Removed: Unresolved Staff Comments
−Removed: do not own any real estate or other physical properties materially important to our operations.
−Removed: Our executive offices are located at
−Removed: 4995 Murphy Canyon Road, Suite 300, San Diego, CA 92123 and our telephone number is 760-471-8536.
−Removed: Legal Proceedings
−Removed: is no material litigation, arbitration, governmental proceeding or any other legal proceeding currently pending or known to be contemplated
−Removed: against us, any of our property, or any members of our management team in their capacity as such.
−Removed: Mine Safety Disclosures
+Added: adversely affect prevailing market prices for the common stock.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.